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ABSTRACT
Hjortland, Nicole M. Ph.D., Purdue University, December 2016. Defining the Regulatory Determinants in Substrate Catalysis by Biochemical, Biophysical, and Kinetic
studies for the Development of Specific Small–Molecule Inhibitors of Ubiquitin Specific Protease 7 and 17. Major Professor: Andrew D. Mesecar.
Ubiquitination is an important post–translational modification involved in maintaining cellular homeostasis by regulating many delicate cellular processes, including
the cell–cycle, membrane protein trafficking, endocytosis and apoptosis. Ubiquitin
Specific Proteases (USPs) remove ubiquitin modifications from protein substrates to
reverse the signal imposed by the ubiquitination. Perturbations in the expression
levels of USPs has been implicated in many types of cancers where patients show
significant elevation in cellular levels of specific USPs. This suggests that targeting
specific upregulated members of the USP family in specific disease states would be
ideal for the development of personalized anti–cancer therapeutics.
Each member of the USP family is composed of a conserved catalytic domain
flanked by a variety of other domains that make the function of each USP unique.
These flanking domains are important for substrate recognition, regulation, and function. The conserved catalytic domains of the USPs share high structural similarities,
and within two regions of the catalytic domain they also share high sequence similarity. These regions are referred to as the Cys and His boxes, and they contain the
catalytic triad composed of a cysteine, histidine, and aspartate residues. These structural and sequence similarities make the task of inhibiting specific members of the
USP family substantially more difficult. Therefore, it is essential that we thoroughly
characterize not only the enzymatic activity of the catalytic domain of the specific
USP of interest; but also the structure and function of the flanking domains that

xxi
make the USP unique. Along these lines, this dissertation describes the enzymatic
and biochemical characterization of two USP family members, USP17 and USP7.
USP17 is a cytokine–inducible USP that is required for cell–cycle progression
through the G1 –S and G2 –M checkpoints. No structural information specific to
USP17 is available, but cellular studies have determined that USP17 contains the
conserved catalytic domain at the N–terminus and two hyaluronan binding motifs at
the C–terminus. Cellular characterization of USP17 has led to the identification of
three substrates that USP17 deubiquitinates: the Ras Converting Enzyme 1 (RCE1),
the Cell Division Cycle 25A (CDC25A) phosphatase, and a component of the Sin3 co–
repressor complex SDS3. Under normal cellular conditions, USP17 is only expressed
during the cell–cycle checkpoints and if USP17 is expressed at other times, cellular
proliferation ceases. However, the upregulation of USP17 has been implicated in
both breast and prostate cancer, and it is thought that the persistent overexpression
of USP17 applies continuous stress on the cell–cycle through perturbation of the
Ras and CDC25A signaling pathways. As such, USP17 is an important target for
inhibition leading to the development of anti–cancer therapeutics.
Here the novel expression, refolding, and purification methodology for USP17 is
reported. USP17 is highly insoluble when expressed in E. coli expression systems,
and, as such, no methodology for the recombinant expression and purification had
previously been reported. Numerous USPs have successfully been expressed from
baculovirus expression systems, including the well characterized USP7. USP17 was
successfully expressed and purified from the baculovirus expression system, however
due to high levels of degradation, the yield of intact USP17 was low. Therefore, a
suitable buffer was identified and optimized for the refolding of active USP17 expressed in E. coli inclusion bodies. After refolding, active intact USP17 was purified
using two chromotographic steps to ≥ 98% purity. The ability to purify milligram
quantities of USP17 allowed for the enzymatic and biochemical characterization of
USP17 including the determination of the steady–state kinetic parameters, defining the oligomeric state, and substrate specificity. Finally, in collaboration with the

xxii
Biomolecular Screening and Drug Discovery Facility in Bindley Biosciences Center,
the recombinatly expressed USP17 underwent and initial round of high–throughput
screening for the identification of potential small–molecule inhibitors.
Ubiquitin Specific Protease 7 (USP7/HAUSP) is to date the most well–studied
human deubiqutinating enzyme of the USP class that regulates many high profile signaling pathways in the cell, including regulation of the tumor suppressor p53/MDM2
pathway. When the cell is under normal conditions, USP7 primarily deubiquitinates
MDM2. However, when the cell experiences genotoxic stress the focus of USP7s
deubiquitination shifts from MDM2 to p53. Furthermore, under genotoxic stress,
guanosine 5–monophosphate synthase (GMPS) binds to and allosterically activates
USP7 to enhance the rate of deubiquitination and thereby stabilize p53. Disruption
of the p53 signaling pathway is responsible for roughly 50% of human cancers due to
mutation or inactivation of p53. USP7 has been identified as being upregulated in
many forms of cancer, essentially silencing p53 through the inappropriate stabilization of MDM2. This is only one of the pathways that identify USP7 as a promising
target for inhibition and development of anti–cancer therapeutics.
While no full length USP7 structure has been solved, there is significant structural
data of the individual domains of USP7 that have aided in our understanding of
USP7’s enzymatic activity and protein–protein interactions. The catalytic domain
of USP7 has significantly lower activity than the full length enzyme and requires
intramolecular activation by the C–terminal ubiquitin–like domains (HUBL) 4 and
5. Previous reports have suggested that HUBL domains 1–3 are not involved in the
intramolecular activation of USP7; but rather act as a scaffold for the binding of the
allosteric activator GMPS for enhanced activation of USP7. Utilizing kinetic and
biochemical techniques, the importance of HUBL domains 1–3 in the intramolecular
activation of USP7 was elucidated, and the results are striking.
The role of the HUBL domains 1–3 in the intramolecular activation of USP7 was
evaluated using nine different USP7 truncations: USP7FL , USP7CD , USP7CD –H1–5,
USP7CD –H4–5, TRAF–USP7CD , H1–5, H4–5, H1–2, and H1–3. With the exception

xxiii
of USP7FL which was prepared from the baculovirus expression system, each truncation was expressed from E. coli and purified using three sequential chromotographic
steps. All truncations were purified in milligram quantities with ≥ 98% purity. The
steady–state kinetic parameters were determined for the active truncations (USP7FL ,
USP7CD , USP7CD –H4–5, and TRAF–USP7CD ) with the fluorogenic substrate Ub–
Rho110. The values obtained validated the requirement of HUBL domains 4 and
5 to achieve full activity of USP7. Interestingly, the parameters associated with
the TRAF–USP7CD truncation suggest an interaction between Ub–Rho110 and the
TRAF domain that has not been previously reported. Fixed yet variable kinetic
studies defined striking differences between the nonessential activation parameters,
αKA,app , αKm,app , α–, and β–, of USP7CD in trans by either H1–5 and H4–5. Upon
further biochemical evaluation, it was determined that H1–3 act as a rheostat to
regulate the level of activation H4–5 can apply to USP7.
A promising small molecule inhibitor of USP7 was identified for USP7FL by HTS.
A structure activity relationship in regards to the halogen substiutent within the identified scaffold was developed in collaboration with the Computational and Medicinal
Chemistry core of the Purdue Center for Cancer Research. To determine which domains are required for inhibition by these compounds, USP7FL , USP7CD , USP7CD –
H1–5, USP7CD –H4–5, and TRAF–USP7CD were evaluated for inhibition. Interestingly, it was found that no inhibition could be measured without HUBL domains
1–3 present. With this finding, the mode of inhibition of these compounds was determined to be partial Non–Competitive, suggesting these inhibitors act via a novel
allosteric inhibition mechanism. Many attempts were made to determine where these
compounds bind to USP7 using both kinetic and biophysical approaches, however,
no conclusive results were obtained. When combined, these observations support the
importance of having an intact H1–3 for the intramolecular activation of USP7 and
support that the novel allosteric inhibitors developed require H1–3 for inhibition. Recent x–ray structures of a USP7 truncation of USP7CD –H1–3 may aid in identification
of a more precise location for the design of inhibitors that target H1–3 domains.
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CHAPTER 1. INTRODUCTION
1.1

Ubiquitination Cycle

1.1.1

Ubiquitination

Over the past 10 years our interest and understanding of the post–translational
modification process of ubiquitination has greatly increased. The significance ubiquitination in maintaining cellular homeostasis by the regulation of many delicate cellular processes, including the cell–cycle, membrane protein trafficking, endocytosis,
and apoptosis has become increasingly clear [1–4]. The ubiquitin protein itself is a
conserved 76–residue polypeptide that folds into the highly stable β–grasp fold. The
conjugation of ubiquitin to a protein substrate requires three enzymes: the ubiquitin–
activating enzyme (E1 ligase), the ubiquitin–conjugating enzyme (E2 ligase), and the
ubiquitin–protein ligase (E3 ligase). The ubiquitination process begins with an E1
ligase activating the C–terminus of a ubiquitin molecule through an ATP–dependent
process forming a covalently bound intermediate between the active site of an E1
ligase ubiquitin (Figure 1.1). The activated ubiquitin is then transferred from an
E1 ligase to the active site residue of the E2 ligase. The E3 ligase is responsible
for recruiting the specific protein substrate for ubiquitination. Together the E2 and
E3 ligases conjugate the ubiquitin to the protein by the formation of an isopeptide
bond between the –amino of a specific lysine residue of the protein substrate and the
C–terminus of ubiquitin [4, 5]. This process is reversed by deubiquitinating enzymes
described in Section 1.2
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Fig. 1.1. Ubiquitination Cycle. Ubiquitination is a three step process. The
C–terminus of a ubiquitin molecule is activated by the E1 Ligase through an
ATP dependent process. The activated ubiquitin is then transferred to the E2
Ligase. The E3 Ligase is responsible for substrate recognition, and, together
with the E2 Ligase, the activated ubiquitin molecule will be conjugated to the
recruited substrate through the formation of an isopeptide bond between the
C–terminus of ubiquitin and a specific lysine of the substrate. This process may
be repeated numerous times to build ubiquitin chains from the lysines within
ubiquitin itself.

1.1.2

E1, E2, and E3 Ligases

The cascade of E1, E2 and E3 ligases involved in the ubiquitination process serves
to regulate and add specificity to the process. The human genome encodes for only
2 E1 ligases and 37 E2 ligases. In contrast, over 600 E3 ligases are encoded in the
genome. With such a small number of E1 and E2 ligases, there can be minimal specificity towards specific protein substrates in the preparation of the ubiquitin molecule.
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Instead, the specificity of the ubiquitination process is primarily the responsibility of
the E3 ligases. The E3 ligases recognize both the E2 ligase and the protein substrate
requiring ubquitination. There are two main types of E3 ligases, the HECT–type and
the RING–type. The HECT–type ligases function alone as a single E3 ligase molecule
in a two step process. The HECT–type E3 ligases form a covalent bond intermediate
with the activated ubiquitin prior to transferring it to a protein it has recruited. Alternatively, the RING–type E3 ligases form multi–subunit complexes that can bind
both the E2 ligase and a recruited protein substrate at once. With this ability, the
RING–type E3 ligases transfer the activated ubiquitin molecule directly from the E2
ligase to the recruited protein substrate without forming a covalent intermediate. As
a modular system, the RING–type E3 ligases can assemble to recognize different E2
ligases and different substrates in response to signals within the cell [6].

1.1.3

Ubiquitin Chains

A protein substrate can be modified by a single ubiquitin protein (mono-ubiquitination)
or a chain of ubiquitin molecules (poly-ubiquitination) [3]. Ubiquitin chains are
formed by the conjugation of the activated C–terminus of a ubiquitin molecule to
the –amino of a lysine residue of a ubiquitin molecule already conjugated to the
substrate [5]. Ubiquitin has seven different lysine residues from which poly–ubiquitin
chains can be conjugated, Lys6 , Lys11 , Lys27 , Lys29 , Lys33 , Lys48 , Lys63 , in addition to the amino group of the N–terminal methionine, a modification referred to
as linear ubiquitin [3]. The variety of ubiquitin chains that can be formed and the
downstream consequences of the specific chain adds complexity to ubiquitin signaling that is lacking in other posttranslational modifications, such as phosphorylation.
The outcomes of Lys48 and Lys63 poly–ubiquitination are the best understood thus
far. Lys48 chains commonly target protein substrates for proteasomal degradation,
while Lys63 chains are associated with enzyme activation [3]. Compared to Lys48 and
Lys63 , an understanding of the physiological responses to the other ubiquitin chain
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types is lacking. However, recent work has shed some light on the importance of Lys11
and Lys33 . The Lys11 linkage has been described as a degradation signal, similar to
Lys48 [7]. Lys33 chains have been shown to be involved in enzyme activation, similar
to Lys63 [7, 8].

1.2

Deubiquitinating Enzymes (DUBs)
Deubiquitinating enzymes (DUBs) counteract ubiquitination by cleaving the isopep-

tide bond between the –amino group of the protein substrate and the C–terminal
group of ubiquitin. Approximately 98 human DUBs have been identified by sequence
and structural similarity and organized based on these similarities into six families
Figure 1.2: the Ubiquitin C–terminal Hydrolases (UCH), the Ubiquitin Specific Proteases (USP), the Machado–Joseph Disease Protein Domain Proteases (MCPIP), the
Ovarian Tumor Proteases (OTU), the Josephine and Metalloenzymes (JAMM), and
the monocyte chemotactic protein–induced protein family (MCPIP), as displayed in
Figure 1.2 [1]. The members of these families are cysteine proteases, with the exception of the JAMM family, which is composed of metalloproteases. While they
all perform the deubiquitinating function, structural studies have elucidated high
variability within the catalytic domain between the families [1, 9].
DUBs aid in maintaining cellular homeostasis by six general processes. (1) Ubiquitin is translated as a single polypeptide chain, which requires DUBs to process
the chain and release the individual ubiquitin molecules for conjugation to protein
substrates by the ligase cascade. (2) When a protein is ubiquitinated to signal for
degradation by the proteasome, DUBs will remove the ubiquitin tag from the substrate prior to degradation of the protein by the proteasome so as to recycle the
ubiquitin molecules for future use. (3) DUBs can prevent protein degradation by the
26S proteasome by removing ubiquitin from targeted proteins. (4) The ubiquitination of a protein can act as an on/off switch for that protein’s function. By removing
ubiquitin from these types of proteins DUBs regulate the activity of the protein. (5)
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DUBs can edit ubiquitin chains and hence signaling by altering the ubiquitination
pattern on a particular protein. (6) A ubiquitin chain on a DUB binding partner can
act as a signal to attract a DUB. This interaction can modulate the activity of the
DUB or binding partner as a result [10].
DUBs recognize their substrates either by the substrate itself or by the specific
ubiquitin chain that decorates the substrate [10, 11]. As previously discussed in Section 1.1.3, ubiquitin chains can be built out from seven different lysine residues within
the ubiquitin molecule (Lys6 , Lys11 , Lys27 , Lys29 , Lys33 , Lys48 , Lys63 ) in addition
to the amino group of the N–terminal methionine. [3] The resulting ubiquitin chains
extending from these different lysines assume different topologies that DUBs can
recognize [10, 11]. Many DUBs are promiscuous and can process all ubiquitin chain
linkages to some extent, in which case specificity is most likely inferred by the ubiquitinated substrate itself rather than the ubiquitin chain [10,11]. In some cases, however,
DUBs can process only certain ubiquitin chains that they recognize directly. In both
cases, DUBs can cleave the ubiquitin chains either by endo– or exo–trimming [10,12].
For endo–trimming, the DUB cleaves an isopeptide bond located within the ubiquitin chain, not the bond that links the ubiquitin molecule directly to the substrate
or the last ubiquitin molecule in the chain. For exo–trimming the DUB cleaves the
isopeptide bond between the substrate and the ubiquitin chain or the last ubiquitin
molecule of the chain. Furthermore, some DUBs are capable of processing a mono–
ubiquitinated substrate, while others are not and require a ubiquitin chain to perform
catalysis [10, 12].

1.2.1

Ubiquitin Specific Proteases (USPs)

The USP family is the largest of the DUB families with around 60 members. The
USP family is the focus of the work described within this dissertation. USPs are
multi–domain enzymes that can range in size from 40 kDa, in the case of USP12, up
to 400 kDa, in the case of USP34 [1]. The USP catalytic domain assumes a papain–
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Fig. 1.2. Classification of human DUBs There are six families of human
DUBs represented by the various colors: USPs (pink), UCH (purple), OTU
(blue), MJD (green), MCPIP (yellow), and JAMM (orange). The known individual members of each family are listed within the appropriate section. The
asterisks denote DUBs that have been characterized to be upregulated in cancer. Figure adapted from data summarized in [1, 13].

like fold (Figure 1.3A) that is structurally conserved throughout the family [1, 4].
The papain–like fold resembles a right hand with the fingers, thumb, and palm motifs
(Figure 1.3A) [1]. Within the catalytic domain, there are two regions of high sequence
similarity, which are referred to as the Cys (green) and His (cyan) boxes (Figure 1.3B).
These conserved boxes are situated between the thumb and palm motifs and contain
residues essential for catalysis including the catalytic triad that is composed of the
catalytic cysteine (Cys box), and the supporting residues histidine and aspartate (His
box) (shown as orange sticks in Figure 1.3B) [4, 9, 14].
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Structural studies and comparisons between the USP family members have elucidated internal mechanisms the USPs utilize for regulation. One mechanism by which
USPs are internally regulated is by the misalignment of their catalytic triad. The catalytic triad within the unligated structure both of USP1 and USP7 are positioned in a
non–functional state [15–17]. However, ubiquitin–bound structures show the catalytic
triad realigns into a functional state, suggesting that only when ubiquitin is bound is
the USP functional [10, 16, 17]. All USPs contain loops within their catalytic domain
referred to as blocking loops 1 and 2. However, the sequence and length of these loops
are not conserved within the family. In the case of USP8 and USP14, these blocking
loops physically occlude the active site and prevent catalysis (Figure 1.3C) [10,18,19].
The mechanism by which these loops move to allow ubiquitin binding is still being
defined. Finally, while not clearly defined as a regulatory mechanism, a loop termed
the ”switching loop” has been described in USP4 and USP7 (Figure 1.3C) to be
important for the allosteric activation of catalytic activity [20, 21].
What makes each USP unique are the domains that flank the conserved catalytic
domain. These domains commonly include Ubiquitin–Like domains (UBL), Zinc–
finger motifs, and Ubiquitin–interacting domains [9, 10]. These domains are often
responsible for substrate recognition, protein–protein interactions, or even the regulation of USP activity [12,17,19,20]. Of particular interest for this dissertation are the
UBL domains. UBL domains share the common β–grasp fold of ubiquitin but lack
the C–terminal glycine required for conjugation. UBL domains are found throughout nature and are surprisingly commonplace in USPs [22, 23]. Thus far, at least 16
members of the USP family have been identified as containing UBL domains, and it
appears that the role of these UBL domains differs from USP to USP. The first USP
associated UBL domain was discovered within USP14. This UBL domain appears
to be required for recruiting and associating USP14 with the proteasome [19]. USP4
also contains a UBL domain that was originally thought to have a role in inhibiting
the catalytic activity of USP4 by blocking the active site, however this finding has yet

8
to be validated [21]. In the case of USP7, the UBL domains have a role in catalysis
as well as serving as a binding platform for protein–protein interactions [20, 22].

1.2.2

Catalytic Mechanism of Ubiquitin Specific Proteases

The catalytic mechanism of USPs is illustrated in Figure 1.4. The USP catalytic
triad is composed of a cysteine that acts as the nucleophile, a histidine that serves
as a general acid–base, and an aspartate that stabilizes the histidine to promote the
deprotonation of the cysteine residue. Within the unbound state of the USP, the histidine deprotonates the cysteine residue to generate the reactive thiolate (E). When
the USP binds substrate, the ES complex is formed. The reactive thiolate will nucleophilically attack the isopeptide bond between the ubiquitin molecule and the protein
substrate forming a tetrahedral intermediate (FP). The tetrahedral intermediate is
unstable and quickly collapses by general acid assisted protonation by the histidine,
releasing the product from the ubiquitin forming a thiol–ester intermediate (F). An
active site water molecule then acts as a nucleophile to attack the carbonyl carbon of
the thiol–ester intermediate forming a second tetrahedral intermediate (FQ). Again,
the tetrahedral intermediate collapses through the general acid assisted protonation
by the histidine, the ubiquitin molecule dissociates, and the enzyme returns to its
initial state (E + Q).

1.3

USPs and Cancer
USPs regulate many sensitive pathways, as described in Section 1.2. As a result,

the USPs are commonly associated with oncogenic pathways and are often a driving
force of cancerous growth [13,24]. The USPs and other DUBs upregulated in cancers
are denoted in Figure 1.2 with an asterisk. The role each USP has in cancer is not
always clear. Often times an individual USP can have both oncogenic and tumor suppressive traits, depending upon the specific pathway of involved or the tissue being
studied [13]. By characterizing individual USPs and developing a more comprehensive
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Fig. 1.3. Conserved USP Catalytic Domain A. Conserved papain–like fold
present in USP catalytic domains. The fingers, thumb, and palm motifs are as
labeled. Structure is of USP7 catalytic domain, PDB: 4M5W. B. Highlighted
sequence–conserved Cys (green loop) and His (cyan loop) boxes. The catalytic
triad is shown in orange: Cysteine, contained in the Cys box loop, and the
Histidine and Aspartate, contained within the His box loop. C. Highlighted
structural features blocking loops and switching loop in purple. The blocking
loops are present in all USPs but vary in sequence and length. The switching
loop has only been described as an important feature of USP4 and USP7.
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Fig. 1.4. Catalytic Mechanism for Ubiquitin Specific Proteases To
assume the proper ionization state for catalysis (E), the active site histidine of
the USPs catalytic triad acts as a general base to extract a proton from the
catalytic cysteine. In the ionized state, the enzyme can form an ES complex
with an ubiquitinated substrate. The thiolate ion then attacks the carbonyl
of the last glycine residue of the ubiqutin molecule to form the tetrahedral
intermediate FP. The unstable oxyanion drives the protonation of the leaving
group product (the now deubiquitinated substrate) by the catalytic histidine
to form the acyl enzyme (F). An activated water molecule then attacks the
newly formed carbonyl to again form an oxyanion tetrahedrial intermediate
and re–protonating the active site histidine (FQ). By general acid protonation
of the thiolate by the histidine the tetrahedral intermediate collapses which
regenerates free enzyme (E+Q).

understanding of how they regulate specific pathways, we can develop an understanding of how to target these enzymes for inhibition. The work described within this
dissertation pertains to characterizing the enzymatic activity of two USPs associ-
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ated with promoting cancer when misregulated, USP17 (Section 1.3.1) and USP7
(Section 1.3.2).

1.3.1

USP17

USP17 was originally identified as a member of the murine hematopoietic specific genes as DUB3 [25]. It is a 58 kDa enzyme with the catalytic domain located
near the N–terminus and two predicted hyaluronan binding motifs at the C-terminus
(Figure 1.5A) [25, 26]. No structural data for USP17 is currently available, however sequence alignments of USP17 with other well studied USPs (USP8, USP7, and
USP14) reveal that USP17 contains its catalytic triad within the conserved Cys and
His boxes as described in Section 1.2.1 (Figure 1.5B, catalytic residues highlighted
in yellow). The activity of USP17 is closely associated with the cell–cycle. Cellular
expression of USP17 is cytokine–inducible and is required for cell–cycle progression
through the G1 –S and G2 –M checkpoints. If USP17 is expressed at different times
during the cell–cycle besides these checkpoints, cellular proliferation ceases [25, 27].
Characterization of USP17 function has thus far been based primarily on cell–based
studies and has led to the identification of three protein substrates of USP17: Ras
Converting Enzyme 1 (RCE1), the Cell Division Cycle 25A (CDC25A) phosphotase,
and a component of the Sin3 co–repressor complex SDS3 [28,29]. While under normal
conditions the overexpression of USP17 ceases proliferation, work by McFarlane and
coworkers described that the persistent overexpression of USP17 applies continuous
stress on the cell–cycle resulting in cancerous proliferation in both breast and prostate
cancers [25,27]. The effects of overexpression of USP17 and its effect on the substrates
RCE1 and CDC25A have been elucidated and are discussed in section Section 1.3.1.

USP17 and RCE1
In the Ras pathway, USP17 has the function of regulating RCE1. RCE1 is an
endoplasmic reticulum, integral transmembrane protease responsible for processing
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C–terminal -CAAX motif of Ras, which is required for isoprenylation. The removal of
the ”AAX” residues exposes a cysteine, which undergoes further modification (methylation and palmitoylation) for localization of Ras to the plasma membrane where Ras
is activated for signaling through the MAP kinase pathway. RCE1 is activated only
when ubiquitinated by Lys63 chains. In a healthy cell, USP17 regulates this pathway
by removing the ubiquitin from RCE1 rendering it inactive for proper Ras processing [28, 30]. It is unclear at this time how the upregulation of USP17 disrupts this
pathway leading to cancer, but it has been hypothesized that due to the innappropriate expression of USP17, Ras does not translocate to the plasma membrane
appropriately. A build up of Ras within an intermediate state leads to prolonged
stress within the cell and further impairs proper cell–cycle signaling [27].

Fig. 1.5. USP17 Domain Organization and Sequence Alignment A.
Schematic displaying the domains of USP17 identified thus far. B. A sequence alignment of the conserved Cys and His boxes of USP17 against USP8
(GenBank: 001122082), USP7 (GenBank: 003461), and USP14 (GenBank:
005142.1). Catalytic triad residues denoted by yellow highlighting.
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USP17 and CDC25A
USP17 has been shown to have an important role in controlling the cell–cycle
through the deubiquitination of CDC25A [29]. CDC25A is a cell–cycle phosphatase
required for cell–cycle progression at the transition checkpoints and for response to
DNA damage [29, 31]. CDC25A dephosphorylates the CDK2–Cyclin complex for
transition through the cell–cycle checkpoints. USP17 is responsible for stabilizing
CDC25A by removing Lys48 conjugated ubiquitin chains during the the transition
checkpoints. Under normal conditions, CDC25A is ubiquitinated for degradation
in a timely manner after transition through cell–cycle checkpoints (Figure 1.6A).
The upregulation of USP17 leads to increased deubiquitination and inappropriate
stabilization of CDC25A [29, 31]. Continuous upregulation of CDC25A stresses cell–
cycle progression and leads to DNA damage and instability. Cells that experience
persistent DNA damage often become cancerous (Figure 1.6B). The over–expression
of USP17 has been attributed to promoting breast cancer and prostate cancer and is
capable of inducing cellular transformation [25, 27, 31, 32]. The partial knock down
of USP17 by siRNA was shown to reduce growth of breast tumor xenographs by
50% [29].

1.3.2

USP7

One of the most well studied DUBs is the ubiquitin specific protease 7 (USP7),
also known as the herpes virus-associated ubiquitin-specific protease (HAUSP). Xray crystal structures of each domain of USP7 are available as individual proteins,
however, a full–length structure has yet to be determined. USP7 comprises of seven
domains (Figure 1.7); a TNF receptor associated factor (TRAF) domain, a catalytic
domain, and five ubiquitin-like (UBL) domains [19, 20, 33]. The N–terminal TRAF
domain is proposed to be responsible for substrate binding and specificity [33]. The
catalytic domain maintains the conserved papain–like fold seen throughout the USP
family, (Figure 1.3) [19]. Interestingly, the purified catalytic domain is 120–fold less
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Fig. 1.6. The role of USP17 in the CDC25A pathway A. Under normal conditions, USP17 deubiquitinates CDC25A preventing the degradation of
CDC25A by the proteasome. Stabilized CDC25A dephosphorylates the Cyclin–
CDK2 complex for progression of the cell cycle through the G1 –S checkpoint.
B. Under cancerous conditions (such as breast cancers), USP17 is upregulated
which increases the amount of CDC25A present in the cell. This perturbation leads to increased progression of the cell–cycle and unregulated cellular
proliferation.

active than that of the full–length enzyme as measured with the fluorogenic substrate ubiquitin–7-amino–4-methylcoumarin (Ub–AMC) [34]. The poor activity of
the isolated catalytic domain has been attributed to the observation that the catalytic triad is misaligned in the unbound structure of USP7 (PDB: INB8 and 4M5W)
presumably making it catalytically inefficient [15,16]. However, in a crystal structure
of the catalytic domain bound to ubiquitin aldehyde (PDB: 1NBF), the catalytic
triad is properly aligned for catalysis, suggesting that a rearrangement of the catalytic triad by binding of the substrate may be required for catalysis, as mentioned
in Section 1.2.1 [16]. Furthermore, as discussed in Section 1.2.1, a comparison of the
unbound structure of the catalytic domain to the ubiquitin aldehyde–bound structure
shows that significant movement of blocking loops 1 (residues 408-429, BL1) and 2
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(residues 459-462, BL2), as well as the switching loop (residues 285-291), are required
to unblock the active site for the binding of ubiquitin–aldehyde [15, 19].
At the C–terminus of USP7 are five consecutive UBL domains referred to as
the HAUSP ubiquitin-like (HUBL) domains [20]. The sequence identity of the UBL
domains relative to each other and to ubiquitin is very low, and as a result, UBL
domains are often only identified by determining their structures [22]. This remains
true for the HUBL domains where the sequence identity among them is only 3 to
15%, or to ubiquitin, varying from 6 to 19% [20]. The significance of the HUBL
domains in regulation of USP7 catalysis is slowly being defined and it is now clear
that the HUBL domains, specifically HUBL domains 4 and 5, are required for full
activity of USP7 [20, 34]. However, a detailed mechanism of how interactions with
HUBL domains 4 and 5 influence USP7s activity has yet to be fully elucidated [20]
and is a main topic of this dissertation.

Fig. 1.7. Domains of USP7 USP7 is comprised of seven domains: the N–
terminal TRAF domain (grey), the conserved catalytic domain (pink), and five
UBL domains (rainbow).
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USP7 has many defined substrates involved in cell–cycle and growth signaling
pathways. These substrates include tumor suppressors PTEN, FOXO4, and p53,
as well as the E3 ligase ICP0, which is important for herpesvirus infection [35–39].
The upregulation of USP7 leads to many types of cancers by perturbing the balance
of these signaling pathways. Cancers associated with USP7 upregulation include
prostate, breast, glioma, lung, multiple myeloma, colon, and neuroblastoma [35, 36,
40–43].

USP7 and MDM2/p53
The most well studied substrates of USP7 are the tumor suppressor p53 and E3
ligase MDM2. Both substrates are associated with multiple myeloma. Recent advancements in the understanding of mulitple myeoma carcinogenesis have shown that
the tumor suppressor p53 is silenced in the majority of cases. While p53 is mutated
or deleted in about 50% of cancers, this is rarely the case in multiple myeloma [44].
p53 is directly regulated by ubiquitin–dependent degradation by MDM2. MDM2
autoubiquitinates itself for proteasomal degradation. In normal conditions, USP7 is
responsible for deubiquitinating MDM2, thereby stabilizing MDM2 and allowing for
continued proteasomal degradation of p53 [42]. Both USP7 and MDM2 levels are
upregulated in multiple myeloma cells, which is effectively silencing p53 and resulting
in unchecked oncogenic proliferation (Figure 1.8) [44, 45].

USP7 and PTEN/FOXO4
Mono–ubiquitination of the USP7 substrates phosphatase/tumor suppressor PTEN
and tumor suppressor FOXO4, signals for their translocation to the nucleus [35, 36].
Within the nucleus both PTEN and FOXO4 function as transcriptional regulators
for tumor suppression [35, 36]. As depicted in Figure 1.9, USP7 is responsible for the
deubiquitination of both substrates, which leads to their export from the nucleus.
The upregulation of USP7 in cancers, such as prostate and breast cancers, leads to
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Fig. 1.8. The role of USP7 on the p53/MDM2 pathway. A. Under normal conditions, E3 ligase MDM2 ubiquitinates both p53 and itself for
degradation by the proteasome. USP7 regulates the balance between MDM2
and p53 through deubiquitination. B. Under cancerous conditions, such as
multiple myeoma, USP7 levels are upregulated, which leads to increased levels
of MDM2. The effects of stabilizing MDM2 to such an extreme, essentially
leads to the silencing of p53 and unchecked cellular proliferation.

the perturbation of these signaling pathways and increased export of these critical
tumor suppressors from the nucleus. Without successful PTEN or FOXO4 signaling
within the nucleus, inappropriate cellular proliferation results [35, 36].

1.4

Statement of Intent
The USP family of enzymes play an important role in maintaining homeostasis

due to their regulation of a vast number of cellular processes including cell–cycle
regulation, DNA damage repair, chromatin remodeling, or signaling pathways by
deubiquitination [1]. Each USP family member shares a structurally conserved catalytic domain and is accessorized with other functional domains flanking the catalytic
domain (Figure 1.3). It is the composition and function of these additional domains
that makes the function of each USP family member unique. Almost one half of the
USP family members identified thus far are upregulated in cancer (Figure 1.2). Of
particular interest for the research described herein are USP17 and USP7 and the
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Fig. 1.9. USP7 deubiquitination of PTEN and FOXO4. Tumor suppressors PTEN and FOXO4 are both mono–ubiquitinated within the cytoplasm
which signals for their translocation to the nucleus. USP7 maintains PTEN and
FOXO4 levels by deubiquitination which subsequently signaling for their export
from the nucleus. Increased levels of USP7 leads to the inappropriate export
of these critical tumor suppressors from the nucleus and results in unregulated
cellular proliferation and cancer.

role they play in promoting cancer. The overarching goal of this dissertation project
is to characterize how each USP processes ubiquitin substrates as well as define the
role of the additional domains within the enzyme. Understanding how each of these
enzymes differs from the other members of the USP family may aid in the identification and development of specific small molecule inhibitors towards both enzymes.
These inhibitors could further aid in the study of the enzymatic function of each USP
and serve as a foundation for the development of anti–cancer therapeutics.
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CHAPTER 2. ENZYMATIC CHARACTERIZATION OF RECOMBINANTLY
EXPRESSED USP17
Parts of the data and text in this chapter have been included in the manuscript in
preparation entitled ”Steady–state kinetic studies reveal that the anti–cancer target
Ubiquitin–Specific Protease 17 (USP17) is a highly efficient deubiquitinating enzyme”

2.1

Abstract
USP17 is a deubiquitinating enzyme that is responsible for the regulation of cell–

cycle progression by stabilizing the Cell Division Cycle 25 A (CDC25A) phosphatase
by deubiquitination. Upregulation of USP17 in numerous cancer phenotypes stabilizes CDC25A which leads to cellular proliferation and cancer, suggesting that an
inhibitor of USP17 may have therapeutic value in the treatment of cancer. Towards
this goal, we developed a robust expression, purification, and assay system for USP17
enabling its enzymatic and structural characterization and the identification of inhibitors of this potential drug target. USP17 was expressed in E. coli as inclusion
bodies and then solubilized, refolded, and purified using affinity–chromatography followed by size–exclusion chromatography. Milligram quantities of highly pure, recombinant USP17 can be produced from a liter of culture, and the resulting enzyme is
catalytically more efficient (kcat /Km 1̄.5 M −1 sec−1 ) than other human USPs studied to
date. Analytical–size exclusion chromatography, analytical ultracentrifugation, and
dynamic light scattering studies suggest that the quaternary structure of USP17 is a
monomer. Steady–state kinetic studies show that USP17 efficiently hydrolyzes both
ubiquitin-AMC (kcat = 1.5 sec−1 and Km = 1.0 µM) and ubiquitin-rhodamine110
(kcat = 1.8 sec−1 and Km = 2.0 µM) substrates. Ubiquitin chain cleavage assays
reveal that USP17 efficiently cleaves di–ubiquitin chains with Lys11 , Lys33 , Lys48 and
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Lys63 linkages and tetra–ubiquitin chains with Lys11 , Lys48 and Lys63 linkages but is
inefficient in cleaving di–ubiquitin chains with Lys6 , Lys27 , or Lys29 linkages or linear
ubiquitin chains. The substrate specificity of USP17 is most similar to that of USP1,
where both USPs display higher specificity than other characterized members of the
USP family.

2.2

Introduction
Deubiquitinating enzymes (DUBs) reverse the process of ubiquitination by hy-

drolyzing ubiquitin from the protein substrate to that it is conjugated [1, 2]. Thus
far, approximately 100 human DUBs have been identified in the human genome, and
they are involved in regulating a number of cellular processes and disease states [1,2].
DUBs are classified into six families, of them, the largest family is the Ubiquitin
Specific Protease (USP) family with roughly 60 members [1, 2]. The USPs are multi–
domain enzymes that can range in size from ∼40 kDa, in the case of USP12, up to
∼400 kDa, in the case of USP34 [1]. Each USP contains a catalytic domain which
shares the highly conserved papain–like fold composed of a catalytic triad of cysteine,
histidine, and aspartate residues [1, 2]. Other domains within the USPs are often
important for protein–protein interactions and/or substrate recognition. A detailed
review of the domains and their functions has been described elsewhere [2, 20].
USP17 was originally identified as a member of the murine hematopoietic specific
genes as DUB3 [25]. Expression of USP17 within the cell is cytokine–inducible, and
is required for cell–cycle progression through the G1 − −S and G2 − −M checkpoints.
A well–characterized substrate of USP17 is the cell division cycle 25A (CDC25A)
phosphatase. In a normal cell, CDC25A is responsible for dephosphorylation of Cdk1
and activation of the Cdk1–CyclinB complex for the progression of the cell–cycle
(Figure 1.6 A) [29]. Cellular levels of CDC25A are regulated by the ubiquitin–
proteasome system through Lys48 ubiquitin chains. During the G1 −−S and G2 −−M
checkpoints, USP17 is expressed to deubiquitinate and stabilize CDC25A in order to
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promote cell–cycle progression through these checkpoints [29]. In numerous cancer
phenotypes, expression of USP17 is upregulated outside of these checkpoints which
causes an excess of stabilized CDC25A that applies stress to the cell–cycle resulting
in unregulated cancer cell proliferation (Figure 1.6 B) [27, 29, 46]. Other identified
substrates of USP17 include the Ras converting enzyme 1 (RCE1) and the histone
deacetylase dependent Sin3A co–repressor complex, SDS3, both of them also play a
role in cell–cycle regulation [28, 30, 47].
USP17 is a 58 kDa protein that has its conserved catalytic domain near the N–
terminus as well as two hyaluronan binding motifs predicted to reside within the C–
terminal region (Figure 1.5A) [25, 26]. A sequence alignment of the catalytic regions
of USP17 against three well studied USPs (USP8, USP7, and USP14) is shown in
(Figure 1.5B). As with other USPs, there are three well conserved residues (Cys89,
His334 and Asp350) that form the catalytic triad. Experimental binding studies
by Ramakrishna and coworkers have shown the two predicted hyaluronan binding
motifs bind to hyaluronan, a polysaccharide that is responsible for numerous cellular
processes, including the regulation of cell division [26]. Many USPs are predicted
to contain hyaluronan binding motifs, including the well–studied USP7, however the
interactions between the USPs and hyaluronon itself is poorly understood [48]. In
the case of USP17, the hyaluronan binding motifs have been shown to be important
for the interaction of USP17 with SDS3 [49].
McFarlane and coworkers have shown that the persistent overexpression of USP17
applies stress to the cell–cycle which results in proliferation of both breast and
prostate cancers [25, 27]. Combining this finding with the characterization of the
role of USP17 in CDC25A–driven cellular proliferation by Pereg and coworkers, together these studies strongly suggest that inhibitors of USP17 activity may serve as
anti–cancer drugs. While previous work has been able to define the role of USP17 in
celluo, without the ability to recombinatly express and purify USP17, further characterization of USP17 as well as the identification of USP17 inhibitors is severely
limited. This chapter describes a reliable and robust method for the expression and
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purification of recombinant USP17 which enables the production of highly pure and
active USP17 that is amenable to enzymatic and structural characterization as well
as inhibitor identification.

2.3

Experimental Procedures

2.3.1

Design of Expression Plasmid for USP17 from E. coli

The human gene of usp17 (GenBank: Q0WX57.2) was codon optimized for E. coli
expression, synthesized, and inserted into the pET11a expression vector by BioBasic
Inc. The coding region for USP17 was amplified using forward and reverse primers
containing complementary sequences to the expression vector, pEV–L8, a modified
pET30 vector. The primers used are listed 5’ to 3’ where the uppercase bases are
complimentary to the pEV–L8 vector and the lower case bases are complimentary to
the USP17 gene: forward primer: GAGAACCTGTACTTCCAATCCAATatggaagacgatagcctgtac, reverse primer: cgtgacgaccagacagttATTTAACCTTCACCTATTGCCTAGGCTTAAGCT. The master mix for a single 25 µL PCR reaction is summarized
in Table 2.1.

Table 2.1
PCR composition for the sub–cloning of the usp17 gene
Component

Final Concentration

Volume

1x

5 µL

10 mM dNTPs

0.2 mM

0.5 µL

50 µM Forward Primer

0.25 µM

0.125 µL

50 µM Reverse Primer

0.25 µM

0.125 µL

USP17–pET11a plasmid

50–100 ng

–

Phusion High–Fidelity DNA Polymerase

0.5 units

0.25 µL

N/A

to 25 µL

5x Phusion HF Buffer

Sigma–Water
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The PCR reaction was performed with a Bio–Rad MJ Mini Personal Thermal
Cycler with the following reaction scheme:
• Initial Denaturation: 98 ◦ C – 3 minutes
• Denaturation: 98 ◦ C – 30 seconds
• Annealing Gradient: 58–64 ◦ C – 30 seconds
• Extension: 72 ◦ C – 60 seconds
• Repeat Denaturation – Extention Steps for 30 cycles
• Completion: 72 ◦ C – 10 minutes
• Hold: 4 ◦ C
The expression vector pEV–L8 was digested with restriction enzyme SspI in a
50 µL reaction (1x Buffer G (Promega), 1 unit of SspI (Promega), and 5 µg pEV–
L8) incubated in a 37 ◦ C water bath for one hour. The PCR amplicon was then
combined in a 1:1 ratio (by concentration) with the digested the pEV–L8 vector by
ligation–independent recombinant cloning using the linearized pEV–L8 vector, and
XL1–Blue supercompetent cells. The resulting USP17 pEV–L8 expression plasmid
sequence was confirmed at the Purdue University Genomics Core Facility, and was
then transformed into E. coli BL21 (DE3) cells for protein expression.

2.3.2

Site–Directed Mutagenesis for USP17 Catalytic Mutants

The catalytic cysteine of USP17 was mutated to a serine within the pEV–L8
expression vector using the QuikChange site–directed mutagenesis protocol from
(Stratagene). The primers are as follows 5’ to 3’ where the bold text base correspond
to the mutation: forward: GGGCAATACCTCCTATGTTAACGCATCTCTGC, rev
erse:CATAGGAGGTATTGCCCATGTTCTGCAGACC.
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The catalytic cysteine to alanine mutant pEV–L8 vector was also made as described for the cysteine to serine mutant, however this construct was not utilized
within the work described in this text. The mutagenesis primers are as follows 5’ to
3’ where the bold text bases corresponds to the mutation: forward: GGGCAATAC
CGCCTATGTTAACGCATCTCTGCAATG, reverse: GTTAACATAGGCGGTA
TTGCCCATGTTCTGCAGACC. The master mix for a single 25 µL PCR reaction
is summarized in Table 2.2.

Table 2.2
PCR composition for site–directed mutagenesis of the usp17 gene
Component

Final Concentration

Volume

1x

5 µL

10 mM dNTPs

0.2 mM

0.5 µL

10 µM Forward Primer

0.5 µM

1.25 µL

10 µM Reverse Primer

0.5 µM

1.25 µL

USP17–pEV–L8 plasmid

50–100 ng

–

Phusion High–Fidelity DNA Polymerase

0.5 units

0.25 µL

N/A

to 25 µL

5x Phusion HF Buffer

Sigma–Water

The PCR reaction was performed with a Bio–Rad MJ Mini Personal Thermal
Cycler with an initial denaturation for 30 seconds at 98 ◦ C. Sixteen cycles were
completed of denaturation at 98 ◦ C for 10 seconds followed by an annealing gradient
of 60–73 ◦ C for 30 seconds and an extension at 72 ◦ C for three minutes. After the
16 cycles were complete, the reactions were held at 72 ◦ C for 60 minutes. The PCR
reactions were visualized on a 1% agarose gel, and, as all reactions produced product,
the PCR reactions were pooled, and underwent a DpnI digest to remove the original
template DNA. The DpnI digest mixture was prepared with 5 µL of 10x Tango Buffer
(Thermo Scientific), 1 µL of DpnI Restriction Enzyme (Thermo Scientific), and 44
µL of PCR Product.
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The reaction was run for 2.5 hours in a 37 ◦ C incubator. The digested sample
was transformed by electroporation into E. coli XL1–Blue cells, and streaked onto
Kanamycin plates for growth overnight at 37 ◦ C. A single colony was used from each
mutation to innoculate a 2 mL LB culture supplemented with 50 µg/mL Kanamycin.
The cultures were grown at 37 ◦ C overnight with shaking at 200 rpm in an Infors
Multitron shaker. The cells were harvested, and mini–prepped the following morning
using the Qiagen Mini–Prep Kit (Cat# 27104) to isolate the mutant plasmid. The
resulting plasmids were sequenced at the Purdue University Genomics Core Facility.

2.3.3

Design of Expression Plasmids for USP17 Truncations from E. coli

As depicted in Figure 2.1B. three truncations of USP17 were made to attempt to
improve solubility and stability. These truncations were made by ligation–independent
cloning as described for the subcloning of usp17 from pET11a into pEV–L8 described
above. The truncations and corresponding primers are displayed below. Only the
USP17 complimentary region for each primer is displayed from 5’ to 3’ within Table 2.3

Fig. 2.1. USP17 Truncations A. Schematic displaying the domains of USP17
identified thus far. B. Outlines the three truncations of USP17 that were
attempted to be expressed and purified.

The following sequence was added to the 5’ side of the forward primers, and is
complimentary to the pEV–L8 vector for homologus recombination: GAGAACCT-
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Table 2.3
Primers for Truncations of USP17
Truncation Residues

Forward Primer

Reverse Primer

A80–Q530

gcaggtctgcagaacatg

ttgacagaccagcagtgc

M1–E390

atggaagacgatagcctgtac

ttcacgaccacgcga

A80–E390

gcaggtctgcagaacatg

ttcacgaccacgcga

GTACTTCCAATCCAAT. The following sequence was added to the 3’ side of the
reverse primers, and is complimentary to the pEV–L8 vector for homologus recombination: ATTTAACCTTCACCTATTGCCTAGGCTTAAGCT. The PCR mix for a
single 50 µL reaction was composed as described in Table 2.4.

Table 2.4
PCR composition for truncations of USP17
Component

Final Concentration

Volume

1x

10 µL

10 mM dNTPs

0.2 mM

1 µL

10 µM Forward Primer

0.25 µM

1.25 µL

10 µM Reverse Primer

0.25 µM

1.25 µL

USP17–pEV–L8 plasmid

50–100 ng

–

Phusion High–Fidelity DNA Polymerase

0.5 units

0.25 µL

N/A

to 50 µL

5x Phusion HF Buffer

Sigma–Water

The PCR reaction was performed with a Bio–Rad MJ Mini Personal Thermal
Cycler with an initial denaturation at 95 ◦ C for three minutes. This initial step was
followed by 30 cycles of the following: denaturation at 95 ◦ C for 10 seconds, annealing
at 49 ◦ C for 30 seconds, and extension at 72 ◦ C for 1.5 minutes. The reaction was

27
held at 72 ◦ C to allow for completion for 10 minutes then held at 4 ◦ C until further
processing.
Each truncation PCR amplicon was then inserted into the pEV–L8 vector by
ligation–independent recombinant cloning using linearized pEV–L8 vector, digested
by restriction enzyme SspI, and XL1–Blue supercompetent cells as described above.
The resulting USP17 pEV–L8 truncation expression plasmids were sequenced at the
Purdue University Genomics Core Facility to confirm correct sequence, and was then
transformed into E. coli BL21 (DE3) cells for protein expression.

2.3.4

Design and Amplification of Expression Plasmid for USP17 for Baculovirus Expression

To express within the baculovirus expression system, usp17 (GenBank: Q0WX57.2)
was codon optimized for Spodoptera frugiperda 9 (Sf9 ) expression and synthesized by
BioBasic Inc. The gene was inserted into the pVL–1392 vector modified with a 10His
tag and a Green Fluorescent Protein (GFP) N-terminal tag by BioBasic Inc. The
vector was transformed into E. coli XL1–Blue cells, and the cells were streaked onto
LB agar containing 50 µg/mL Carbenicillin, and allowed to grow overnight at 37 ◦ C.
A single colony was used to innoculated 2 mL of LB media supplemented with 50
µg/mL Carbenicillin, then placed in an incubated Infors Multitron shaker at 37 ◦ C
shaking at 200 rpm and allowed to out grow for eight hours. Of the 2 mL culture,
25 µL of culture was then added to 25 mL of LB supplemented with 50 µg/mL of
Carbenicillin in a 250 mL flask. The flask was placed in the incubated shaker at
37 ◦ C with shaking at 200 rpm overnight. The cells were centrifuged with a Sorvall
RC 6+ ThermoScientific Centrifuge in a Fiberlite F13–14 x 50cy fixed angle rotor at
3000 x g at 4 ◦ C for 15 minutes. The expression plasmid was isolated from the cells
by gravity flow using the Qiagen Midi–Prep Kit (Cat#: 12143). The isopropanol
precipitation described in the protocol by Qiagen was performed in a chemical fume
hood for sterility.
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2.3.5

Expression, Solubilization, Refolding, and Purification of USP17
and USP17C89S from E. coli

Five liters of E. coli BL21 (DE3) cells harboring the USP17 pEV–L8 expression
vector were grown from five separate one liter cultures of LB medium supplemented
with 50 µg/mL Carbenicillin in 2 L Fernbach flasks. Shaking was performed at 37 ◦ C
and 200 rpm in an Infors Multitron shaker until an A600 ∼ 0.6 was reached. Cultures
were the cooled for 30 minutes at 4 ◦ C, and USP17 expression was induced with 1 mM
IPTG. Cultures were incubated at 25 ◦ C with shaking at 200 rpms for an additional
18 hours.
E. coli cells were harvested by centrifugation with a Sorvall RC 6+ ThermoScientific Centrifuge in a Fiberlite F9–4x1000y rotor at 3000 x g at 4 ◦ C for 20 minutes.
The E. coli cells were resuspended in lysis buffer (50 mM Tris pH 7.5, 10 mM β ME,
and 150 mM NaCl) supplemented with 50 µg/mL DNase and 200 µg/mL Lysozyme
by adding 5 mL of lysis buffer per gram of cells. To lyse, the resuspended cells were
sonicated on ice with a Branson Digital Sonifer at 60% with cycles of five second
pulses and nine seconds of rest for a total of 12 minutes. The soluble lysate was
separated from the inclusion body fraction by centriguation in the Sorvall RC 6+
ThermoScientific Centrifuge with the Fiberlite F13–14 x 50cy fixed angle rotor at
28,880 x g at 4 ◦ C for 30 minutes. The resulting supernatant was decanted from the
inclusion body pellet. The resulting inclusion body was washed 3 times by homogenization with 50 mL of lysis buffer containing 1% T ritonT M X − 100. Between each
wash, the sample was centrifuged at 28,800 x g for 10 minutes. A final wash was
performed identically with unsupplemented lysis buffer.

Refolding of USP17
The washed inclusion body was then re–solubilized in 250 mL of re–solubilization
buffer (6 M GuHCl, 50 mM CHES pH 9.5, and 10 mM βME) overnight in a sealed
Nalgene bottle with a magnetic stir bar at room temperature on a stir plate with
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rapid stirring at a rate of 600 rpm. The 250 mL of solublized inclusion body was
refolded dropwise at room temperature into 5 L of refolding buffer (50 mM CHES pH
9.5, 10 mM βME, 0.7 M GuHCl, and 5% Glycerol) in a Nalgene bottle stirring on a
magnetic stir plate at 600 rpms. Once all the protein had been refolded, the bottle
was sealed, and the sample was incubated for 30 minutes stirring at 600 rpms. The
refolded protein was then concentrated to 1 mg/mL in a volume of ≤ 500 mL using
the Millipore Prep/Scale-Tangential Flow Filter concentrating system with a 1.5 L,
10,000 MWCO cartridge. The concentrated protein was centrifuged at 28,880 x g at
4 ◦ C for 30 minutes, and filtered through a 0.45 µm filter to remove precipitant.

Nickel Affinity Chromatography
A 5 mL HisTrap Ni–NTA (GE Healthcare) chromatography column was equilibrated with Buffer A (50 mM CHES pH 9.5, 10 mM βME, 0.7 M GuHCl, 20 mM
Imidizole, and 5% Glycerol). The filtered–refolded protein was then loaded onto
the equilibrated HisTrap Ni–NTA column overnight at 4 ◦ C with a flow rate of 0.5
mL/min.Unbound proteins were washed from the column using 15 column volumes
of Buffer A that was applied at a flow rate of 2 mL/min.Bound proteins were eluted
from the column using a 20 column volume gradient of 0-100% Buffer B (50 mM
CHES pH 9.5, 10 mM βME, 0.7 M GuHCl, 450 mM Imidizole, and 5% Glycerol) that
was applied at a flow rate of 2 mL/min. Fractions of five milliliters were collected
throughout the gradient. The concentration of the protein in fractions was measured
using the Microassay Bio-Rad Bradford Protein Assay. Peak fractions 6–14 containing USP17, as determined by SDS–PAGE (Figure 2.2A.) and specific activity, were
pooled.

Gel–Filtration Chromatography
The pooled Nickel Affinity sample was concentrated to 7 mg/mL in a volume
of ≤ 10 mL using ultrafiltration with a 30,000 Da MWCO membrane (Millipore).
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The concentrated sample was injected onto a 300 mL Superdex 75 (GE Healthcare)
SEC column equilibrated with Size Exclusion Buffer (50 mM CHES pH 9.5, 10 mM
βME, 0.7 M GuHCL, and 5% Glycerol). The column was run at 1 mL/min and 5 mL
fractions were collected continuously throughout. Peak fractions 15 and 16 containing
USP17, as confirmed by SDS–PAGE (Figure 2.2B) and specific activity, were pooled,
flash–frozen in liquid nitrogen, and stored at -80 ◦ C until further use. Approximately
4.2 mg of pure protein can be obtained from one liter cell culture. A summary of the
percent enzyme yield, total activity, and fold–purification after each chromatography
step is summarized in Table 2.5. The catalytic mutant, USP17C89S, was purified
from 1 L of culture identically (Figure 2.3) except the activity assays were omitted
since the enzyme was inactive.

Table 2.5
Purification summary of USP17 from 5 L culture of E. coli BL21-DE3
Protein

Total Activity

Specific Activity

Fold

(mg)

Units

(Units/mg)

Purification

Soluble Lysate

870

5.37

0.006

N/A

N/A

Refolded Protein

494

14.01

0.028

1

100

Nickel Pool

72

3.84

0.123

4

13

Superdex 75

21

3.12

0.147

5

10.5

Sample

2.3.6

% Yield

Expression and Refolding Tests for Truncactions of USP17 from E.
coli

For each construct, a 2 mL LB culture supplemented with 50 µg/mL Kanamycin
was grown overnight at 37 ◦ C with shaking at 200 rpm in an Infors Multitron shaker.
The next morning, 125 µL of each culture was used to innoculate a 5 mL LB culture
supplemented with 50 µg/mL Kanamycin. Each culture was incubated at 37 ◦ C with
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Fig. 2.2. Purification of USP17. A. Left–Elution profile from Hi–Trap
(GE Healthcare) column charged with Nickel Sulfate. Right–12.5% SDS–PAGE
analysis of the eluted fractions, of which fractions 6–14 were pooled. Red arrow
indicates expected size of USP17. Molecular weight marker sizes as indicated.
B. Left–Elution profile from Superdex 75 column. Right– 12.5% SDS–PAGE
analysis of eluted fractions, of which fractions 15 and 16 were pooled. C. A
summary 12.5% SDS–PAGE analysis of each step of the purification of USP17.
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Fig. 2.3. Purification of USP17C89S. A. A summary 12.5% SDS–PAGE
analysis of each step of the purification of USP17C89S.

200 rpm shaking until the A600 reached 0.6 at that time 1 mM IPTG was added to
the culture to induce USP17 truncation expression. Three time points for expression
of each truncation was tested: 4, 6, and 18 hours all at 25 ◦ C with shaking at 200
rpm. The temperature and shaking speed was held identical to that of the full–length
enzyme. Samples were lysed by OTG detergent, as described below, and analyzed by
SDS–PAGE. Regardless of the time allowed for expression, large quantities of USP17
was clearly visible in the inclusion body indicating that even the truncations were
still insoluble when expressed within E. coli. Refolding attempts were made with the
catalytic truncation, residues A80–E390, identically to wild–type USP17 described
above, however the protein precipitated upon refolding. No further attempts were
made to refold the other truncations.
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2.3.7

Expression and Purification of USP17 from the Baculovirus Expression System

Many full–length USPs are successfully expressed from the Baculovirus Expression System (BES) to optimize for solubility and properly folded enzymes. The BES
used for the expression of USP17 was the BD BaculoGold system [50]. This system
utilizes the Autographa californica nuclear polyhedrosis virus (AcNPV) for the recombinant expression of USP17. The usp17 gene encoded in the modified pVL1392
vector (described above) was introduced into the AcNPV vector through homologous
recombination and replaces the viral gene for polyhedrin, a gene not essential for the
tissue culture lifecycle of the virus [50]. The recombination event requires the co–
transfection of linearized AcNPV DNA and the usp17 –pVL1392 into the Spodoptera
frugiperda, (Sf9) insect cells. In general, recombinant proteins produced within this
system can range between 0.1 – 50% of the total insect cell proteins produced [50].
The materials utilized for the recombinant expression of USP17 within BES are described within Table 2.6.

Maintaining Sf9 Cells
Sf9 cells were maintained in suspension in 250 mL flasks with 20 mL aliquots at
a density ranging between 80–350 x 104 cells/mL at 28 ◦ C with shaking at 90 rpm.
Once cells reached the middle of the log phase of their growth, a density of 250–350
x 104 cells/mL, they are split to a density of 80–100 x 104 cells/mL in supplemented
media (Sf9 –II SFM (1x), 5% FBS, and 1x Antibiotic–Antimycotic). Once the cell
passage number reached 50, cells were disposed of and a new passage was thawed.
Viability of cultured cells was analyzed every two days by hemocytometer.
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Table 2.6
Baculovirus Expression System Materials
Material

Vendor

Catalog Number

BD BioSciences

Discontinued

Synthesized by BioBasic

N/A

SF9– II SFM (1x) Media

Life Technologies

10902–088

100x Antibioitic–Antimycotic

Life Technologies

15240–062

Fetal Bovine Serum (FBS)

Life Technologies

16140–071

Cellfectin II Reagent

Life Technologies

10362–100

Sf9

Gibco–Invitrogen

11496–015

Sigma–Aldrich

658170

Thermo Scientific

178883

Falcon

353646

Linearized Baculovirus DNA
USP17–pVL–1392

5 Cellstar Greiner
T175 Flasks Nunclon Delta Surface
Falcon Multiwell 6–Well

Freezing Sf9 Cells
Sf9 cells to be frozen were grown to a density of 2–3 x 106 cells/mL and centrifuged
at 500 x g for five minutes at room temperature in a 50 mL Falcon Tube. The media
was aspirated, and the cells were resuspended in supplemented media to a density of
1 x 107 cells/mL. Resuspended cells were aliquoted in 1 mL volumes into cryogenic
vials. The vials were pre–labeled with the date, cell–line, and passage number. The
vials were placed into a cryosafe cooler filled with isopropanoyl and stored at –80 ◦ C
overnight. The next morning the cells were transferred to a liquid nitrogen cell dewer
in the vapor phase (not submerged in liquid nitrogen).

Thawing Sf9 Cells
Sf9 cells were removed from the vapor phase of the liquid nitrogen cell dewer and
were rapidly thawed in a water bath at 37 ◦ C for two minutes. Thawed cells were
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then gently transferred to 30 mL of freshly prepared room temperature, supplemented
media. Cells were centrifuged at 1000 x g for five minutes and the media was aspirated.
Cells were resuspended in 20 mL of fresh supplemented media and grown in suspension
a 250 mL flask.

Transfection, Homologus recombination of AcNPV Baculovirus DNA with
usp17, and P1 Virus Production
A six–well plate was seeded to 70–80% confluency with Sf9 cells, ∼ 2.6 106 cells
per well and were allowed to adhere for five minutes at room temperature. The
media was aspirated and 1 mL of unsupplemented Sf9 –II SFM (1x) media was added
to each well. The cells were incubated for one hour at 28 ◦ C. During the incubation
period, the mixtures displayed in Table 2.7 were made for USP17, but also for any
control vectors (i.e. Empty Vector pVL1392 and USP7–pVL1392) were prepared as
follows. Mix A was prepared in a 1 mL eppendorf tube as described in Table 2.7
and incubated for 30 minutes. Twenty minutes into Mix A’s incubation, Mix B was
prepared as described in Table 2.7. Mix B was allowed to incubate for five minutes
before 100 µL of unsupplemented media was added, and mixed by pipetting up and
down once, SLOWLY. Mix A was then added to Mix B, and mixed by slowly swirling.
The combined mixture was allowed to incubate for 30 minutes. After the one hour
incubation period the cells were evaluated, and the wells with the best confluency were
chosen for transfection. The cells were transfected by adding the mixture drop–wise
to the appropriate wells. The plate was swirled to combine and allowed to incubate
at 28 ◦ C for four hours. The cells were then evaluated to confirm they were still
fixed to the plate and alive. At that time the media was aspirated, and 2 mL of
fresh supplemented media was added to each transfected well. The cells were then
incubated at 28 ◦ C for 5 days to grow a P1 virus stock.
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Table 2.7
Baculovirus Transfection Mixes
Mix A

Mix B

8 µL Cell–fectin

1.5 µL USP17–pEV–L8 Vector (1–2 ng/µL)

100 µL Sf9 –II SFM (1x) Media

1.5 µL Linearized Baculovirus DNA

– Gently mix by pipetting

–Stir with pipette to mix

P2 Virus Production
Two T75 flask per P1 viral stock generated was seeded with 5 mL of Sf9 cells
at a density of 2–3 x 106 cells/mL and were allowed to incubate for five minutes at
room temperature within the fume hood. The flasks were then evaluated for 70–80%
confluency and were placed at 28 ◦ C for at least one hour to allow the cells to adhere.
In the case of successful homologous recombination for both usp17 and the empty
vector control P1 viral stocks can be evaluated for fluoresence of the GFP tag. If
weak fluorescence was observed the P1 viral stocks were harvested. After the one
hour incubation cell attachment was confirmed, and the media was aspirated. The
P1 viral stock of USP17 was added drop–wise to one flask while the empty vector
control P1 stock was added drop–wise to the other. The flasks incubated for one
hour at 28 ◦ C with gentle rocking back and forth every 20 minutes to ensure even
coverage of the cells with virus. After the one hour incubation was complete, 10 mL
of supplemented media was added to the flask and the flasks were placed at 28 ◦ C for
two days.

P3 Virus Production
The T75 flasks were evaluated for fluorescence of GFP to confirm successful P2
viral production. If P2 virus could be detected, the media was harvested containing
the P2 viral stock. Two T175 flasks were seeded with 15 mL of Sf9 cells at a density
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of 2–3 x 106 cells/mL with an additional 5 mL of supplemented media. Again, one
flask was for usp17 and the other for the empty vector control. The cells were allowed
to incubate for five minutes, and 70–80% confluency was confirmed. The cells were
then stored at 28 ◦ C for one hour to allow them to adhere. After the incubation,
the media was aspirated from the flasks and 2 mL of the P2 viral stocks was added
drop–wise to each the flask accordingly. The flasks were stored at 28 ◦ C for one hour,
rocking every 20 minutes to ensure even coverage of the cells with virus. After one
hour, an additional 20 mL of supplemented media was gently added to each flask,
and the flasks were placed at 28 ◦ C for three days.

USP17 Protein Expression from Sf9 cells
The T175 flasks were evaluated for fluoresence of GFP to confirm successful P2
viral production after 3 days of expression. If fluoresence levels were low, cells would
be incubated for additional time up to five days total from the initial infection day.
The P3 virus was harvested, and stored in a 50 mL Falcon tube, parafilmed, at 4 ◦ C
for up to six months. At least two days prior to protein expression, the cells were split
to a density of 1–2 x 106 cells/mL in a volume of 200 mL in a 2 L Fernbach flask. The
day before expression the density of the cells was evaluated, and the cells were again
split to 1–2 x 106 cells/mL in 200 mL in 2 Fernbach flasks, one for USP17 expression
and one for empty vector expression (i.e. GFP only). The morning of expression,
the density of the cells was again evaluated to confirm the cells were at a density of
2.5–3.5 x 106 cells/mL. If the density was low, the cells were allowed to grow for an
additional day to ensure the proper density at time of infection. To infect 200 mL of
cells at a density of 2.5–3.5 x 106 cells/mL for protein expression, 8 mL of P3 viral
stock was added. The flasks were allowed to shake a 90 rpm at 28 ◦ C for three days.
The cells were harvested by centrifugation in a Sorvall RC 6+ ThermoScientific
Centrifuge with a Fiberlite F9–4x1000y rotor at 3000 x g for 20 minutes at 4 ◦ C. The
cells were re–suspended in a buffer containing 500 mM NaCl, 10 mM Imidizole, 10
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mM βME, and 20 mM Tris pH 7.5 and lysed by sonication with a Branson Digital
Sonifer at 50% with pulsing of five seconds on and five seconds off for a total of four
minutes. The lysate was clarified by centrifugation with a Beckman Coulter Avanti
J–30I centrifuge in the JA–17 rotor at 80,000 x g for one hour at 4 ◦ C. The clarified
lysate was initially analyzed for USP17 expression via SDS–PAGE and fluorescence
imaging (Figure 2.4). The resulting SDS–PAGE gel was placed on an UV lightbox
to observe the GFP tag. The gel was then stained with Coomassie Brilliant blue
for visualization of all the protein bands. The presence of multiple bands in the
SDS–PAGE imaged by UV indicates that USP17 is actively degraded by proteases
within the Sf9 cells. As significant degradation and low yields of expression (≤ 0.5
mg/ 200mL culture) of USP17 within this system was observed, this method was not
further pursued for large scale recombinant USP17 production.

Fig. 2.4. Purification of USP17 from Baculovirus Expression System.
Left–SDS–PAGE evaluation of the Sf9 cell lysate of USP17 expression from the
Baculovirus Expression System. Right–SDS–PAGE evaluation by UV imaging
of the Sf9 cell lysate of USP17 expression from the Baculovirus Expression
System.
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2.3.8

Measuring Protein Concentration

Microassay Bio–Rad Bradford Protein Assay
This assay was used throughout purifications to estimate the total protein concentration in the sample. The coomassie dye was prepared by diluting the Bio–Rad
5 x concentrate to 1x with nanopure water. A standard curve was prepared using
Bio–Rad BSA powder that had been diluted to a stock concentration of 1.36 mg/mL
in nanopure water. This stock was then diluted to a working stock of 0.5 mg/mL in
the same purification buffer the protein sample to be measured was currently residing. This dilution was made with 18.4 µL of the BSA stock diluted into 31.6 µL of
purification buffer. A standard curve of 0, 0.125, 0.25, 0.375, and 0.5, mg/mL was
built by pipetting the following volumes of the working stock of BSA into a 96–well
clear, flat–bottom microtiter plate: 0, 2.5, 5.0, 7.5, and 10 µL, respectively. The
protein samples were added to the plate in a volume of 1, 5, or 10 µL depending
on how concentrated the sample to allow the staining to fall within the standard
curve. To each well 200 µL of the 1x Bio–Rad coomassie dye was added to each well
containing protein or the BSA standard curve. Using a microplate mixer, the plate
was mixed thoroughly for 30 seconds, and any bubbles within the wells were popped.
Using the BioTek H1 Synergy plate reader, the absorbance of each well was read at a
λ of 595nm. The absorbance of the BSA standard curve was plotted in terms of the
corresponding concentration and fit using linear regression. The resulting standard
curve was then used to estimate the protein concentration in the protein samples.

A280 Determination of Protein Concentration
To obtain a more accurate measurement of pure protein the concentration was
measured using absorbance, rather than the Microassay Bio–Rad Bradford Protein
Assay. The A280 of pure samples was measured using the Take3 microplate in 2 µL
volumes with a pathlength of 0.05 cm. The protein concentration was determined
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using the Beer–Lambert equation with the experimentally determined extinction coefficient for that sample.

2.3.9

Determination of the Extinction Coefficient for USP17

The concentration of purified USP17 and USP17C89S was determined using the
Microassay Bio-Rad Bradford Protein Assay. Each protein was diluted to 1 mg/mL
in both Size Exclusion Buffer (native state) and 6 M GuHCl (denatured state). The
extinction coefficient for purified USP17 was experimentally determined as described
by von Hippel et al [51]. The Take 3 microplate was used to measure the A280 for the
protein diluted in buffer and GuHCl, each in triplicate, with the BioTek H1 Synergy.
The background absorbance was subtracted from the measured absorbance for the
protein sample. Using the Beer–Lambert equation, the molar extinction coefficients
were determined for both the native and denatured proteins. The true molar extinction coefficient was then determined by dividing the native molar extinction coefficient
by the denatured molar extinction coefficient, and multiplying by the computationally estimated molar extinction coefficient calculated from the primary sequence of
the protein using Expacy’s Protparam tool [52]. The molar extinction coefficient of
USP17 was calculated as 58,104 M −1 cm−1 and 58,338 M −1 cm−1 for USP17C89S as
described by von Hippel et al [51].

2.3.10

SDS–PAGE Analysis

Protein sample concentration was measured by a Microassay Bio–Rad Bradford
Protein Assay. SDS–PAGE samples were prepared by mixing 5–10 µg of protein
sample with 4 µL of 5x SDS Sample Loading Buffer (0.2 M Tris–HCl pH 6.8, 10%
SDS, 10% glycerol, 0.02% Bromophenolblue, and 5 mM βME). Samples were heated
at 95 ◦ C for 2 minutes immediately prior to loading into the SDS–PAGE gel. Gels
were run at 200 volts for 40 minutes. USP17 analyzed by 10% or 12.5% SDS–PAGE
gel depending on the purpose.
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2.3.11

OTG Lysis for Protein Expression Analysis

For each sample to be tested, 1.5 mL of the culture was micro–centrifuged in an
eppendorf tube for 5 minutes at 13,500 x g at 4 ◦ C. The supernatant was decanted
and the cell pellet was re–suspended in 175 µL of OTG buffer (1% Octylthioglucoside (OTG) and 10 mM Tris pH 7.5). To the re–suspended sample, 0.01 mg/mL
of DNAseI was added and gently vortexed to mix. The sample was centrifuged as
described previously. The supernatant, corresponding to the soluble lysate, was removed, and stored on ice. The remaining pellet was re–suspended in 200 µL of OTG
buffer supplemented with 5 µL of 10 mg/mL Lysozyme and vortexed for one minute.
To the sample, 800 µL of of nanopure water was added the sample was vortexed
again followed by centrifugation as described previously. The resulting supernatant
was decanted and the pellet was washed with 1 mL of nanopure water and pelleted
again. This was repeated once more to ensure the sample contains no lysozyme. The
resulting sample is the inclusion body, or insoluble lysate, and was re–solubilized in
6 M GuHCl. The soluble and insoluble lysates were analyzed by SDS–PAGE.

2.3.12

Kinetic Assays of USP17

Specific Activity Assays
The specific activity was measured throughout each USP17 purification using
the fluorogenic synthetic substrate ubiquitin–rhodamine 110 (Ub–Rho110, Boston
Biochem). Ub–Rho110 is internally quenched when the rhodamine 110 molecule is
conjugated to the ubiquitin moiety through a peptide bond. Upon cleavage of the
peptide bond the quenching is released, and fluorescence from the rhodamine 110 is
emitted. This substrate works as a generic substrate for many USP enzymes (Figure 2.5). The Ub–Rho110 is provided from Boston Biochem at a stock concentration
of 250 µM in 100% DMSO which is normalized to 1 µM in Substrate Buffer (50 mM
Tris pH 7.5, 1 mM EDTA, 100 mM NaCl, and 0.05% CHAPS) and diluted into each
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assay at a final concentration of 500 nM. The protein concentration was measured by
the Microassay Bio–Rad Bradford Protein Assay and was normalized in Assay Buffer
(50 mM Tris pH 7.5, 0.1 mg/mL BSA, 5 mM DTT, and 0.01% T ritonX T M − 100) to
a working concentration of 10 nM. The final concentration of protein in each activity
analysis was 5 nM. First, 15 µL of the working concentration of Ub–Rho110 (1 µM)
was added to a Costar 96 half–volume black plate, and the background fluorescence
was read as a filter based assay using a BioTeK Synergy H1 plate reader every 10
seconds at an excitation λ of 485 nm and emission λ of 528 nm for two minutes.
Following the background read, 15 µL of protein was added to the plate, the plate
was mixed for 10 seconds and the assay was read under the same conditions for 30
minutes total or until the reactions started to plateau.

Fig. 2.5. Fluorogenic Kinetic Assay for USPs. The fluorogenic substrate
Ub–Rho (as well as Ub–AMC, not shown) is composed of a ubiquitin molecule
conjugated through a peptide bond to a Di–glycl Rhodamine 110 molecule.
Many USPs are able to cleave the peptide bond similarly to what is described
in Figure 1.4. Once the peptide bond between the ubiquitin and rhodamine
molecules is broken fluoresence is emitted and is measured.

Determination of the Extinction Coefficient of the Substrate
The extinction coefficient of Ub–Rho110 was determined anew each day of the purification. To determine the extinction coefficient, five serial dilutions of Ub–Rho110
were made to the working concentrations of 0.03 µM to 1 µM. First, 15 µL of each
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dilution of Ub–Rho110 was added to the plate. Second, 15 µL of a highly concentrated USP stock was added the plate and mixed. The plate was read identically to
that of the specific activity assays. The reactions were allowed to plateau and the
maximum artificial fluorescence units (AFU) was measured. The resulting maximum
AFU values were plotted in terms of the corresponding concentration of Ub–Rho110.
The plot was fit using linear regression and the resulting slope corresponds to the
extinction coefficient in units of AFUs per concentration of Ub–Rho110 (AFU/µM).

Specific Activity Analysis
The initial slope of each specific activity reaction in units of fluorescence per
unit time (AFU/min) was converted to the amount of product produced per unit
time (µM/min) with the determined extinction coefficient of the substrate. Units, as
defined by µmol/min, were obtained for each sample by dividing by the total assay
volume. The specific activity of the sample, Units/mg of enzyme, was determined by
dividing by the milligrams of protein present in the assay. The fractional recovery of
activity was determined by dividing the total units of the sample by the total units
of the refolded protein then multiplying by 100 to obtain a percentage. The fold in
purification after each chromatography step was determined by dividing the specific
activity of each sample by the specific activity of the refolded protein.

Steady–State Kinetic Assays
A fluorogenic activity assay for USP17 was developed in a 96–well, black half–
volume plate (Corning Costar) to evaluated the kinetics of the deubiquitinating activity of USP17. Two substrates were used, ubiquitin 7–amino–4–methylcoumarin
(Ub-AMC, LifeSensors) and Ub–Rho110. Assays were performed in 30 µL reaction
volumes and in triplicate. Enzymatic reactions were initiated by the addition of 15
µLof enzyme followed by brief shaking (10 seconds) using the plate reader shaker. The
rate of hydrolysis was analyzed at 10 second intervals over a time period of 30 minutes
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using a BioTeK Synergy H1 plate reader equilibrated at 25 ◦ C. Both substrates were
measured as a filter based assay. The Ub–Rho110 was measured at the wavelengths
described previously, while Ub–AMC was measured at an excitation λ of 360 nm and
emission λ of 460 nm. Background fluorescence was measured first by pipetting 15 µL
of the serially diluted substrate into the plate and at the appropriate wavelengths for
2 minutes total as described previously. Following the background read, 15 µL of the
working stock of USP17 was added to the plate, the plate was mixed for 10 seconds,
and the assay was read under the same conditions for 30 minutes total, or until the
reactions plateaued. The rate of hydrolysis was analyzed in 10 second intervals for
30 minutes using the BioTeK Synergy H1 plate reader equilibrated at 25 ◦ C. The
initial slope of each reaction in Arbitrary Fluorescence Units (AFU) per unit time
(AFU/min). These values were then converted to the amount of product produced
per unit time (µM/min) using the fluorescence extinction coefficient of the product
(either released AMC or Rho110). The extinction coefficient of both substrates was
determined as described previously described for Ub–Rho110 in Section 2.3.12.
To determine the Km and the kcat values of USP17, the enzyme concentration
was held constant at 3.125 nM and the substrate concentrations (Ub–AMC or Ub–
Rho110) were varied from 0.01 µM to 10 µM. The enzyme was diluted in Assay
Buffer, and the substrates were diluted in Substrate Buffer. The resulting rate values
in µM/min were then converted into turnover number in units of sec−1 by dividing the rates by the enzyme concentration (V/[E]). These apparent turnover values
were then plotted as a function of substrate concentration, and the data were fit to
the Michealis–Menten equation (Equation (2.1)) using non–linear regression and the
Enzyme Kinetics Module in the program SigmaPlot (v12: Systat Software Inc.).

v=

Vmax [S]
Km + [S]

(2.1)
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2.3.13

Evaluation of USP17 Stability

Aliquots of purified enzyme at a concentration of 1.26 mg/mL were incubated at 4
◦

C, 25 ◦ C, or 37 ◦ C for 1 to 3 days. At each time point, the sample was centrifuged at

13,500 x g for five minutes and the protein concentration was measured by A280 using
the determined extinction coefficient of USP17 (Section 2.3.9). The specific activity
of the samples was determined as described above except with a final concentration
of enzyme of 6.25 nM of the enzyme and 0.5 µM of the Ub–Rho110. The percent
remaining activity was determined at the same enzyme and substrate concentration
by calculating V/[E] as described in Section 2.3.12, and calculating a percentage from
the day 0 V/[E] measurement.

2.3.14

Analytical Size Exclusion Chromatography

The proteins ferritin, aldolase, conalbumin, and ovalbumin from GE Healthcare
HMW calibration kit (Cat# 28–4038–42) was diluted to 3 mg/mL in Analytical
Buffer(50 mM HEPES pH 7.5, 700 mM GuHCl, and 2 mM Tris(2–carboxyethyl)
phosphine (TCEP)), with the exception of ferritin which was diluted to 0.3 mg/mL.
BSA was diluted to 1.23 mg/mL. The proteins were combined into three separate
injections to optimize for resolution: aldolase and ovalbumin, conalbumin and ferritin,
and BSA. Each set of proteins was injected onto a 24 mL Superdex 200 Increase
10/300 (GE Healthcare) 24 mL (Vt ) analytical size exclusion chromatography (SEC)
column using an isocratic gradient at 4 ◦ C and a flow rate of 0.5 mL per minute.
For each protein the elution volume (Ve ) was measured. A dextran sample (included
with the GE Healthcare HMW kit) was injected at 1 mg/mL to determine the void
volume (Vo ) of the column under these conditions. The average distribution coefficient
(Kaverage ) [53] for each protein was determined by

Kaverage =

(Ve − Vo )
(Vt − Vo )

(2.2)
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A standard curve of log(Mr ) vs Kaverage was plotted and fit using linear regression,

Kaverage = −0.2641(Mr ) + 1.641

(2.3)

An aliquot of 500 µL of USP17 at a concentration of 1.26 mg/mL in Analytical Buffer was injected onto the same column. The Kaverage was calculated with
Equation (2.2) and molecular weight was determined with Equation (2.3).

2.3.15

Analytical Ultracentrifugation

Analytical Ultracentrifugation was performed with the assistance of the Purdue
Biophysical Analysis Laboratory. To determine the oligomeric state of USP17, sedimentation velocity experiments were performed at 25 ◦ C on the Beckman–Coulter
XLA ultracentrifuge using 5.6 µM (0.4 mg/mL) USP17 in Analytical Buffer. The
sample was run in an AN–60 Ti rotor at 50,000 rpm. Absorbance optics at 280
nm was utilized for protein detection. Solvent density, viscosity, and partial specific
volumes were calculated using SEDNTERP. SEDPHAT was used to fit the data to
estimate the sedimentation coefficient (s) to be 2.955 ± 0.002 which corresponds to
a molecular weight estimate of 65.2 kDa.

2.3.16

Dynamic Light Scattering

Three milligrams of thawed USP17 was concentrated to ≤ 500 µL using ultrafiltration with a 10,000 MWCO membrane (Millipore) and was then injected onto a 24
mL Superose 6 Increase (GE Healthcare) SEC column equilibrated with Analytical
Buffer. The column was run at a flow rate of 1 mL/min throughout. The eluted peak
was collected as one fraction and analyzed by SDS–PAGE and the specific activity
was determined. The fraction was then concentrated to above 1 mL and diluted to
three concentrations, 0.5, 0.75, and 1 mg/mL, in Analytical Buffer. Dynamic light
scattering (DLS) was performed for each USP17 concentration using a Malvern Zetasizer Nano S with a HeNe laser at 633 nm. The three concentrations of USP17
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were measured at a fixed scattering angle of 173◦ (back scatter) in 100 µL aliquots
at a constant temperature of either 4 ◦ C or 25 ◦ C. Size analysis was performed by
number distribution curves, and were utilized to determine the molecular weight and
oligomeric state using the Malvern DTS Software. The number size distribution represents the number of particles in the different size bins as determined by the Malvern
DTS Software.

2.3.17

Evaluation of pH on the Activity of USP17

The effect of pH on the activity of USP17 was tested from pH 6.0 to 10.5 in half–
step increments using a wide pH range buffer system (75 mM Tris, 25 mM Acetic
Acid, 25 mM MES, 25 mM Glycine, 0.1 mg/mL BSA, 0.01% T ritonT M X −100, and 5
mM DTT) at each pH tested [17]. USP17 was diluted to a final concentration of 6.25
nM and Ub–Rho110 was diluted in the same buffer at each pH to two concentrations
(0.5 µM and 5 µM) that are below and above the Km value. Enzymatic activity was
measured in triplicate as previously described (Section 2.3.12). The resulting data
were fit to a bell–shaped profile representing two ionizations, pKa and pKb , with the
kinetics module of SigmaPlot (v13: Systat Software Inc.).

2.3.18

Ubiquitin Chain Processing Assay

The substrate specificity of USP17 was tested against the di–ubiquitin chains of
the eight linkage types (Lys6 , Lys11 , Lys27 , Lys29 , Lys33 , Lys48 , Lys63 , and linear
(Boston Biochem)), as well as Lys48 , Lys63 tetra–ubiquitin chains (LifeSensors), and
Lys11 tetra–ubiquitin chains (Boston Biochem). For reactions containing USP17
a concentration of 40 nM was used. Each di–ubiquitin reaction contained 4 µM
of the ubiquitin chain, and was incubated with or without enzyme at 25 ◦ C for
120 minutes. The tetra–ubiquitin reactions contained 2 µM of the ubiquitin chains,
and were incubated with or without enzyme for a range of times from 10 to 120
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minutes at 25 ◦ C. Reactions were analyzed by NuPAGE Novex 4-12% Bis-Tris mini
gels (Invitrogen) stained with Coomassie Brilliant Blue.

2.4

Results
The methodology for the expression and purification of recombinant USPs is di-

verse. A number of expression constructs and expression methods have been used to
produce recombinant USPs, and a summary of these approaches is provided in Table 2.8. While there are a few USPs (i.e. USP12 and USP16) that can be expressed
and purified from E. coli as full–length constructs, many USPs are insoluble when
expressed from E. coli [11, 54]. An alternative approach for the expression of full–
length USPs has been to utilize the labor–intensive baculovirus expression system
(BES) which has successfully produced full–length USP1, USP2, and USP7 proteins
[11, 17, 54]. However, the most common approach for producing recombinant USPs
is to truncate the USP of interest into its individual domains in order to obtain high
yields of soluble protein within E. coli. With this approach, high priority is placed on
the catalytic domain, as demonstrated for the well–characterized USP7, USP8, and
USP14 catalytic domain constructs [11, 16, 18–20, 54]. However, it is often found that
the enzymatic activity of the catalytic domain is significantly differs from that of the
full–length enzyme, making production of full–length USPs a necessity for advanced
studies. We therefore pursued approaches for the production of full–length USP17.

2.4.1

High yields of USP17 can be obtained by refolding from bacterial
inclusion bodies

USP17 with a N–terminal 6His tag was expressed and purified from E. coli inclusion bodies. The expression and refolding procedure involved washing the resulting
inclusion bodies with 1% T ritonT M X − 100 by homogenization, and then solubilizing
the protein using 6 M GuHCl. Refolding of active USP17 was achieved by rapid dilution of the protein into a refolding buffer containing only 0.7 M GuHCl. Purification
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Table 2.8
USP Expression Systems
Construct

Expression System

Reference

U SP 1

Full–Length

BES

Villami et al. [17]

U SP 7

Full–Length

BES

Faesen et al. [20]

U SP 7CD

Catalytic Domain

E. coli

Faesen et al. [20]

U SP 8CD

Catalytic Domain

E. coli

Avvakumov et al. [18]

U SP 11

Full–Length

E. coli

Faesen et al. [11]

U SP 12

Full–Length

BES

Luna–Vargas et al. [54]

U SP 14

Catalytic Domain

E. coli

Hu et al. [16]

U SP 16

Full–Length

E. coli

Luna–Vargas et al. [54]

U SP 17

Full–Length

Refolded

This work

of the active, refolded USP17 was achieved in two steps including nickel–metal–chelate
affinity chromatography followed by SEC. From 5 L of E. coli culture, approximately
21 mg of USP17 can be obtained and the enzyme is >95% pure as judged by SDSPAGE (Figure 2.2). From SDS-PAGE analysis, USP17 has an estimated weight of
60 kDa, that is close to the expected size of USP17 with a 6His tag (∼62 kDa). The
specific activity and yield of USP17 was measured at each step during the purification, and the results are summarized in Table 2.5. The activity measurements are
normalized to the refolding step, the first step where fully active enzyme is present.
The resulting calculated yield of USP17 was 10.5%, and the overall improvement in
purification was 5–fold.

2.4.2

USP17 degradation during expression

During the development of the USP17 purification procedure, it was evident from
SDS–PAGE analyses and confirmed by western blot with an antibody towards the
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6His tag that USP17 is prone to some truncation. These truncations are either the
result of self–degradation or USP17 or the susceptibility of USP17 to protease degradation during expression (Figure 2.2A). While a high yield of the full–length enzyme
can be purified in high yield away from the truncations by the refolding method described above (Figure 2.2A), three different expression methods were attempted to
identify the cause and reduce the amount of degradation observed. First, USP17 was
expressed with a N–terminal 10His–GFP tag by baculovirus infection of Sf9 cells. The
yield of USP17 from Sf9 cells was significantly less than what can be obtained by refolding, and degradation was still apparent as observed with a GFP–tagged version of
USP17 in Figure 2.4, lane 2. Second, we expressed, refolded from inclusion body, and
purified a catalytic mutant of USP17, USP17C89S Figure 2.3, to evaluate if the degradation is autocatalytic or the result of proteases within the cell during expression.
During the purification of USP17C89S the degradation pattern of USP17 was again
observed Figure 2.3 indicating that USP17 is susceptible to protease degradation during expression. This conclusion is further supported by the absence of truncations
appearing after the purification is complete, suggesting purified full–length USP17
is stable and not prone to self–degradation. Third, attempts were made to truncate
USP17 to improve solubility and prevent degradation Figure 1.5, a technique utilized
by many other USPs as summarized in Table 2.8. However none of the USP17 truncations were soluble or able to refold in a stable form from E. coli inclusion bodies.
In summary, the refolding and purification methodology described in Section 2.4.1 is
the best procedure for obtaining high yields of recombinant full–length USP17.

2.4.3

Important Refolding Buffer and Purification Observations

Three significant observations were made regarding the stability of USP17 during the optimization of the refolding and purification of USP17 from inclusion body.
First, during the optimization of the refolding buffer, it was found that if the GuHCl
concentration was reduced to < 0.7 M USP17 precipitated immediately upon rapid
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dilution. Second, while USP17 can actively refold at a pH of 7.5, significantly more
precipitant is observed than when USP17 is refolded at pH 9.5. Finally, to obtain a
high yield of pure full–length USP17, 5% glycerol is required in the refolding buffer,
and all subsequent purification buffers to aid in stabilization. Without the glycerol
present, USP17 would precipitate throughout the purification, specifically when concentrated for SEC. Furthermore, the glycerol acts as a cryo–protectant when USP17
is flash frozen in liquid nitrogen and stored at -80 ◦ C.

2.4.4

Refolded USP17 is unstable at temperatures ≥ 25 ◦ C

The stability of USP17 at different temperatures was tested by incubating USP17
at 4 ◦ C, 25 ◦ C, or 37 ◦ C for 1–3 days. After incubation, the samples were centrifuged
and the remaining USP17 concentration, the remaining activity (Figure 2.6A), and
the specific activity were measured (Figure 2.6B). Large amount of precipitation was
visualized in the samples incubated at 37 ◦ C for each day. Almost a complete loss
in both activity and specific activity was measured on day one and each day after,
suggesting the remaining soluble protein was inactive. Large amounts of precipitation was again visualized for samples stored at 25 ◦ C. After day one of the 25 ◦ C
samples only ∼10% of the activity remained, a substantial loss that is reflected in
the specific activity measurement as well. Minimal remaining activity or specific activity remained for days two and three for the samples stored at 25 ◦ C suggesting
the remaining soluble enzyme was inactive. The samples stored at 4 ◦ C had minimal
precipitation and only lost ∼35% of the total activity after day one. This trend was
reflected in the specific activity measurement as well. Unlike the other temperatures
tested, no further loss in total activity was observed after days two and three for the
4 ◦ C samples, suggesting that any aggregation or inactivation that occurred during
incubation happened within the first 24 hours and not thereafter. The remaining
specific activity over time and temperature are summarized in Figure 2.6.
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Fig. 2.6. Retention of USP17 Specific Activity Aliquots of USP17 were
stored at 4 ◦ C, 25 ◦ C, or 37 ◦ C for one, two, or three days. At each time
point the sample was centrifuged and the remaining enzyme concentration was
measured by A280 , and adjusted with the determined extinction coefficient to
6.25 nM. A. Remaining activity was measured with 0.5 µM Ub–Rho110. B.
Specific activity was calculated as described in Section 2.3.13 with the same
concentrations of substrate and enzyme as A. All assays were done in triplicate.
Error, SD.

2.4.5

USP17 is a monomer in solution

To analyze the homogeneity and oligomeric state of refolded USP17, three methods
were used: analytical–SEC, Analytical Ultracentrifugation (AUC), and dynamic light
scattering (DLS). For each technique USP17 was diluted in the same Analytical Buffer
for consistency.
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Analytical Size–Exclusion Chromatography (SEC)
A 500 µL sample of USP17 at a concentration of 1.26 mg/mL was passed over a
24 mL Superdex 200 (GE Healthcare) SEC column at 4 ◦ C. The elution profile (Figure 2.7A) displayed a broad peak, and the average distribution constant, Kaverage , of
the maximal height and the half maximal heights was calculated. Using the standard
curve constructed under the same conditions (Figure 2.7B), the molecular weight of
the peak corresponds to 122 kDa and ranged from 86 to 153 kDa.

Analytical Ultracentrifugation
Analytical ultracentrifugation (AUC) was also performed to determine the oligomeric
state of USP17 in solution. For this technique, 5.6 µM (0.4 mg/mL) sample of USP17
was analyzed at 50,000 rpm at 25 ◦ C. Under these conditions, the resulting sedimentation coefficient was determined to be 2.955 ± 0.002 which corresponds to 65.2 kDa
(Figure 2.7C).

Dynamic Light Scattering
The third method for analyzing the homogeneity and oligomeric state of refolded
USP17 was DLS. USP17 was passed over a Superose 6 Increase (GE Healthcare)
SEC column, and the peak fraction of pure USP17 was concentrated to 1 mg/mL.
To evaluate the differences observed between the analytical–SEC and AUC results,
USP17 was evaluated at 1, 0.75, and 0.5 mg/mL, and at two temperatures, 4 and 25
◦

C. The hydrodynamic radius measured at 4 ◦ C (Figure 2.7D) ranged from 3.5 ± 0.8

nm and 3.75 ± 0.8 nm for 0.75 mg/mL and 0.5 mg/mL respectively. These numbers
equate to a molecular weight range of 64 ± 2 kDa to 73 ± 2 kDa. The hydrodynamic
radii broadened slightly for each concentration when measured at 25 ◦ C (Figure 2.8).
For example, at 0.75 mg/mL of USP17 the hydrodynamic radius was 3.5 nm at 4 ◦ C
and 4 nm at 25 ◦ C, that increased the calculated molecular weight from 64 kDa to
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93 kDa respectively. The hydrodynamic radius and the resulting molecular weights
from all conditions tested are displayed in Table 2.9.

Table 2.9
Estimated molecular weight of USP17 by dynamic light scattering
USP17 Concentration (mg/mL)
Temperature
4 ◦C
25 ◦ C

2.4.6

0.5

0.75

1

RH (nm)

3.7 ± 0.8

3.5 ± 0.8

3.6 ± 0.9

MW (kDa)

73 ± 2

64 ± 2

67 ± 2

RH (nm)

3.6 ± 0.8

4±1

4.1 ± 0.9

MW (kDa)

67 ± 2

93 ± 3

90 ± 3

Steady–State Kinetic Characterization of USP17

The steady–state kinetic parameters were determined for USP17 by measuring
the kinetic response of USP17 to increasing concentrations of two fluorogenic synthetic substrates, Ub–AMC and Ub–Rho110. As shown in Figure 2.9, USP17 can
be readily saturated by both substrates. The data in Figure 2.9 were fit to the
Michealis–Menten equation and the resulting kinetic parameters from those fits are
summarized in Table 2.11. The kinetic parameters suggest that USP17 recognizes and
hydrolyzes both Ub–AMC and Ub–Rho110 with nearly equal efficiencies (kcat /Km =
1500 x103 M −1 sec−1 for Ub–AMC and 880 x103 M −1 sec−1 for Ub–Rho110). Ub–AMC
is the more commonly utilized fluorogenic substrate within the deubiquitinating enzyme literature. As such, Table 2.10 compares the kinetic parameters of USP17 with
Ub–AMC as a substrate, to those of other human USPs characterized to date [11].
Interestingly, USP17 catalyzes the hydrolysis of Ub–AMC 3–fold more efficiently than
USP7 as a result of the lower Km value associated with USP17. Similar to other USPs,
USP17 catalyzes poorly the hydrolysis of the fluorogenic peptide substrate RLRGG–
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Fig. 2.7. Determination of Oligomeric State of USP17. A. Elution
profile of USP17 from a 24 mL Superdex 200 (GE Healthcare) column. B.
Standard curve built from the average distribution coefficient (Kavereage ) vs
log (Mr ) of well characterized proteins, black circles. The Kaverage of USP17
was determined from the elution profile in (A) and fit to the standard curve
to determine the molecular weight of USP17, orange triangle. C. AUC sedimentation velocity (AUC-SV) analysis at loading a concentration of 5.6 µM
of USP17. Plot of the distribution of sedimentation coefficients c(s) versus s,
where s is plotted in Svedberg units, (S) calculated from AUC sedimentation
velocity experiments. D. DLS curves at 4 ◦ C of USP17 at three concentrations
0.5 mg/mL (deep red), 0.75 mg/mL (teal), and 1 mg/mL (purple). All assays
were performed in triplicate.
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Fig. 2.8. Summary of DLS Analysis of USP17 at Two Temperatures.
DLS curves of USP17 at two temperatures: 4 ◦ C (Orange) and 25 ◦ C (Blue) at
three concentrations of USP17 (A.) 0.5 mg/mL, (B.) 0.75 mg/mL, and (C.)
1 mg/mL. All assays were performed in triplicate.

AMC and the ubiquitin–like modifier substrate ISG15–AMC, that is involved in the
innate immune response.

Table 2.10
Kinetic Parameters of Well–Characterized USPs with Ub–AMC

a
b

U SP 121−785

U SP 2CD

kcat

kcat /Km

(µM)

(s−1 )

(x10−3 s−1 M −1 )

9.71 ± 0.85

0.079 ± 0.003

9

2.4 ± 0.2

0.35 ± 0.03

146

a

U SP 7

2.89 ± 0.1

1.37 ± 0.01

482

a

U SP 8CD

17.3 ± 2.5

7.90 ± 0.46

464

a

U SP 11

0.77 ± 0.13

0.074 ± 0.003

0.147

a

U SP 12

12.01 ± 4.2

0.0023 ± 0.002

0.2

a

U SP 16

1.42 ± 0.25

0.069 ± 0.003

49.3

0.98 ± 0.06

1.47 ± 0.02

1500

USP17
a

Km

Values obtained from Faesen et al. [11]. [b] Values obtained from
Bozza et al. [55]. USP17 values reported in this work.
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Fig. 2.9. Kinetic response of USP17 to increasing concentrations of
Ub–Rho110 and Ub–AMC Michealis–Menten plots of USP17 with fluorogenic substrates: Ub–Rho110 (purple, closed circles) and Ub–AMC (orange,
closed squares). Both substrates were evaluated in a concentration range of
0.04 to 10 µM with 3.125 nM USP17. Assays were performed in triplicate.
Curves were fit to Equation (2.1), and the kinetic parameters, Km and kcat ,
were determined for each substrates.

Table 2.11
Kinetic Parameters of USP17 with Ub–AMC and Ub–Rho110

2.4.7

Ub–AMC

Ub–Rho110

Km (µM)

0.98 ± 0.06

2.0 ± 0.1

kcat (s−1 )

1.47 ± 0.02

1.76 ± 0.05

kcat /Km (x10−3 s−1 M −1 )

1500 ± 90

880 ± 50

Effect of pH on USP17 Activity

The kinetic response of USP17 to variable pH values over the pH range of 6 to
10.5 was measured using Ub–Rho110 as a substrate and the results are shown in
Figure 2.10. The rates of hydrolysis of Ub–Rho110 were evaluated at subsaturating
(0.5 µM) and near saturating (5 µM) concentrations of Ub–Rho110 to look for an
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observed shift in pKa values. Ten pH values spaced 0.5 pH units apart were chosen,
and the rates were measured in triplicate. The plots of the data in Figure 2.10
show typical bell–shaped curves, and therefore the data were fit to the equation that
describes the kinetic model of an enzyme undergoing two ionizations with two pKa
values (pKa and pKb ). The resulting curve fits are shown in Figure 2.10 for both
subsaturating and saturating substrate concentrations, and the resulting pKa for 0.5
µM Ub–Rho is 6.83 ± 0.07, which is similar to the pKa value at 5 µM Ub–Rho110
which is 6.75 ± 0.04. The pKb value at 0.5 µM Ub–Rho110 is 9.13 ± 0.07 which
is similar to the pKb value of 9.35 ± 0.04 at 5 µM Ub–Rho110. The lack of any
significant differences in the pKa and pKb values at subsaturating and saturating
concentrations suggests that ionizations in the free enzyme (E) and substrate–bound
enzyme complex (ES) are the same, and that substrate binding does not influence
the pKa values.

Fig. 2.10. Kinetic response of USP17 to varying pH. The activity of
USP17 was measured with Ub–Rho110 from pH 6 to 10.5 with 6.25 µM USP17.
Two concentrations of Ub–Rho110 surrounding the Km value were tested, 0.5
µM and 5 µM. Assays were performed in triplicate. Curves were fit with a
bell–shaped rate profile within SigmaPlot (v13: Systat Software Inc.).
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2.4.8

Substrate Specificity of USP17 for different Ubiquitin Chain Linkages

Ubiquitination of protein substrates involves one of the seven lysine residues of
ubiquitin. The topology of the chain is directly dependent on the specific lysine
residue that is used to conjugate one ubiquitin to the next. These differences confer an
additional layer of specificity for ubiquitin signaling beyond recognition of the protein
substrate. Previous cell–based assays have demonstrated that USP17 can process
Lys63 chains conjugated to RCE1 and SDS3 and Lys48 chains from CDC25A [29, 30,
47]. To expand upon this information, we performed a di–ubiquitin panel of all seven
lysine linkages and the linear peptide linkage (linear) to determine the specificity of
USP17. Di–ubiquitins with different isopeptide linkages (Lys6 , Lys11 , Lys29 , Lys33 ,
Lys48 , or Lys63 ) or linear were incubated with USP17, and the reaction products
were analyzed by SDS–PAGE Figure 2.11. USP17 was able to process all linkages to
a certain extent, with the exception of linear. As was expected, USP17 was able to
process Lys48 and Lys63 almost fully to mono–ubiquitin, as well as Lys11 and Lys33
(Figure 2.11 A, Top Panel). A substantial amount of uncleaved di–ubiquitin remained
for Lys27 , Lys29 , and Lys6 chains (Figure 2.11 A, Bottom Panel). A comparison of
these cleavage patterns to other characterized USPs is displayed in Table 2.12 [11].
This comparison suggests that USP17 is most similar to USP1, and is less promiscuous
than other members of the USP family. Next we evaluated how USP17 processed
ubiquitin chains by incubating USP17 with tetra–ubiquitin chains of either Lys48
(Figure 2.11 B), Lys63 (Figure 2.11 C), or Lys11 (Figure 2.11 D) by evaluating the
cleavage pattern over time. The data suggests that all three chain types are processed
by exo–trimming to a similar extent within the time range tested.
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Fig. 2.11. Ubiquitin Chain Recognition by USP17. For all reactions,
40 nM USP17 was combined with ubiquitin substrate, and allowed to incubate
at 25 ◦ C. A. Survey of the hydrolysis of di–ubiquitin chains by USP17. Each
assay contained 4 µM of the di–ubiquitin chain (Lys6 , Lys11 , Lys27 , Lys29 ,
Lys33 , Lys48 , Lys63 , and linear), and was allowed to incubate for 2 hr. Di–
ubiquitin chains were incubated without enzyme as a negative control. B, C,
and D. time–dependent hydrolysis of 2 µM Lys48 tetra–Ub (B.), Lys63 tetra–
Ub (C.), and Lys11 tetra–Ub (D.) by USP17. Aliquots were removed at four
time points and quenched with sample buffer, and analyzed by NuPAGE Novex
4–12% Bis-Tris mini gels (Invitrogen) stained with Coomassie Brilliant Blue.

Table 2.12
Comparison of USP17 Di–Ubiquitin Linkage Preferences of Various USPs
Lys11

Lys27

Lys29

Lys33

Lys48

Lys63

Linear

a

U SP 1

+++

++

+

+

++

+++

+++

-

a

U SP 7

+++

+++

++

+

++

+++

+++

-

a

U SP 8CD

+++

+++

+++

+++

+++

+++

+++

-

a

U SP 11

+++

+++

+++

++

+++

+++

+++

-

a

U SP 16

++

+++

+++

+++

+++

+++

+++

+

++

+++

+

+

+++

+++

+++

-

U SP 17
a

Lys6

Values obtained from Faesen et al. [11]. USP17 values reported in this work.
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2.5

Discussion

2.5.1

New methodology for expression and purification of USPs

The USP family of DUBs has a wide functional diversity in maintaining homeostasis within the cell through their regulation of many signaling pathways, including the
ubiquitin–proteasome, DNA repair, and the cell–cycle. As a result, the mis–regulation
of the USPs themselves frequently results in the development of cancer. With this
realization, there is a great need to expand upon the number of USPs that have been
expressed and purified allowing for more in depth kinetic, biochemical, biophysical,
and structural studies of the USP family. Furthermore, these advanced approaches
can be used in conjunction with the development of small molecule inhibitors to
further probe the functional roles of the USPs in cells, and ultimately therapeutic
compounds. Of the USPs that have been expressed via recombinant systems, few
of them have yet to produce full–length enzymes due to their inherent insolubility
when expressed in E. coli. Therefore, it is not uncommon to see full–length USPs
expressed from the more labor–intensive, often low–yielding baculovirus expression
systems. To obtain higher yields of soluble USPs, the individual catalytic domains
or other domains of USPs have more often been produced.
Similar to other USPs, we found that USP17 is highly insoluble when expressed
in E. coli. USP17 is a critical DUB involved in many pathways that dictate cell–cycle
progression. Both in cellulo and in vitro based studies have elucidated the importance
of USP17s activity on the stabilization of phosphatase CDC25A [29]. However, until
our work reported here, recombinant expression and purification methods for USP17
had not been developed or reported, which greatly limited our ability to study this
important enzyme. We were able to develop and optimize a reproduciable procedure
for the expression, refolding, and purification of USP17 from E. coli inclusion bodies.
With large quantities of recombinant USP17 in hand, we were able to interrogate the
biochemical, kinetic and oligomeric properties of USP17, and determine its substrate
specificity towards ubiquitin and ubiquitin–like substrates. The findings described
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build upon our knowledge of the USP family and have important implications for the
development of anti–cancer therapeutics.

2.5.2

Instability of USP17 may be a potential regulatory mechanism

Our observations during the expression of USP17 from both baculovirus E. coli
reveled that USP17 is prone to proteolytic degradation. Native USP17 expression in
human cells only occurs for a short period of time during the transitions from G1 − S
and G2 − M checkpoints in the cell–cycle. When expression of USP17 occurs outside
of these checkpoints, proliferation ceases. It is possible that this observed instability
of USP17 is a regulatory mechanism within the cell, and as such, USP17 is prone
to degradation to ensure that the presence of active USP17 is short lived, and that
timely progression of the cell–cycle occurs. Alternatively, as is commonly seen with
recombinant proteins, neither expression system may contain the required machinery
to properly refold USP17, resulting in unfolded regions of USP17 being susceptible
to proteolysis. It is not likely that USP17 itself is responsible for its degradation,
as similar degradation patterns are observed for the refolded catalytic mutant. This
evidence suggests that proteases native to Sf9 and E. coli are responsible for the
observed degradation of USP17.

2.5.3

Obscurity of the oligomeric state of USP17

Three approaches were utilized to determine the oligomeric state of USP17: analytical–
SEC, AUC, and DLS techniques. USP17 was determined to be a monomer in solution
by AUC when evaluated at 25 ◦ C and a concentration of 0.4 mg/mL. It was also observed to be a monomer in solution at 4 ◦ C and at concentrations ranging from 0.5 to
1 mg/mL by DLS. However, USP17 was determined to shift to a more dimeric state
when evaluated by either analytical–SEC at 1.3 mg/mL and 4 ◦ C or by DLS at 25
◦

C and at concentrations from 0.75 to 1 mg/mL. Taken together, the results suggest

USP17 primarily assumes a monomeric state at lower concentrations, i.e. under the
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conditions of our kinetic assays, but the equilibrium may shift towards a dimer at
higher USP17 concentrations, i.e. <1 mg/mL, and this dimerzation may have some
temperature dependence.

2.5.4

Kinetic efficiency of USP17 is significantly greater than that of
other USPs

The kinetic parameters of USP17 were determined for both Ub–Rho110 and Ub–
AMC substrates, and only modest differences in the kinetic parameters were observed.
Of greater interest are the significant differences observed between the kinetic parameters for USP17 with Ub–AMC and the reported kinetic parameters for other USPs
(Table 2.10) [11]. The catalytic efficiency USP17 (kcat /Km ) is 3–fold higher than
that of the very efficient and full–length USP7 [11], and is 7,500 times more efficient
than the catalytic domain of USP2. A possible explanation for the higher observed
catalytic efficiency for USP17 may reflect its minimal expression time within the cell–
cycle. Without such high activity, USP17 may not be able to progress the cell–cycle
efficiently within its short time frame or window of expression. A comparison to other
USPs involved in proliferation supports this hypothesis. For example, the expression
of USP1 is associated with low levels of DNA damage, and only has a short window
of expression during the S–phase of the cell–cycle, similar to the expression pattern
of USP17 [2]. However, USP1 is not required for cell–cycle progression, and, consequently, the activity of USP1 need not be as high as USP17 [2]. These differences
may be further evidence of the significant role USP17 has in progressing the cell–
cycle in a coordinated timely manner as compared to other USPs involved in cellular
proliferation.
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2.5.5

USP17 processes ubiquitin chains associated with degradation and
enzyme activation

A number of USPs have so far been investigated for their ability to recognize
and process the ubiquitin chains, and each has been found to exhibit its own degree
of chain linkage specificty or promescuity (Table 2.12). This specificity is partially
implied by the different topologies the specific ubiquitin chains assume and whether
or not the USP is capable of accessing each iso–peptide bond. Faesen and coworkers
performed a di–ubiquitin panel to assess the ability of a variety of USPs to process
over time the eight different ubiquitin chain types [11]. While subtle differences could
be observed between the USPs ability to process the chains, it was clear that the
majority of the USPs tested were promiscuous, and could process the majority of
the chains with the exception of linear chains [11]. USP17 appears to be a bit more
specific about the topology of each linkage than other members of the USP family
(Table 2.12). While USP17 could process each of the ubiquitin chain types, with the
exception of linear ubiquitin, it did so to varying degrees. USP17 easily processed
Lys48 and Lys63 , supporting the previous cell–based findings [29,30,47]. Interestingly,
USP17 processed the Lys33 chain relatively well, a chain type that is not easily
processed by most USPs, and has recently been associated with the modulation of
kinase activity [8, 11]. USP17 also easily processed Lys11 , which has been described
as a strong degradation signal, similar to the Lys48 chains [7, 11, 46].The observed
cleavage pattern by USP17 is most similar to the cell–cycle dependent USP1, whose
importance was described in Section 2.5.4.
We also determined the efficiency by which USP17 processes longer ubiquitin
chains, including Lys48 , Lys63 , and Lys11 linked tetra–ubiquitin chains was examined.
The cleavage pattern for both chain types suggest USP17 efficiently deubiquitinates
each of these substrates, and utilizes an by exo–trimming mechanism, as no accumulation of a single intermediate ubiquitin species other than mono–ubiquitin was
observed [12]. Furthermore, as these chains assume significantly different topologies,
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these findings suggest that the specificity of USP17 is more likely dependent on the
protein substrate the ubiquitin chain is conjugated to, not the chain itself [12].

2.5.6

USP17 activity is optimal between pH 7 and 9

The effects of pH on the ability of USP17 to process substrate was evaluated
by varying the pH and Ub–Rho110 concentration. When the data was plotted, both
concentrations of Ub–Rho110 surround the Km (0.5 and 5 µM) in terms of pH assumed
a bell–shaped curve. By analysis of these curves, the pKa and pKb values could be
determined from the acidic limb (left hand side) and the basic limb (right hand side),
respectively. The resulting pKa for 0.5 µM Ub–Rho was 6.83 ± 0.07, which was similar
to the pKa at 5 µM Ub–Rho110 of 6.75 ± 0.04. This similarity was reflected in the pKb
values with 0.5 µM Ub–Rho110 at 9.13 ± 0.07 compared to 5 µM Ub–Rho110 at 9.35
± 0.04. These values most likely correlate to the catalytic histidine (pKa ) and cysteine
(pKb ) residues of the enzyme. The estimated pKa values suggest that at pH values
below 6.75 the catalytic histidine will exist predominantly as a positively–charged
imidazolium ion, a state unable to deprotonate the cysteine to perform catalysis.
The estimated pKb values suggest that at pH values above 9.35 the catalytic cysteine
will exist predomainatly as a thiolate and not require deprotonation. Therefore, only
at pH values between 6.75 and 9.35 will both the cysteine and histidine exist in the
proper ionization states to perform the following catalytic steps (Figure 1.4):
• The nucleophilic attack on the substrate to form the ES complex
• The general–acid assisted protonation of the leaving group in the FP state
• The deprotonation of the water molecule in the F state
• The protonation of the thiolate in the EQ state
Furthermore, at pH values above 9.35 the catalytic histidine residue will be deprotonated, therefore not capable of the general–acid assisted protonation of the leaving
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group in the FP state. Minimal differences were observed between the estimated pKa
and pKb values at the two substrate concentrations suggesting that the ionization
state of the substrate is not influencing the formation of the USP17– Ub–Rho110
complex. Furthermore, as the difference in the pKa and pKb values at the two substrate concentrations is minimal, the pH does not have a large affect on the Km or
kcat of the system.
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CHAPTER 3. EXPRESSION AND PURIFICATION OF USP7 AND USP7
TRUNCATIONS
Parts of the data and text in this chapter have been published in various journal
articles (insert references here).

3.1

Introduction
Human USP7 is a 125 kDa protein that is composed of seven different domains,

an N–terminal Tumor Necrosis Factor receptor associated factor (TRAF) domain,
the conserved papain–like catalytic domain, and 5 consecutive ubiquitin like (UBL)
domains (Figure 3.1). The X–ray crystal structures have been solved for each of
these domains by others in the field, however a structure of full–length human USP7
(USP7FL ) remains to be elucidated [19, 20, 33]. Our studies with USP7 have focused
on elucidating the interactions between these different domains using steady–state
kinetic, isothermal calorimetry, and gel–shift approaches. To perform these types of
experiments eight different truncations of USP7 were cloned, expressed, and purified.
This chapter describes the design, synthesis, sub–cloning, expression, and purification
of each USP7 construct depicted in Figure 3.1 that were utilized in Chapter 4 and
Chapter 6, as well as, the manuscripts in prep cited above.

3.2

Experimental Procedures

3.2.1

Baculovirus Expression and Purification of Full–Length USP7 (USP7FL )

Disclaimer: With the exception of the expression from the baculovirus expression
system, this section was performed by a previous post–doc in the lab. The data included
within this section is the extent of what was provided once I took over the project.
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Fig. 3.1. Truncations of USP7. Depicted above are the nine constructs that
were utilized for the studies described within Chapter 4 and Chapter 6. For each
truncation, the residue range is reported as well as the domains encompassed
within that range are depicted.
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Biotechnology company, BioBasic Inc., codon optimized human USP7FL (1–1102)
for baculovirus expression, and performed the cloning of the gene into a modified pVL–
1392 vector containing an N–terminal 10His, green fluorescent protein (10x His–GFP)
tag. The DNA sequence was verified by DNA sequencing at the Purdue University
Genomics Core Facility. A culture volume of 200 mL was used for USP7FL expression
by following the BD BaculoGold system in Sf9 identically to as described in Section 2.3.7. The Sf9 cells expressing USP7FL were harvested by centrifugation with a
Sorvall RC 6+ ThermoScientific Centrifuge with a Fiberlite F9–4x1000y rotor (3000x
g for 20 minutes at 4 ◦ C) after 3 days of expression. Approximately 2 g of cell pellet
was obtained from the 200 mL of Sf9 culture under the given expression conditions.
The cells were resuspended in 15 mL of Buffer α (20 mM HEPES pH 7.5, 500 mM
NaCl, and 10 mM Imidazole) and lysed, on ice, by sonication with a Branson Digital
Sonifier at 50% amplitude alternating five seconds on and five seconds off for eight
pulses total. The lysate was clarified in Oak Ridge tubes with a Beckman Coulter
Avanti J–30I centrifuge in the JA–17 rotor (80,000 x g for one hour at 4 ◦ C).

Nickel Batch Affinity Chromatography
The 15 mL of clarified lysated was bound to 0.5 mL of Ni–NTA resin (GE Healthcare), and unbound protein was washed off with 10 mL of Buffer α. The resin was
washed with 10 mL of Buffer β (20 mM HEPES pH 7.5, 500 mM NaCl, 50 mM Imidazole) to remove weakly bound non–specific proteins. USP7FL was eluted with 3 mL
of Buffer δ (20 mM HEPES pH 7.5, 500 mM NaCl, and 450 mM Imidazole). The 3.6
mg of eluted USP7FL fusion protein was then digested with PreScission protease to
remove the 10x–His–GFP tag at a 1:1 ratio of USP7FL to PreScission Protease. The
reaction was allowed to proceed overnight at 4 ◦ C. PreScission protease was prepared
as described in Section 3.2.2.
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Gel–Filtration Chromatography
As the final step of purification, the cleaved USP7FL protein was purified by a
HiPrep 300 16/60 Sephacryl S300 prep grade column equilibrated with Buffer γ (20
mM HEPES pH 7.5, 200 mM NaCl, 10 % glycerol, and 10 mM βME) at a flow rate
of 0.5 mL/min with 5 mL fractions collected throughout the run. The pooled sample
was flash frozen in liquid nitrogen and stored at -80 ◦ C.

3.2.2

Preparation of PreScission Protease

Expression of PreScission Protease
The expression plasmid pGEX–6P encoding for GST–PreScission protease, as well
as the expression and purification protocol, was gifted to us by Professor Jue Chen at
Purdue University (now at Rockefeller). The plasmid was transformed by electroporation into E. coli BL21 (DE3) cells, and streaked onto LB plates supplemented with
50 µg/mL Carbenicillin. From the colonies that grew, a slurry was made by adding
5 mL of LB media to the plate and gently swirled. The slurry was then added to 100
mL of LB media supplemented with 50 µg/mL Carbenicillin. The culture was grown
at 37 ◦ C with shaking at 200 rpm in an Infors Multitron incubated shaker until the
cell density resembles that of a normal culture grown overnight (A600 ∼6). A 20 mL
aliquot of the culture was used to inoculate 1 L of LB media supplemented with 50
µg/mL of Carbenicillin in a Fernbach flask. The culture was grown at 37 ◦ C until
A600 ∼0.6, about one to two hours. The culture was then cooled to 30 ◦ C, and GST–
PreScission Protease expression was induced with IPTG at a final concentration of
0.5 mM from a 1 M stock. The culture was incubated with shaking at 30 ◦ C for 15–17
hours for expression. The cells were harvested with a Sorvall RC 6+ ThermoScientific
Centrifuge with a Fiberlite F9–4x1000y rotor at 3000 x g for 15 minutes at 4 ◦ C, and
the cell pellet was placed at -80 ◦ C for storage.
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Purification of PreScission Protease
The cell pellet containing expressed GST–PreScission was removed from the -80
◦

C and thawed on ice. The cells were resuspended in 20 mL of PreScission Lysis

Buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 5 mM βME, 5 mM EDTA, 1 mM
PMSF, lysozyme, and 3 µg/mL DNAse) and lysed by sonication with a Branson
Digital Sonifer at 60% amplitude for three minutes in a metal beaker surrounded by
an ice/ethanol bath. Lysate was centrifuged with a Beckman Coulter Avanti J–30I
centrifuge in a JA–17 rotor at 80,000 x g for one hour at 4 ◦ C. The supernatant was
separated from the insoluble portion, and mixed with 5 mL of Glutathione Sepharose
resin equilibrated with Wash Buffer (20 mM HEPES pH 7.5, 5 mM βME, and 5 mM
EDTA) in a 50 mL Falcon tube. The mixture was incubated at 4 ◦ C with gentle
rocking for two hours. The GST–PreScission protease bound Glutathione Sepharose
resin was centrifuged at 500 x g for five minutes and the supernatant was decanted.
The resin was washed with a total of 300 mL of wash buffer in 50 mL aliquots. Each
aliquot was added to the resin and and incubated with gentle rocking at 4 ◦ C for 10
minutes, then centrifuged with a Sorvall RC6+ ThermoScientific Centrifuge with a
Fiberlite F13–14 x 50cy fixed angle rotor at 500 x g for five minutes. This was repeated
until all 300 mL of wash buffer had been utilized. To elute GST–PreScission Protease
from the Glutathione Sepharose resin 50 mL of Elution Buffer (50 mM HEPES pH 8,
150 mM NaCl, 5 mM βME, and 10 mM reduced Glutahione) was added to the resin,
and incubated for 30 minutes with gentle rocking at 4 ◦ C. The sample was again
centrifuged with the Sorvall RC6+ ThermoScientific Centrifuge with a Fiberlite F13–
14 x 50cy fixed angle rotor at 500 x g for five minutes. The supernatant containing the
eluted PreScission protease was collected, and dialyzed against two liters of dialysis
buffer (50 mM HEPES pH 8, 150 mM NaCl, 1 mM DTT, and 10 mM EDTA) at 4 ◦ C
overnight using SnakeSkin Dialysis Tubing (10,000 MWCO). The following morning,
the protein was analyzed by SDS–PAGE and Microassay Bio–Rad Bradford Protein
Assay. To store, 20% glycerol was added directly to the sample, the protein was the
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diluted to 1 mg/mL with dialysis buffer, and 1 mL aliquots were made. The aliquots
were flash frozen in liquid nitrogen and stored at -80 ◦ C.

3.2.3

E. coli Expression and Purification of USP7 Truncations

Truncations of USP7 were expressed and purified from E. coli to elucidate the
mechanism by which USP7 is internally activated (Chapter 4) as well as evaluate
the mode of inhibition by identified USP7 specific inhibitors (Chapter 6). A total of 8 truncations were made: the catalytic domain (USP7CD , residues 208–560),
catalytic domain fusion with HUBL domains 4 and 5 (residues 209–1102 ∆567–
879, USP7CD –H4–5), USP7 without the N–terminal TRAF domain (residues 209–
1102, USP7CD –H1–5), TRAF and catalytic domain of USP7 (residues 1–560, TRAF–
USP7CD ), HUBL domains 1–5 (H1–5, residues 560–1102), HUBL domains 4–5 (H4–5,
residues 890–1102), HUBL domains 1–2 (H1–2, residues 560–775), and HUBL domains 1–3 (H1–3, residues 560–888). Each truncation was cloned, expressed and
purified using the following general procedure. Nuances that pertained to individual
truncations are described within their individual results section.

Expression Construct Design
The desired amino acid residues for the USP7CD , USP7CD –H4–5, USP7CD –H1–5,
TRAF–USP7CD , H1–5, and H4–5 truncations (illustrated in Figure 3.1) was codon
optimized by BioBasic Inc for expression within E. coli. Each gene was then synthesized by BioBasic Inc with a N–terminal 6His tag and a Tobacco Etch Virus (TEV)
cleavage site. Finally, BioBasic Inc inserted each synthesized gene into the pET–11a
vector between NdeI and BamHI restriction sites.
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Truncation Protein Expression
For protein expression, E. coli BL21–DE3 electro–competent cells were transformed by electroporation with the pET–11a plasmid containing the truncation gene
of interest. The transformed cells were gently resuspended in SOP media, and allowed
to outgrow for one hour at 37 ◦ C in a 14 mL round bottom culture tube shaking in
an Infors Multitron incubated shaker at 200 rpm. An aliquot of 100 µL of the cells
were then spread onto LB agar supplemented with 50 µg/mL of carbenicillin. A
single colony was picked from the agar plate to innoculate 150 mL of LB media supplemented with 50 µg/mL carbenicillin. The cells were grown overnight at 37 ◦ C.
Three one–liter cultures of LB media supplemented with 50 µg/mL carbenicillin were
prepared. Each flask was innoculated with 25 mL each of the overnight culture. The
cultures were grown to an A600 of ∼0.6. Cells were cooled to 18 ◦ C, and expression
was induced with a final concentration 0.25 mM IPTG from a 1 M stock. The cultures
were incubated with shaking in the Infors Multitron incubated shaker at 18 ◦ C for
18 hours. The cells were harvested by centrifugation with a Sorvall RC6+ ThermoScientific Centrifuge with a Fiberlite F9–4x1000y rotor (3000 x g for 20 minutes at 4
◦

C). The cell pellet weight was noted, and 5 mL of Buffer A (10 mM Imidazole, 10

mM Tris pH 7.5, 5 mM βME, 500 mM NaCl, and 5% glycerol) for every one gram of
cell pellet was used to resuspend the cells. The resuspended cells were supplemented
with 50 µg/mL DNase and 200 µg/mL lysozyme. The cells were lysed with a Branson
Digital Sonifier at 60% amplitude pulsing for five seconds on and nine seconds off for
a total of 12 minutes on. The lysate was clarified with the same centrifuge with the
Fiberlite F13–14 x 50cy fixed angle rotor (28,880 x g for 20 minutes at 4 ◦ C), and the
supernatant was filtered through a 0.45 µm filter.

Nickel Affinity Chromatography and TEV Cleavage
The clarified lysate was loaded onto a 5 mL HisTrap column at 2 mL/min (GE
Healthcare) equilibrated with Buffer A. Unbound protein was washed off with 50
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mL of Buffer A at a flowrate of 2.5 ml/min. A 100 mL linear gradient of 0–100%
of Buffer B (450 mM Imidazole, 10 mM Tris pH 7.5, 5 mM βME, 500 mM NaCl,
and 5% glycerol) was run to elute bound proteins. Fractions (5 mL) were collected
throughout the gradient. Fractions were pooled based on concentration, SDS–PAGE
analysis, and specific activity measurements (if the truncation contained the catalytic
domain). The pooled protein concentration was measured by Bradford assay and the
protein was combined at a 1:25 ratio of TEV protease to truncation and dialyzed in
Buffer A without imidizole overnight at 4 ◦ C to remove the 6His tag.

Reverse Nickel Affinity Chromatography
The TEV protease digested sample containing the cleaved 6His tag was loaded
onto the 5 mL HisTrap column previously equilibrated with Buffer A, at a flowrate
at 2 mL/min. The flowthrough was collected either as 5 mL fractions or as a pool.
Unbound sample was washed with 40 mL of Buffer A and a linear gradient of 0–100%
of Buffer B was run over 100 mL at a flow rate at 2.5 mL/min. The sample was
pooled based on concentration, SDS–PAGE analysis, and specific activity measurements (when appropriate).

Gel–Filtration Chromatography
The pooled sample from the Reverse Nickel Affinity Chromatography was concentrated using ultrafiltration (Millipore) with an appropriate molecular weight cut
off membrane to the truncation being purified to < 2 mL. The concentrated samples
was injected onto 300 mL GE Healthcare size–exclusion chromatography column previously equilibrated with Buffer C (10 mM Tris pH 7.5, 100 mM NaCl, 5% Glycerol,
and 5 mM βME). The type of size–exclusion chromatography column utilized was
determined based on the truncations size: Superdex 75 (USP7CD , USP7CD –H4–5,
TRAF–USP7CD , H1–5, H4–5, H1–2, and H1–3) or Superdex 200 (USP7CD –H1–5).
All columns were run at a flowrate of 1 mL/min, and 5 mL fractions were collected

75
throughout. Fractions to be pooled were determined by concentration, SDS-PAGE
analysis, and specific activity measurements (if applicable). The pooled fractions
were flash frozen in liquid nitrogen, and stored at -80 ◦ C.

3.2.4

Expression and Purification of USP7 sans the TRAF domain (USP7CD –
H1–5)

The expression construct design and protein expression of USP7CD –H1–5 was
performed identically to as described in Section 3.2.3.

Nickel Affinity Chromatography
The clarified lysate of USP7CD –H1–5 was loaded onto a 5 mL HisTrap column at
2 mL/min (GE Healthcare) equilibrated with Buffer A. Unbound protein was washed
off with 50 mL of Buffer A at a flowrate of 2.5 mL/min. A 100 mL linear gradient of
0–100% of Buffer B was run to elute bound proteins. Fractions (5 mL) were collected
throughout the gradient. Fractions were pooled based on concentration, SDS–PAGE
analysis, and specific activity measurements.

Superdex 200 Chromatography and TEV Cleavage
The pooled sample was concentrated using ultrafiltration with a 50,000 MWCO
membrane (Millipore) to < 3 mL, and injected onto a 300 mL Superdex 200 (GE
Healthcare) size–exclusion chromatography column previously equilibrated with Buffer
C. The column was run at 1 mL/min, and 5 mL fractions were collected throughout
the run. To determine which fractions to pool, peak fractions were analyzed by Bradford assay, SDS–PAGE, and specific activity measurements. The pool was combined
in a 1:8 ratio of TEV:USP7CD –H1–5 and stored overnight at 4 ◦ C for removal of the
6His tag.
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MonoQ Chromatography
The TEV protease digested USP7CD –H1–5 sample was diluted in Buffer D (10
mM Tris pH 7.5, 5 % glycerol, and 5 mM βME) 1:3 to reduce the sodium chloride
concentration to < 20 mM. The diluted sample was concentrated to < 50 mL with
ultrafiltration with a 50,000 MWCO membrane (Millipore). The concentrated sample
loaded onto an 8 mL MonoQ column (GE Healthcare) equilibrated in Buffer D at a
flowrate of 1 mL/min. Unbound sample was washed with 75 mL of Buffer D at 1
mL/min. A linear gradient of 0–100% of Buffer E (10 mM Tris pH 7.5, 500 mM NaCl,
5 % glycerol, and 5 mM βME) was run at 2.5 mL/min over 100 mL, and 5 mL fractions
were collected throughout the run. Fractions were analyzed by concentration, SDS–
PAGE, and specific activity measurements, those containing USP7CD –H1–5 of the
highest purity and activity were pooled, flash frozen in liquid nitrogen, and stored at
-80 ◦ C.

3.2.5

Sub–Cloning and Construct Design for H1–2

Primers were designed to amplify the bases encoding for the USP7 HUBL domains 1 and 2 (residues 560–775) from the H1–5–pET–11a vector for insertion into
the pEV–L8 vector by ligation independent cloning techniques. The forward and
reverse primers used are listed below from 5’ to 3’. The bases in bold are bases complimentary to the pEV–L8 vector that allows for homologus recombination. Forward:
GAGAACCTGTACTTCCAATCCAATGAAGCACATCTGTACATGCAG. Reverse: TCGAATTCGGATCCGTTATCCACTTCCAATCGTTTTCCGGGTC
GTC. The master mix for a single 50 µL PCR reaction was as described in Table 3.1.
The PCR reaction was performed with a Bio–Rad MJ Mini Personal Thermal Cycler
with the reaction scheme described in Table 3.2.
The PCR products were analyzed with a 1% agarose gel supplemented with 1x
GelRed dye that was run for 40 minutes at 100 volts. The successful reactions were
pooled and the cleaned using the Qiagen PCR clean–up protocol. The PCR ampli-
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Table 3.1
PCR composition for the sub–cloning of the H1–2 gene
Component

Final Concentration

Volume

1x

5 µL

10 mM dNTPs

0.2 mM

0.5 µL

10 µM Forward Primer

0.25 µM

5 µL

10 µM Reverse Primer

0.25 µM

5 µL

USP17–pET11a plasmid

50–100 ng

–

Phusion High–Fidelity DNA Polymerase

0.5 units

0.4 µL

N/A

to 50 µL

5x Phusion HF Buffer

Sigma–Water

Table 3.2
PCR composition for the sub–cloning of the H1–2 gene
Step

Temperature

Time

Initial Denaturation

95 ◦ C

3 minutes

Denaturation

95 ◦ C

30 seconds

Annealing

48 ◦ C

30 seconds

Extension

72 ◦ C

1.5 minutes

Repeat steps 2-4 for 30 cycles
Completion

72 ◦ C

Hold

4 ◦C

5 minutes

con was then inserted into the pEV–L8 vector by ligation–independent recombinant
cloning using linearized pEV–L8 vector, digested by restriction enzyme SspI, and
XL1-Blue supercompetent cells, as described in Chapter 2. The construct was verified by DNA sequencing at the Purdue University Genomics Core Facility.
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3.2.6

Sub–Cloning and Construct Design for H1–3

Primers were designed to amplify the bases encoding for the USP7 HUBL domains 1 and 3 (residues 560–888) from the pET–11a vector encoding for H1–5. This
region was inserted into the pEV–L8 vector by ligation independent cloning techniques, as described in Section 3.2.5. The forward and reverse primers used are listed
below from 5’ to 3’. The bases in bold are bases complimentary to the pEV–L8
vector that allow for homologus recombination. Forward: GAGAACCTGTACTTCCAATCCAATGAAGCACATCTGTACATGCAG. Reverse: TCGAATTCGGATCCGTTATCCACTTCCAATGAAGTCCGTGATTTTCATTTTCAG. The PCR master mix, PCR reaction, and the homologus recombination cloning was identical to
what was described in Section 3.2.5. The construct was verified by DNA sequencing
at the Purdue University Genomics Core Facility.

3.2.7

Expression and Purification of Tobacco Etch Virus (TEV) Protease

Expression of TEV Protease
The expression plasmid (pRK793) encodes for the Maltose Binding Protein (MBP)–
6His tag– TEV(S219V)– polyarginine tag TEV construct. The S192V mutation eliminates the internal autoinhibition regulation of TEV protease. Between the MBP and
N–terminal histidine tag is a TEV protease recognition site (ENLYFQG/S). During
expression, soluble TEV protease will cleave itself from the MBP fusion protein exposing the N-terminal 6His tag for use during purification. The plasmid is transformed
into E. coli BL21–RIL (codon +) cells, and streaked onto LB plates supplemented
with 50 µg/mL Carbenicillin and 30 µg/mL Chloramphenicol. The plates were allowed to grow overnight at 37 ◦ C. A single colony was picked and used to innoculate
30 mL of LB supplemented with 50 µg/mL Carbenicillin and 30 µg/mL Chloramphenicol. The started culture was grown at 37 ◦ C shaking at 200 rpm overnight.
Three Fernbach flasks containing 1 L of LB media supplemented with 50 mg/mL
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Carbenicillin and 30 mg/mL Chloramphenicol were prepared. Each flask was innoculated with 10 mL of the starter culture, and grown at 37 ◦ C to an A600 of 0.5. The
flasks were then induced with 1 mM IPTG, and allowed to express for four hours
at 30 ◦ C. Cells were harvested by centrifugation with the Sorvall RC6+ ThermoScientific Centrifuge with the Fiberlite F9–4x1000y rotor at 4000 x g for 20 minutes
at 4 ◦ C. The pelleted cell weight was 12.81 g for 3 L of culture. The pelleted cells
were resuspended in 25 mL of TEV Lysis Buffer (20 mM Tris pH 8.0, 100 mM NaCl,
10 % glycerol, and 10 mM βME) and lysed by sonication with a Branson Digital
Sonifer at 55% amplitude pulsating for 10 seconds on and 10 seconds off for a total of
seven minutes. During sonication, the cells were in a metal beaker surrounded by an
ice/ethanol slurry to keep sample from overheating. The lysed cells were centrifuged
in the same centrifuge with the Fiberlite F12–14 x 50cy fixed angle rotor at 28,880 x
g for 25 minutes at 4 ◦ C.

Purification of TEV Protease
The clarified lysate containing active TEV protease cleaved from MBP was then
loaded onto a 5 mL HisTRAP column at 2 mL/min (GE Healthcare) equilibrated
with TEV Buffer A (20 mM Tris pH 8.0, 100 mM NaCl, 10% Glycerol, 10 mM βME,
and 10 mM Imidizole). The column was washed with 10 column volumes (50 mL)
of TEV Buffer A to remove nonspecific proteins. TEV protease was eluted from the
column with a gradient from 0–100% TEV Buffer B (20 mM Tris pH 8.0, 100 mM
NaCl, 10% Glycerol, 10 mM βME, and 250 mM Imidizole) over 20 column volumes
(100 mL). During the gradient 5 mL fractions were collected. The fractions were
analyzed by 12.5% SDS–PAGE gel, and pure fractions were pooled. The pooled TEV
sample was immediately dialyzed for three to four hours against 2 L of TEV Dialysis
Buffer (20 mM Tris pH 8.0, 100 mM NaCl, 10% Glycerol, 10 mM βME, and 1 mM
EDTA) to remove the imidizole and add EDTA to the buffer. The dialysis buffer
was refreshed with 2 L of fresh TEV Dialysis Buffer and the TEV protease sample

80
was dialyzed overnight. The following morning the dialysis buffer was refreshed again
with 2 L of fresh TEV Dialysis Buffer, and the TEV protease sample was dialyzed
for an additional four hours. The TEV protease sample was then concentrated using
ultrafiltration with a 3,000 MWCO membrane (Millipore) to a concentration of 1
mg/mL. TEV was then flash frozen in 1 mL aliquots in liquid nitrogen and stored at
-80 ◦ C. On average, one can expect 50 mg of TEV protease per liter of cell culture.
The TEV purification is summarized in Figure 3.2.

Fig. 3.2. Summary of the TEV Protease Purification. 12.5% SDS–
PAGE summary of the TEV protease purification. The red arrow indicates the
purified TEV protease at the expected size of 27 kDa. The yellow arrow is the
cleaved Maltose Binding Protein. Molecular weight marker sizes as indicated.

3.2.8

Kinetic Assays of USP7

The specific activity was measured throughout each purification of the USP7 constructs containing the catalytic domain (USP7FL , USP7CD , USP7CD –H4–5, USP7CD –
H1–5, and TRAF–USP7CD ) using the fluorogenic synthetic substrate ubiquitin–rhodamine
110 (Ub–Rho110, Boston Biochem). Ub–Rho110 is internally quenched when the rhodamine 110 molecule is conjugated to the ubiquitin moiety by a peptide bond. Upon
cleavage of the peptide bond the quenching is released, and fluorescence from the
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rhodamine 110 can be measured. This substrate works as a generic substrate for
many USP enzymes (Figure 2.5). The Ub–Rho110 is provided from Boston Biochem
at a stock concentration of 250 µM in 100% DMSO which is normalized to 1 µM
in Substrate Buffer (50 mM Tris pH 7.5, 1 mM EDTA, 100 mM NaCl, and 0.05%
CHAPS), and diluted into each assay at a final concentration of 500 nM. The protein
concentration was measured by the Microassay Bio–Rad Bradford Protein Assay and
was normalized in Assay Buffer (50 mM Tris pH 7.5, 0.1 mg/mL BSA, and 0.01%
Trition X–100) to a working concentration of 250 nM for TRAF–USP7CD , 10 nM for
USP7CD and USP7CD –H4–5, or 2 nM for USP7CD –H1–5. First, 15 µL of the working
concentration of Ub–Rho110 (1 µM) was added to a Costar 96 half–volume black
plate, and the background fluorescence was read using a BioTeK Synergy H1 plate
reader every 10 seconds at an excitation λ of 485 nm and emission λ of 528 nm for
two minutes. Following the background read, 15 µL of protein was added to the plate
(a 2–fold dilution), the plate was mixed for 10 seconds, then the assay was read under
the same conditions for 30 minutes total or until the reactions started to plateau.

Determination of the Extinction Coefficient of the Substrate
The extinction coefficient of Ub–Rho110 was determined anew each day of each
purification to account for freeze–thaw effects. To determine the extinction coefficient, five serial dilutions of Ub–Rho110 were made to the working concentrations of
0.03 µM to 1 µM. First, 15 µL of each dilution of Ub–Rho110 was added to the plate.
Second, 15 µL of a highly concentrated USP stock was added the plate. The plate
was mixed for 10 seconds and the fluoresence was read with the same program described for the specific activity assays. The reactions were allowed to plateau, and the
maximum artificial fluorescence units (AFU) was measured for each concentration.
The measured AFU’s were plotted against the corresponding Ub–Rho110 concentration to build a standard curve. The resulting plot was fit using linear regression,
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and the resulting slope corresponds to the extinction coefficient in units of AFUs per
concentration of Ub–Rho110 (AFU/µM).

Specific Activity Analysis
The initial slope of each specific activity reaction in units of fluorescence per
unit time (AFU/min) was converted to the amount of product produced per unit
time (µM/min) with the extinction coefficient of the substrate. Units, as defined
by µmol/min−1 , was obtained by dividing by the total assay volume. The specific
activity of the sample, Units/(mg of enzyme), was determined by dividing the Units
by the milligrams of protein present in the assay. The fractional recovery of activity
was determined by dividing the total units of the sample by the total units of the
lysate and multiplying by 100 to obtain a percentage. The fold in purification after
each chromatography step was determined by dividing the specific activity of each
sample by the specific activity of the lysate.

3.2.9

Measuring Protein Concentration

Microassay Bio–Rad Bradford Protein Assay
The Microassay Bio–Rad Bradford Protein Assay was used throughout each purification to estimate the concentraiton of the total protein in the sample. The coomassie
dye was prepared by diluting the Bio–Rad 5x dye concentrate to 1x with nanopure
water. A standard curve was prepared using Bio–Rad lyophilized bovine serium albumin (BSA) that had been resuspended to a stock concentration of 1.36 mg/mL in
nanopure water. This stock was then diluted to a working stock of 0.5 mg/mL in the
same purification buffer the protein sample to be measured was currently residing. A
standard curve of BSA was measured at 0, 0.125, 0.25, 0.375, and 0.5, mg/mL in a
96–well clear, flat–bottom microtiter plate. The protein samples were added to the
plate in a volume of 1, 5, or 10 µL depending on the concentration of the sample to
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ensure the staining fell within the BSA standard curve. If 1 µL or 5 µL of sample
was used the dilution factor of 10 or 2, respectively, was taken into account for the
final calculation. To each well 200 µL of the 1x Bio–Rad coomassie dye was added
to each sample. Using a microplate mixer, the plate was mixed thoroughly for 30
seconds and any bubbles were popped. Using the BioTek H1 Synergy plate reader,
the absorbance of each well was read at a λ of 595 nm. The absorbance of the BSA
standard curve was plotted in terms of the corresponding concentration, and fit using
linear regression from that the protein concentration of each sample was estimated.

Determination of the Extinction Coefficient of USP7 Truncations
The extinction coefficient was determined for each purified truncation as described
in Section 2.3.9, and are summarized in Table 3.7. Samples labeled with an asterisk
indicate that the purity was too poor or the yield was too low for proper determination
of the extinction coefficient by this method. For those cases the values displayed were
determined computationally by the bioinformatics resource, ExPASy [52].

3.2.10

SDS–PAGE Analysis

Protein sample concentration was measured by a Microassay Bio–Rad Bradford
Protein Assay. SDS–PAGE samples were prepared by mixing 5–10 µg of protein
sample with 4 µL of 5x SDS Sample Loading Buffer (0.2 M Tris–HCl pH 6.8, 10%
SDS, 10% glycerol, 0.02% Bromophenol blue, and 5 mM βME). Samples were heated
at 95 ◦ C for two minutes immediately prior to loading into the SDS–PAGE gel. The
gel was run at 200 volts for 40 minutes. Each USP7 construct was analyzed by 10%
or 12.5% SDS–PAGE gel depending on the size.
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3.3

Results

3.3.1

Expression and Purification of USP7FL

Figure 3.3 displays the SDS–PAGE analysis of purified USP7FL . From this preparation, approximately 1 mg of USP7FL was obtained from 200 mL of Sf9 culture.
The specific activity of USP7FL was only recorded in the notes provided to me for the
final enzyme pool. The specific activity was determined to be 0.1 Units/mg (a unit
is defined as µmol/min−1 ).

Fig. 3.3. SDS–PAGE analysis of purified USP7FL . 10% SDS–PAGE
analysis of the final pool of the purified USP7FL . Red arrow indicates expected
size of USP7FL , 125 kDa. Molecular weight marker sizes as indicated.

3.4

Expression and Purification of USP7 Catalytic Domain (USP7CD )
The expression and purification of USP7CD was performed identically to as de-

scribed in Section 3.2.3. Approximately 10 g of harvested cells were obtained from
the 3 L culture. Figure 3.4 displays the chromatograms and SDS–PAGE analysis
associated with the purification of USP7CD . Figure 3.4A displays the nickel affinity
chromatography where fractions 5–10 were pooled and digested with TEV protease
to remove the 6His tag. Figure 3.4B represents the reverse nickel affinity chromatog-
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raphy where USP7CD was washed out from the column with the unbound proteins.
Figure 3.4C displays the final Superdex 75 chromatography step where fractions 31–34
were pooled. Approximately 67 mg of pure protein was obtained from the 3 L expression. A summary of the percent enzyme yield, total activity, and fold–purification
after each chromatography step is summarized in Table 3.3.

Table 3.3
Purification summary of USP7CD from 3 L culture of E.coli BL21-DE3
Protein

Total Activity

Specific Activity

Fold

(mg)

Units

(Units/mg)

Purification

Lysate

474

0.2

0.0005

1

100

Ni–Pool

177

0.02

0.0001

3

104

Reverse Ni–Pool

81

0.1

0.002

4

50

Superdex 75

71

0.2

0.003

6

22

Sample

3.4.1

% Yield

Expression and Purification of USP7CD H4–5 fusion
(USP7CD –H4–5)

Variations to the expression and purification described in Section 3.2.3 for the
preparation of USP7CD –H4–5 are as follows. Only 1 L of USP7CD –H4–5 was expressed, instead of the described 3 L. During the nickel affinity chromatography, unbound proteins were washed off with only 25 mL of Buffer A instead of the described
50 mL. The pooled fractions from the nickel affinity chromatography was digested
with TEV protease at a 1:5 ratio of USP7CD –H4–5:TEV instead of the 1:25 ratio to
remove the 6His tag.
Approximately 4 g of harvested cells were obtained from the 1 L culture. Figure 3.5
displays the chromatograms and SDS–PAGE analysis associated with the purification
of USP7CD –H4–5. Figure 3.5A displays the nickel affinity chromatography where
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Fig. 3.4. Purification of USP7CD . A. Left–Elution profile from HisTrap
(GE Healthcare) column charged with Nickel Sulfate. Right–12.5% SDS–PAGE
analysis of the eluted fractions, of which the wash and fractions 5–10 were
pooled. Red arrow indicates expected size of USP7CD . Molecular weight marker
sizes as indicated. B. Left–Elution profile from a 5 mL Hi-Trap (GE Healthcare)
column charged with Nickel Sulfate after TEV digest of 6His tag. Right–12.5%
SDS–PAGE analysis of eluted fractions, of which the wash contained USP7CD .
C. Left–Elution profile from a 300 mL Superdex 75 column. Right–12.5%
SDS–PAGE analysis of eluted fractions, of which 31–34 were pooled.
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USP7CD –H4–5 eluted at 30% Buffer A, and fractions 13–15 were pooled. Figure 3.5B
represents the reverse nickel affinity chromatography where USP7CD –H4–5 weakly
associated to the column and eluted after only 10% of Buffer A in fractions 9–10.
Figure 3.5C displays the final Superdex 75 chromatography step where fractions 24–
26 were pooled. Approximately 1.5 mg of pure protein was obtained from the 1
L expression. A summary of the percent enzyme yield, total activity, and fold–
purification after each chromatography step is summarized in Table 3.4.

Table 3.4
Purification summary of USP7CD –H4–5 from 1 L culture of E.coli
BL21-DE3
Protein

Total activity

Specific activity

Fold

(mg)

Units

(Units/mg)

Purification

Lysate

155

4.6

0.03

1

100

Ni–Pool

16.3

2.1

0.13

4

46

Reverse Ni–Pool

5.3

0.7

0.14

5

16

Superdex 75

1.5

0.7

0.18

6

14

Sample

3.4.2

% Yield

Expression and Purification of USP7 sans the TRAF domain (USP7CD –
H1–5)

The alternative purification process utilized for the purification of USP7CD –H1–5
is described in Section 3.2.4. Approximately 10 g of harvested cells were obtained
from the 3 L culture. Figure 3.6 displays the chromatograms and SDS–PAGE analysis
associated with the purification of USP7CD –H1–5. Figure 3.6A displays the nickel
affinity chromatography where fractions 4–10 were pooled, and digested with TEV
protease to remove the 6His tag. Figure 3.6B summarizes the Superdex 200 size–
exclusion chromatography where fractions 34–36 were pooled. Figure 3.6C displays
the MonoQ chromatography where fractions 20–24 were pooled. Approximately 12
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Fig. 3.5. Purification of USP7CD − H4 − 5. A. Left–Elution profile from
a 5 mL Hi-Trap (GE Healthcare) column charged with Nickel Sulfate. Right–
10% SDS–PAGE analysis of the eluted fractions, of which fractions 13–15 were
pooled. Red arrow indicates expected size of USP7CD –H4–5, 68 kDa. Molecular
weight marker sizes as indicated. B. Left–Elution profile from a 5 mL Hi-Trap
(GE Healthcare) column charged with Nickel Sulfate after TEV digest of 6His
tag. Right–SDS–PAGE analysis of eluted fractions, of which 9 and 10 contained
USP7CD –H4–5. C. Left–Elution profile from a 300 mL Superdex 75 column.
Right– 10% SDS–PAGE analysis of eluted fractions, of which fractions 24–26
were pooled.
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mg of USP7CD –H1–5 was obtained from the 3 L culture. A summary of the percent
enzyme yield, total activity, and fold–purification after each chromatography step is
summarized in Table 3.5

Table 3.5
Purification summary of USP7CD –H1–5 from 1 L culture of E.coli
BL21-DE3
Protein

Total Activity

Specific Activity

Fold

(mg)

Units

(Units/mg)

Purification

Lysate

447

16

0.04

1

100

Ni–Pool

103

30

0.3

8

180

Superdex 200

16

5

0.3

8

28

Mono Q

12

3

0.2

7

18

Sample

3.4.3

% Yield

Expression and Purification of TRAF–USP7CD

No variations of the Section 3.2.3 protocol were made for the expression and purification of TRAF–USP7CD . Approximately 10.5 g of harvested cells were obtained from
the 3 L culture. Figure 3.7 displays the chromatograms and SDS–PAGE gels associated with the purification of TRAF–USP7CD . Figure 3.7A displays the nickel affinity
chromatography of TRAF–USP7CD where fractions 5–12 were pooled. Figure 3.7B
summarizes the reverse nickel affinity chromatography where TRAF–USP7CD was
collected in the wash. Figure 3.7C displays the final Superdex 75 chromatography
step where fractions C3–C5 were pooled. Approximately 3.2 mg of pure protein was
obtained from the 3 L expression. A summary of the percent enzyme yield, total activity, and fold–purification after each chromatography step is summarized in Table
3.6.
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Fig. 3.6. Purification of USP7CD –H1–5. A. Left–Elution profile from 5
mL Hi-Trap (GE Healthcare) column charged with Nickel Sulfate. Right–10%
SDS–PAGE analysis of the eluted fractions, of which fractions 4–10 were pooled.
Molecular weight marker sizes as indicated. Estimated weight of USP7CD –
H1–5 is 104 kDa. B. Left–Elution profile from 300 mL Superdex 200 (GE
Healthcare) column. Right–SDS–PAGE analysis of eluted fractions, of which
35–37 containted USP7CD –H1–5. C. Left–Elution profile from 8 mL MonoQ
(GE Healthcare) column. Right– 10% SDS–PAGE analysis of eluted fractions,
of which fractions 20–24 were pooled.
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Fig. 3.7. Purification of TRAF–USPCD . A. Left–Elution profile from
5 mL Hi–Trap (GE Healthcare) column charged with Nickel Sulfate. Right–
12.5% SDS–PAGE analysis of the eluted fractions, of which fractions 5–12 were
pooled. Molecular weight marker sizes as indicated. Red arrow indicates estimated molecular weight of TRAF–USP7CD , 66 kDa. B. Left–Elution profile
from 5 mL Reverse Hi–Trap (GE Healthcare) column after TEV cleavage of
the 6His tag. Right–SDS–PAGE analysis of eluted fractions, of which the wash
was retained. C. Left–Elution profile from 300 mL Superdex 75 (GE Healthcare) column. Right– 12.5% SDS–PAGE analysis of eluted fractions, of which
fractions C3–C5 were pooled.
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Table 3.6
Purification summary of TRAF–USP7CD from 3 L culture of E.coli
BL21-DE3
Protein

Total Activity

Specific Activity

Fold

(mg)

Units

(Units/mg)

Purification

Lysate

445

0.3

0.0008

1

100

Ni–Pool

10.7

0.02

0.002

2

6

Reverse Ni–Pool

8.6

0.007

0.003

4

2

Superdex

3.2

0.004

0.002

3

1

Sample

3.4.4

% Yield

Expression and Purification of USP7 HUBL domains 1–5 (H1–5)

Variations to the expression and purification described in Section 3.2.3 for the
preparation of H1–5 are as follows. The pooled fractions from the nickel affinity
chromatography was digested with TEV protease at a 1:15 ratio of TEV:H1–5 instead
of the described 1:25 ratio to remove the 6His tag. During the reverse nickel affinity
chromatography step, the column was washed with a total of 120 mL of Buffer A,
instead of the described 40 mL.
Approximately 10.5 g of harvested cells were obtained from the 3 L culture. Figure 3.8 displays the chromatograms and SDS–PAGE analysis associated with the
purification of H1–5. Figure 3.8A displays the nickel affinity chromatography where
fractions 3–16 were pooled, and digested with TEV protease to remove the 6His tag.
Figure 3.8B summarizes the reverse nickel affinity chromatography where H1–5 was
washed out from the column with the unbound proteins as well as eluted in minimal
imidizole in fraction 3. Figure 3.8C displays the final Superdex 75 chromatography
step where fractions B10–B11 and were pooled. Approximately 17 mg of pure protein
was obtained from the 3 L expression.
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Fig. 3.8. Purification of H1–5. A. Left–Elution profile from 5 mL Hi–Trap
(GE Healthcare) column charged with Nickel Sulfate. Right–10% SDS–PAGE
analysis of the eluted fractions, of which fractions 3–16 were pooled. Molecular
weight marker sizes as indicated. Red arrow indicates estimated molecular
weight of H1–5, 64 kDa. B. Left–Elution profile from 5 mL Reverse Hi–Trap
(GE Healthcare) column after TEV cleavage. Right–SDS–PAGE analysis of
eluted fractions, of which the wash and fraction 3 were pooled. C. Left–Elution
profile from 300 mL Superdex 75 (GE Healthcare) column. Right– 10% SDS–
PAGE analysis of eluted fractions, of which fractions B10–B11 were pooled.
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3.4.5

Expression and Purification of USP7 HUBL domains 4–5 (H4–5)

Variations to the expression and purification described in Section 3.2.3 for the
preparation of H4–5 are as follows. The pooled fractions from the nickel affinity
chromatography was digested with TEV protease at a 1:10 ratio of TEV:H4–5 instead
of the described 1:25 ratio to remove the 6His tag. During the reverse nickel affinity
chromatography step, the column was washed with a total of 30 mL of Buffer A,
instead of the described 40 mL.
Approximately 14 g of harvested cells were obtained from the 3 L culture. Figure 3.9 displays the chromatograms and SDS–PAGE analysis associated with the
purification of H4–5. Figure 3.9A displays the nickel affinity chromatography where
fractions A2–B1 were pooled, and digested with TEV protease to remove the 6His tag.
Figure 3.9B summarizes the reverse nickel affinity chromatography where H4–5 was
washed out from the column with the unbound proteins, as well as eluted with minimal imidizole (≤ 20%) in fractions A1–A9. Figure 3.9C displays the final Superdex
75 chromatography step where fractions C6–C8 and were pooled. Approximately 18
mg of pure protein was obtained from the 3 L expression.

3.4.6

Expression and Purification of USP7 HUBL domains 1–2 (H1–2)

Variations to the expression and purification described in Section 3.2.3 for the
preparation of H1–2 are as follows. During the reverse nickel affinity chromatography
step, the column was washed with a total of 30 mL of Buffer A, instead of the described
40 mL. The H1–2 purification did not proceed past the reverse nickel chromatography
step due to the high level of purity obtained for the H1–2 sample.
Approximately 12 g of harvested cells were obtained from the 3 L culture. Figure 3.10 displays the chromatograms and SDS–PAGE analysis associated with the
purification of H1–2. Due to a computer glitch, the chromatogram associated with
the SDS–PAGE analysis of the nickel affinity chromatography column displayed in
Figure 3.10A was lost. Based on analysis of just the SDS–PAGE gel in Figure 3.10A
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Fig. 3.9. Purification of H4–5. A. Left–Elution profile from 5 mL Hi–Trap
(GE Healthcare) column charged with Nickel Sulfate. Right–12.5% SDS–PAGE
analysis of the eluted fractions, of which fractions A2–B1 were pooled. Molecular weight marker sizes as indicated. Red arrow indicates estimated molecular
weight of H4–5, 25 kDa. B. Left–Elution profile from 5 mL Reverse Hi–Trap
(GE Healthcare) column after TEV cleavage. Right–12.5% SDS–PAGE analysis of eluted fractions, of which the flowthrough and fractions A1–A9 were
pooled. C. Left–Elution profile from 300 mL Superdex 75 (GE Healthcare)
column. Right– 12.5% SDS–PAGE analysis of eluted fractions, of which fractions C6–C8 were pooled.
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fractions 3–19 were pooled, and digested with TEV protease to remove the 6His tag.
Figure 3.10B summarizes the reverse nickel affinity chromatography where H1–2 was
washed out from the column with the unbound proteins as well as eluted with minimal imidizole (≤ 20%) in fractions 5–7. Approximately 132 mg of pure protein was
obtained from the 3 L expression.

3.4.7

Expression and Purification of USP7 HUBL domains 1–3 (H1–3)

Variations to the expression and purification described in Section 3.2.3 for the
preparation of H1–3 are as follows. For both the nickel affinity and reverse nickel
affinity chromatography, the wash step was collected in fractions (5 mL) instead of as
a pool. The TEV protease digestion was performed with a 1:15 ratio of TEV:H1–3.
Approximately 12 g of harvested cells were obtained from the 3 L culture. Figure 3.11 displays the chromatograms and SDS–PAGE analysis associated with the
purification of H1–3. Figure 3.11A displays the SDS–PAGE analysis of the nickel
affinity chromatography where fractions 15–22 were pooled, and digested with TEV
protease to remove the 6His tag. Figure 3.11B summarizes the reverse nickel affinity
chromatography where H1–3 was present in the flowthrough, as well as washed out
in wash fractions 1–3. Figure 3.11C displays the final Superdex 75 chromatography
step where fractions C2–C5 were pooled. Approximately 93 mg of pure protein was
obtained from the 3 L expression.

3.4.8

Purification Summary

Table 3.7 summarizes the molecular weight, determined extinction coefficient,
yield from 1 L of bacterial culture, and the specific activity of the pure protein (if
applicable). The highest protein yields were obtained from the inactive HUBL truncations H1–2 and H1–3. The lowest protein yields were of USP7FL from the baculovirus
expression system and the TRAF–USP7CD truncation. As reported previously, the
specific activity is comparable for USP7FL , USP7CD –H4–5, and USP7CD –H1–5 while
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Fig. 3.10. Purification of H1–2. A. 12.5% SDS–PAGE analysis of the eluted
fractions, of which fractions 3–19 were pooled. Molecular weight marker sizes
as indicated. Red arrow indicates estimated molecular weight of H1–2, 25 kDa.
B. Left–Elution profile from 5 mL Reverse Hi–Trap (GE Healthcare) column
after TEV cleavage. Right–12.5% SDS–PAGE analysis of eluted fractions, of
which the wash and fractions 5–7 were pooled.
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Fig. 3.11. Purification of H1–3. A. Left–Elution profile from 5 mL Hi–Trap
(GE Healthcare) column charged with Nickel Sulfate. Right–12.5% SDS–PAGE
analysis of the eluted fractions, of which fractions 15–22 were pooled. Molecular
weight marker sizes as indicated. Red arrow indicates estimated molecular
weight of H1–3, 38 kDa. B. Left–Elution profile from 5 mL Reverse Hi–Trap
(GE Healthcare) column after TEV cleavage. Right–12.5% SDS–PAGE analysis
of eluted fractions, of which the flowthrough and fractions 1–3 were pooled. C.
Left–Elution profile from 300 mL Superdex 75 (GE Healthcare) column. Right–
12.5% SDS–PAGE analysis of eluted fractions, of which fractions C2–C5 were
pooled.
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removing the HUBL domains significantly decreases the activity as observed with
USP7CD and TRAF–USP7CD .

Table 3.7
Purification Summary and Molar Extinction Coefficients of USP7
Truncations
Molecular Weight
Truncation

(Da)

Extinction Coefficient
(M

−1

*cm

−1

)

Yield

Specific Activity

(mg)

(Units*mg −1 )

USP7FL

125,710

125,584*

5

0.1

USP7CD

41,265

43,316

22

0.003

USP7CD –H4–5

67,811

56,893

1.5

0.2

USP7CD –H1–5

104,405

89,579*

3.6

0.2

TRAF–USP7CD

66,177

74,250*

1.2

0.002

H1–5

63,665

52,842

5.6

N/A

H4–5

25,329

21,403

6

N/A

H1–2

24,801

25,495

44

N/A

H1–3

37,737

33,284

31

N/A

* Values were determined computationally with Expasy due to low concentration or
purity [52]. Unit is defined as µmol*min−1 Yield is per liter of culture

3.5

Discussion
USP7 is a high profile target for the development of anti–cancer therapeutics

due to its well characterized role in many disease states. Furthermore, structural
and kinetic studies have begun to scratch the surface of the importance of specific
interactions between the seven different domains of USP7. However, in our effort to
develop a specific USP7 inhibitor, further elucidation of intramolecular interactions of
the seven domains of USP7 was essential. Towards this goal, we expressed and purified
nine different constructs of USP7. Each construct was codon–optimized, synthesized
with a 6His tag and TEV cleavage site, and cloned into the pET–11a expression
vector by BioBasic Inc to achieve optimal expression in E. coli BL21–DE3 cells. The
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constructs expressed within the soluble fraction in E. coli BL21–DE3 cells and the
purifications utilized the same general sequence of chromatographic steps of nickel
affinity, reverse nickel affinity, and size–exclusion chromatography. Only USP7CD –
H1–5 truncation deviated from this sequence to include a MonoQ chromatographic
step in an attempt to improve overall purity of the protein. The purification protocols
described in this chapter resulted in milligram quantities of highly pure protein for
use with further kinetic and inhibitor characterization. Many of the truncations
described here were expressed and purified in an alternative manner by Faesen and
coworkers [20] however protein yields were not disclosed within the manuscript and a
comparison between the two methodologies cannot be made.
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CHAPTER 4. A TETHERED–RHEOSTAT MODEL FOR THE
INTRAMOLECULAR ACTIVATION OF THE ANTI–CANCER TARGET
USP7/HAUSP BY ITS HAUSP UBIQUITIN–LIKE (HUBL) DOMAINS
4.1

Abstract
Ubiquitin Specific Protease 7 (USP7/HAUSP) is a well–studied deubiquitinating

enzyme that regulates many critical signaling pathways in the cell, including regulation of the tumor suppressor p53/MDM2 pathway. The isolated catalytic domain
of USP7 has 30–fold lower activity than the full–length enzyme. Previous structural
and kinetic studies of USP7 have attributed this lack of activity to the catalytic
triad being misaligned. Additional structures have shown that to achieve full activity, the USP7/HAUSP Ubiquitin-like (HUBL) domains 4 and 5 must be present.
Previous reports have also suggested that HUBL domains 1–3 are simply scaffolds
for protein–protein interactions with USP7 binding partners, such as the allosteric
activator GMPS. Here, the kinetic differences between the activation of the isolated
catalytic domain of USP7 (USP7CD ) in trans by HUBL domains 1–5 and activation
by HUBL domains 4–5 were evaluated, and kinetic and biochemical characterization
of these observed differences revealed the importance of HUBL domains 1–3 in the
intramolecular activation of USP7. A new model for USP7 regulation is proposed
where by the HUBL domains 1–3 act as a rheostat, regulating the level of activation
USP7 experiences both internally as well as by allosteric activator GMPS.

4.2

Introduction
One of the most well studied DUBs is the ubiquitin specific protease 7 (USP7),

also known as the herpes virus-associated ubiquitin-specific protease (HAUSP). USP7
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is renowned for its essential role in the deubiquitination of both the tumor suppressor
protein p53 and its E3 ligase, MDM2 [40–42, 56]. When the cell is under normal
conditions, USP7 primarily deubiquitinates MDM2. However, when the cell experiences genotoxic stress, USP7 shifts its deubiquitination from MDM2 to p53 [33, 57].
Furthermore, under genotoxic stress, guanosine 5–monophosphate synthase (GMPS)
binds to and allosterically activates USP7 to enhance the rate of deubiquitination
which leads to the stabilization of p53 [58].
Disruption of the p53 signaling pathway is responsible for roughly 50% of human
cancers due to mutation or inactivation of p53 [38]. By deubiquitinating MDM2 and
p53, as well as other known USP7 substrates such as tumor suppressors PTEN and
FOXO4, and viral E3 ligase ICP0, USP7 has a hand in pathways involved in viral
infection, cell signaling, proliferation, and apoptosis [35–37, 39, 59]. Therefore, tight
regulation of USP7 activity is essential to maintaining proper cell signaling, and the
up–regulation of USP7 is a major contributing factor in the progression of many
cancers [35, 36, 40–43, 56]. Two research groups have identified compounds that
show potential for the specific inhibition of USP7 [45, 60]. For example, Chauhan
and coworkers have identified a compound series that inhibit cell growth and induces
apoptosis in multiple myeloma cell lines [45]. Alternatively, Colland and coworkers
have identified a compound that can increase cellular levels of p53 leading to p53–
mediated apoptosis [60].
X–ray crystal structures for each domain of USP7 are available as individual proteins, however, a full–length structure has yet to be determined. USP7 is comprised
of seven domains (Figure 4.1 A); a TNF receptor associated factor (TRAF) domain, a catalytic domain, and five ubiquitin-like (UBL) domains [19, 20, 33]. The
N–terminal TRAF domain is proposed to be responsible for substrate binding and
specificity [33]. The catalytic domain maintains the conserved papain–like fold seen
throughout the USP family [19]. Interestingly, the purified catalytic domain is 120–
fold less active than that of the full–length enzyme as measured with the fluorogenic
substrate ubiquitin–7-amino–4-methylcoumarin (Ub–AMC) [34]. The poor activity
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of the catalytic domain has been attributed to the observation that the catalytic triad
is misaligned in the unbound structure of USP7 (PDB: INB8 and 4M5W) presumably
making it catalytically inefficient (Figure 4.1 B) [15, 16]. However, in a crystal structure of the catalytic domain bound to ubiquitin aldehyde (PDB: 1NBF), the catalytic
triad is properly aligned for catalysis, suggesting that an induced–fit rearrangement
of the catalytic triad by binding of the substrate may be required for catalysis (Figure 4.1 B) [16]. Furthermore, a comparison of the unbound structure of the catalytic
domain to the ubiquitin aldehyde–bound structure shows that significant movement
of blocking loops 1 (residues 408-429, BL1) and 2 (residues 459-462, BL2) as well as
the switching loop (residues 285-291) is required to unblock the active site for the
binding of ubiquitin–aldehyde (Figure 4.1 C and D) [15, 19].
At the C–terminus of USP7 are five consecutive UBL domains referred to as the
HAUSP ubiquitin-like (HUBL) domains [20]. UBL domains are found throughout
nature and are surprisingly commonplace in USPs [22, 23]. There are sixteen USPs
that have been described to have UBL domains [22, 23]. UBL domains are defined
by the fact that they contain the highly stable β–grasp fold adopted by ubiquitin.
The sequence identity of UBL domains relative to each other and to ubiquitin is
very low, and, as a result, UBL domains are often only identified by determining
their structures [22]. This remains true for the HUBL domains where the sequence
identity between them is only 3 to 15%, or to ubiquitin, varying from 6 to 19% [20].
Unlike ubiquitin, UBLs do not contain the two terminal glycine residues and cannot
be conjugated to protein substrates.
Information regarding the function of the UBL domains and their interactions
within their respective proteins is lacking [22]. One UBL that is beginning to be
understood is the one within USP14. A UBL domain is present in the structure of
USP14, and is responsible for the association of USP14 with the proteasome [19]. The
binding of USP14 to the proteasome opens up the active site that is blocked by BL1
and BL2. The net result of the unblocking is an increase in catalytic activity [19, 61].
In 2005, the Mesecar lab identified the first viral UBL domain in the Severe Acute
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Fig. 4.1. Domain Organization of USP7 and Active Site Rearrangement Upon Ubiquitin Binding A. Structural representation of the X–ray
crystal structures of the seven domains of USP7. Grey: TRAF domain (PDB:
2F1W). Light pink: catalytic domain (PDB: 4M5W). Orange: HUBL1, Yellow: HUBL2, Green: HUBL3, Blue: HUBL4, Purple: HUBL5 (PDB: 2YLM).
B. A shift in the catalytic triad occurs between unbound (PDB: 4M5W) and
ubiquitin–aldehyde bound catalytic domain (PDB: 1NBF). The distances between the cysteine and the histidine in each form of the enzyme, as well as
how far the cysteine shifts, is labeled. C. Movement of the blocking loops BL1
and BL2 must occur to accommodate ubiquitin binding. D. A shift in the
switching loop (residues 285-291) in the ubiquitin–aldehyde bound structure
alleviates steric hindrance (denoted by the asterisk).
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Respiratory Syndrome virus papain–like protease (SARS-PLpro). This single UBL
domain is thought to be involved in the evasion of the virus from the innate immune
system but its definitive function is still unknown [62]. While USP14 and SARS–
PLpro only contain one UBL domain, it is common for USPs to have multiple UBL
domains [22]. However, no USP has been previously described to have five tandem
UBLs, a feature that is so far unique to USP7. Thus understanding the roles of the
five HUBL domains in USP7 function is of scientific interest.
A number of X–ray crystal structures of the HUBL domains has been determined with different constructs including the complete HUBL domain (PDB 2YLM),
HUBL domains 1–3 in complex with peptide fragments of USP7s substrates ICP0
and DNMT1 (PDB: 4WPH, 4WPI, and 4YOC), as well as a truncation of USP7
containing just the catalytic domain and HUBL domains 1–3 (Kim et al, and PDB:
5J7T) [20, 37, 39, 63, 64]. The complete structure of the HUBL domains suggests that
the individual domains are arranged in a 2–1–2 fashion and can assume an elongated orientation (Figure 4.1, PDB 2YLM) [20, 37]. Two X–ray crystal structures
of HUBL domains 1–3 were determined by Pfoh and coworkers and the structures
show the HUBL domains in two different orientations. These two structures provide
insight into the flexibility of these domains which occurs through a hinge between
HUBL domains 2 and 3 (2/3 hinge) which allows the HUBL domains to assume a
compact orientation in addition to the elongated structure [39]. The X–ray crystal
structure of the catalytic domain with HUBL domains 1–3 was recently solved by
Kim and coworkers. The structure reveals that the HUBL domains are in a compact orientation, supporting the identification of the 2/3 hinge. The structure also
revealed the precise location of the α–helix or ”tether” between the catalytic domain
and the HUBL domains [63]. Biochemical and mutagenesis studies of the rigidity,
length, and localization of charged groups in the tether elucidated its role in the
spatial orientation of the HUBL domains with respect to the catalytic domain [63].
It has long been understood that the HUBL domains are required for full activity of USP7. A kinetics study by Faesen and coworkers suggested that only HUBL

106
domains 4 and 5 are truly required for full activation of USP7 [20, 34]. This finding was supported by X–ray crystal structures determined by Rougé and coworkers
(PDB: 5JTV and 5JTJ) which show the C–terminal peptide of HUBL 5 binding in
an activation cleft, a pocket apparent in X–ray crystal structures of the catalytic
domain bound to ubiquitin [64]. Kinetic studies by both groups support the importance of this peptide in the activation of USP7 [20, 64]. Rogué and coworkers have
hypothesized that the binding of this peptide stabilizes the ubiquitin–USP7 complex
for increased catalytic activity [64]. However, a detailed mechanism of how this interaction influences USP7s activity has yet to be fully elucidated [20]. The activation
USP7 experiences by the binding of this loop within the activation cleft, however,
can be easily disrupted by a single point mutation [20, 64]. Furthermore, it has been
suggested that HUBL domains 1–3 are not involved in the activation process and are
dispensable for intramolecular activation [20]. However, an acidic binding pocket for
allosteric activator GMPS and substrate DNMT1 was discovered in HUBL domain 2
which may shed light on the importance of HUBL domains 1–3 [20, 37, 39].
In this dissertation work, the kinetic mechanism by which the HUBL domains
influence the activity of USP7 is explored and the kinetic data support of the structural model presented by Rougé and coworkers [64]. The results also support some of
the previous kinetic findings that all five HUBL domains, as well as just the HUBL
domains 4 and 5, can increase the activity of USP7. However, through an in depth
kinetic analysis of the role of the HUBL domains, significant differences in the kinetic
parameters that influence the activity of USP7 are observed, and these differences
depend upon which HUBL domains are present. Previously, the role of HUBL domains 1–3 was described as a binding site for substrates as well as the allosteric
activator GMPS, and did not have a direct role in the intramolecular activation of
USP7 [20, 39]. The new findings presented here shed light on the requirement of
HUBL domains 1–3, and their influence on HUBL domains 4 and 5 to achieve the
native form of intramolecular activation of USP7.
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4.3

Experimental Procedures

4.3.1

Kinetic Assays

Steady–State Kinetic Studies
The Km and kcat values of USP7FL and USP7CD were determined with Ub–Rho110.
The purified enzymes were diluted to a working concentration of 2 nM in the Assay
Buffer described in Section 2.3.12. Twelve, two–fold serial dilutions of Ub–Rho110
were made ranging from 0.04 µM to 40 µM in Substrate Buffer described in Section 2.3.12. Assays were performed in 30 µL reaction volumes and in triplicate. The
background rate were measured by pipetting 15 µL into a 96–well Corning Costar
black half–volume plate and measuring the rate of change in fluorescence with a
BioTek Synergy H1 plate reader. Fluorescence measurements were made every 10
seconds at an excitation λ of 360 nm and emission λ of 460 nm over a time period of
two minutes and at 25 ◦ C. Following the measurement of the background, 15 µL of
the working stock of the USP7 enzymes was added to the plate, the plate was mixed
for 10 seconds, and the assay was measured under the same conditions for 30 minutes
total, or until the reactions started to plateau. The final concentration of the USP7
enzymes were 1 nM and the final concentration range for the substrates was 0.01 µM
to 20 µM. The initial slope of each reaction in arbitrary fluorescence units (AFU) per
unit time (AFU/sec) was converted to the amount of product produced per unit time
(M/sec) with the extinction coefficient of the substrate. The extinction coefficient of
both substrates was determined as described for Ub–Rho110 in Section 2.3.12. This
rate value in µM/sec was then converted to the turnover number (V/[E]) by dividing
by the enzyme concentration. The data were then analyzed with the kinetics module of SigmaPlot (v13: Systat Software Inc.) by fitting the resulting curves to the
Michealis–Menten equation (Equation (2.1)) to determine the kcat and Km for each
enzyme.
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Kinetic Studies on the Influence of the HUBL Domains on the Interaction
of Ub–Rho110 with USP7
The kinetic influence the HUBL domains have on the activity of USP7 was kinetically evaluated with USP7CD and HUBL truncations H1–5 and H4–5 in trans. The
kinetic assays were performed by varying the concentration of Ub–Rho110 at a fixed
concentration of the HUBL truncation and vice versa. Two–fold serial dilutions of
Ub–Rho110 were made in Substrate Buffer to obtain a working concentration range
of 0.12 µM to 120 µM. Two–fold serial dilutions of HUBL truncations H1–5 and H4–5
were made in Assay Buffer to obtain a working concentration range of 0.075 µM to
37.5 µM. USP7CD was diluted in assay buffer to a working concentration of 8.6 nM.
Each assay was performed in a 30 µL reaction volumes in triplicate in a Corning
96 half–well black plates. The background rate were measured by pipetting 5 µL of
Ub–Rho110 and 20 µL of the HUBL truncation into a 96–well Corning Costar black
half–volume plate, and measuring the rate of change in fluorescence with a BioTek
Synergy H1 plate reader. Fluorescence measurements were made every 10 seconds at
an excitation λ of 360 nm and emission λ of 460 nm over a time period of two minutes
and at 25 ◦ C. To initiate the reaction, 5 µL of USP7CD was added to the wells and
the plate was read for 30 minutes. The final concentrations of each component is as
follows: Ub–Rho110 ranged from 0.02 µM to 20 µM, HUBL truncation ranged from 0
µM to 25 µM and the USP7CD concentration was held constant at 1 nM. The initial
rates were determined and converted to v/[E] using the extinction coefficient of the
substrate as described in Section 2.3.12. The resulting v/[E] values were plotted as
a function of Ub–Rho110 or as a function of HUBL truncation. The curves of v/[E]
as a function of substrate were fit to the activation models provided in the kinetics
module of SigmaPlot (v13: Systat Software Inc.) to statistically determine the best
model for this system. The equation describing a kinetic model for the non–essential
activation (Figure 4.2) was used to fit the data,
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where E represents USP7CD , A is a HUBL truncation (H1–5 or H4–5), and S is
Ub–Rho110. For the non–essential activation model, enzyme velocity is given by
v = kcat [ES] + βkcat,app [EAS]

(4.2)

Fig. 4.2. Non–essential Kinetic Model. Expansion of the simple enzyme
kinetic scheme to include the potential effects of an activator and the introduction of KA kinetic parameter and kinetic modulators α and β which manipulate
KA , Km , and kcat . E: enzyme, USP7CD , A: activator, HUBL truncation, S:
substrate, Ub–Rho110

From the fit to Equation (4.1), the kinetic parameters: Km,app , kcat,app , KA,app , and
the kinetic modifiers α, and β in the presence of a particular HUBL truncation were
determined. As described in Section 4.4.2 the data were also fit to the substrate–
activator model as well, however the non–essential activation model was determined
to be the best fit by comparing the AICc values.
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4.3.2

Di–Ubiquitin Chain Cleavage Assays

Evaluation of the ability of a particular HUBL truncation to activate USP7CD with
the more native substrate Lys48 was performed with a reaction mixture composed of
4.2 µM of Lys48 di–ubiquitin (Boston Biochem), 50 nM USP7CD , and either 2, 6, or
20 µM of H1–5 or H4–5. A negative control was included with no enzyme. Control
of USP7FL and USP7CD with Lys48 was also included. All reactions were performed
at 25 ◦ C in Assay Buffer for two hours. Reactions were quenched with the addition
of NuPAGE LDS sample buffer (Invitrogen) supplemented with 5 mM fresh DTT.
Samples were analyzed by SDS-PAGE using NuPAGE Novex 4–12% BisTris mini gels
(Invitrogen) stained with Coomassie Brilliant Blue.

4.3.3

Isothermal Calorimetry (ITC) Analysis of Compound Binding

Isothermal calorimetry was utilized to further evaluate the interaction between
USP7CD and the HUBL domain truncations: H1–2, H4–5, and H1–5. All proteins
were dialyzed overnight at 4 ◦ C into Analytical Buffer (50 mM HEPES pH 7.5, 3 mM
TCEP, and 100 mM NaCl). USP7CD was concentrated by ultrafiltration with a 10,000
MWCO membrane (Millipore) and diluted to 30 µM in Analytical Buffer. HUBL
truncations were concentrated in the same fashion with the appropriate MWCO membrane. Each truncation was diluted to 1.5 mM in Analytical Buffer (50 fold higher
than [USP7CD ]). A Malvern MicroCal ITC200 instrument was used for the measurements. A volume of 200 µL of 30 µM USP7CD was added to the cell, and the syringe
volume of the HUBL truncation was 100 µL. The initial injection volume was 0.4 µL
to remove any bubbles from within the system, and the remaining injections had a
volume of 1.8 µL for each USP7 truncation and a total of 22 injections was performed
(40 µL). A three minute delay was programmed between each injection to allow the
signal to return to baseline. All reactions were run at 25 ◦ C. The spin speed was set
to 1000 rpm. For each truncation, blank injections were run by injecting the USP7
truncation into Analytical Buffer. Data was exported into NITPICK software (NIH)

111
and the heat from the blank run was subtracted, and the results were analyzed for
measurable heat.

4.3.4

Interference of USP7FL Activity or USP7CD –H4–5 Activity by HUBL
Truncations in trans

To determine the amount of interference caused by the individual HUBL truncations in trans with USP7FL , the total concentration of Ub–Rho110 was fixed at 1.25
µM, and the USP7FL concentration was fixed at 1 nM. Each HUBL truncation tested
(H1–3, H1–2, H1–5, and H4–5) was prepared as a 1.3x working stock (260 µM). Two–
fold serial dilutions of the HUBL truncations were made resulting in 11 concentrations
of each HUBL truncation ranging from 0.2 µM to 200 µM. A 10x working stock of
USP7FL and 6x working stock of Ub–Rho110 were prepared. All proteins were diluted
in Assay Buffer and Ub-Rho110 was diluted in Substrate Buffer. To a 96–well Corning
Costar black half–volume plate, 5 µL of the working stock of Ub–Rho110 and 23 µL
of each concentration of the particular HUBL truncation being tested was added to
individual wells. The plate was mixed for 10 seconds within the plate reader and the
background rates were measured for two minutes at conditions described previously
(Section 2.3.12). To initiate the reaction, 3 µL of the working stock of USP7FL was
added to the plate, and the plate was shaken within the plate reader for 10 seconds
prior to measuring the activity. The enzymatic activity was measured for 30 minutes
as described previously (Section 2.3.12). The enzymatic activity of USP7FL alone
was measured also measured for comparison. All assays were done in triplicate. The
% Interference was calculated for each concentration of the HUBL truncations using
Equation (4.3).


% Interference = 1 −

Ratesample − Ratebkgd
Rateno interference − Ratebkgd


 × 100

(4.3)
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In Equation (4.3), Ratesample is the initial slope of the original progress curve of
USP7FL in units of AFU/second in the presence of a particular HUBL truncation
and concentration. The Ratenointerf erence is the initial slope of the progress curve of
USP7FL without any interfering HUBL truncation. The Ratebkgd is the background
rate of the Ub-Rho110 in the presence of just the HUBL truncations in the absence
of USP7FL . This control allows us to confirm that no HUBL truncation has enzymatic activity itself. The calculated % Interference were then plotted in terms of
HUBL truncation concentration. The resulting curve was fit to the Michealis–Menten
equation (Equation (2.1)) with SigmaPlot as described previously (Section 2.3.12).
The calculated Km value from the fit corresponds to the IC50 values for the HUBL
truncation, and the Vmax value corresponds to the maximum % Interference inflicted
on the system by the HUBL truncation (Table 4.3). The same experimental set–up
and data analysis was utilized to evaluate the interference of H1–3 and H4–5 with
USP7CD –H4–5.

4.3.5

Analytical Size–Exclusion Chromatography to Evaluate Any Direct
Interaction Between H1–3 and H4–5

USP7 truncations H1–3 and H4–5 were evaluated for direct interaction by size
exclusion chromatography (SEC). H1–3 was diluted to a final concentration of 65 µM
in Analytical Buffer (50 mM Tris pH 7.5, 3 mM TCEP, and 100 mM NaCl) in a final
volume of 200 µL. H1–3 was then injected onto a 24 mL Sepharose 6 (GE Healthcare)
SEC column and run at a flow rate of 0.5 mL/min. After the run of H1–3 alone was
complete, H4–5 was diluted to 65 µM in 200 µL and run identically. To determine if
H1–3 and H4–5 have a direct interaction, a 1:1 molar ratio of H1–3 to H4–5 was mixed
at 65 µM of each component in a volume of 200 µL. The presence of an interaction
was evaluated by the elution profile of the combined H1–3 and H4–5 chromatogram
compared to the individual chromatograms of H1–3 and H4–5.
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4.4

Results

4.4.1

Steady–state kinetic parameters of USP7FL , USP7CD , and
USP7CD − H4 − 5

The full–length USP7 (residues 1-1102, USP7FL ) and the catalytic domain (residues
206-560, USP7CD ) were purified to > 98% purity from Sf9 cells and E. coli cells,
respectively (Chapter 3). The steady–state kinetic characterization of the deubiquitinating activity of each enzyme was performed with the fluorogenic substrate Ub–
Rho110. The initial rates were measured in triplicate and plotted versus increasing
Ub–Rho110 concentrations (Figure 4.3A and B). The resulting data were fit to the
Michealis–Menten equation (Equation (2.1)), and the Km and kcat values derived from
the best–fits for each enzyme combination are summarized in Table 4.1. The resulting Km value for USP7FL was 1.46 ± 0.07 µM and the kcat value was 1.24 ± 0.02
s−1 . The Km value of USP7CD at 1.5 ± 0.5 µM is the same within error as that of
USP7FL . However, the kcat value of USP7CD is only 0.040 ± 0.002 s−1 which is a
30–fold decrease in the maximal rate of USP7CD compared to USP7FL . When the
steady–state kinetic parameters were previously determined using Ub–AMC as the
substrate, a 120–fold difference in the maximal rate between USP7FL and USP7CD
was observed (Table 4.1) [20]. Moreover, the Km value of USP7CD for Ub–Rho110 is
lower than that for Ub–AMC (15.13 ± 1.09 µM). Ub–Rho110 was therefore chosen
for kinetic studies as the concentration of Ub–Rho110 required to reach saturation
relative to Ub–AMC is much lower which will lower the cost substantially, reduce the
chance of inter–filter effects, and allows the kinetic studies to be run over a larger
range of concentrations providing greater accuracy.
The catalytic domain of USP7 tethered to HUBL domains 4 and 5 (residues 2061102 ∆564-879, USP7CD –H4–5) was purified to > 98% purity from E. coli as determined by SDS–PAGE analysis (Chapter 3). The steady–state kinetic parameters were
determined with Ub–Rho110 as described previously (Figure 4.3C). The resulting Km
for USP7CD –H4–5 was 2.2 ± 0.2 µM and the kcat was 1.33 ± 0.05 s−1 (Table 4.1).
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With Ub–AMC the reported Km and kcat values with USP7CD –H4–5 were 2.89 ± 0.20
µM and 1.32 ± 0.03 s−1 , respectively [20]. These results support those by Faesen and
coworkers who found that HUBL domains 4 and 5 can activate USP7 to a similar
extent as with all HUBL domains present in USP7FL [20].

Fig. 4.3. Steady–State Kinetic Response of USP7FL , USP7CD , and
USP7CD − H4 − 5 to the Substrate, Ub–Rho110. Rates for the enzymatic activity are normalized to the total enzyme concentration and plotted
against varying Ub–Rhodamine110 concentration. A. USP7FL at 1 nM, B.
USP7CD at 200 nM, and C. USP7CD –H4–5 at 1 nM. Ub–Rhodamine 110 concentrations varied from 0.02 µM to 20 µM depending on the enzyme being
tested. Error bars, Standard Deviation.

4.4.2

HUBL domains 1–3 modulate the steady–state kinetic parameters
surrounding activation of USPCD in trans

Previous work has suggested that HUBL domains 4 and 5 (H4–5) are required for
activating USP7CD [20,34]. It was further suggested that HUBL domains 1–3 (H1–3)
do not play a role in the intrinsic USP7 activity, and are only required for binding to
the allosteric activator GMPS which increases the kcat over 5–fold [20]. A kinetic approach was taken to further evaluated the role of H1–3 in the intramolecular activation
of USP7. Activity assays were performed with USP7CD by varying the concentrations
of either H1–5 or H4–5 in trans as well as, using fixed, variable concentrations of Ub–
Rho110. The initial rates of hydrolysis were measured for each condition, and plotted
with respect to either the concentration of Ub–Rho110 (Figure 4.4A and B) or to the

a

Values reported by Faesen and coworkers [20].

(x106 * s−1 * M −1 )

0.85 ± 0.04

1.24 ± 0.02

kcat (s−1 )

kcat /Km

1.5 ± 0.5

1.46 ± 0.07

Km (µM)

0.012 ± 0.004

0.040 ± 0.002

USP7CD

USP7FL

Ub–Rho110

0.60 ± 0.07

1.33 ± 0.05

2.2 ± 0.2

USP7CD –H4–5

0.49

1.42 ± 0.02

2.89 ± 0.10

USP7FL

0.004

0.06 ± 0.02

15.13 ± 1.09

USP7CD

Ub–AMCa

0.46

1.32 ± 0.03

2.89 ± 0.2

USP7CD –H4–5

Table 4.1
Steady–state kinetic parameters of USP7FL , USP7CD , and USP7CD –H4–5 constructs as measured with
fluorogenic ubiquitin substrates
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concentration of H1–5 or H4–5 HUBL truncation, (Figure 4.4C and D). All conditions
produced hyperbolic saturation curves for the response of USP7CD to the binding of
the Ub–Rho110 substrate. Surprisingly, distinct differences were observed between
activation by H1–5 and H4–5 in trans. At 25 µM of H1–5, the activity of USP7CD is
increased 40–fold relative to USP7CD alone, while with H4–5, the activity of USP7CD
is increased only 20–fold at 25 µM H4–5 (Figure 4.4A and B). Figure 4.4D shows that
H4–5 just starts to reach saturation at 25 µM with Ub–Rho110, while Figure 4.4C
shows that H1–5 fully saturates within the concentration range tested (0 µM to 25
µM).
The HUBL domains have been described by Faesen and coworkers to activate
USP7, so the data in Figure 4.4 were fit to the non–essential activation model (Equation (4.1)) and the substrate–activator (SA) model using the Enzyme Kinetics Module
of SigmaPlot (v13: Systat Software Inc.) [20]. The SA model requires the substrate
to first interact with the activator to form the true substrate of the enzyme prior
to binding to the enzyme [65]. This is in contrast to the non–essential activation
model which assumes that the reaction can occur in the absence of the activator all
together, just at a reduced rate [65]. It is unlikely that the HUBL domains activate
by substrate-activator (SA) activation, as USP7CD has activity without the HUBL
domains present. Rather, it is more likely that USP7 is an example of non–essential
activation. To test this hypothesis, the Akaike Information Criterion for small sample
size (AICc) values were compared from the fits to each equation. The best model
is determined by the fit that resulted in the most negative AICc value, as the more
negative the AICc value is, the better the fit. It was clear that for both the H1–5
and H4–5 data sets, the fit to the non–essential activation model was best. For H1–5,
the AICc value for the fit to the non–essential activation model was -385, which is
167 points more negative than that of the SA model (-218). This trend is observed
for H4–5 as well; the AICc value for the non–essential activation model (-689) was
312 points more negative than that of the SA model (-377). Using the equation for
non–essential activation (Equation (4.1)) the kinetic parameters Km , kcat , KA , α, and

Fig. 4.4. Steady–State Kinetic Analysis of USP7CD with HUBL Domains in trans. A survey of steady–
state kinetic parameters of the interaction of USP7CD with HUBL truncations H1–5 or H4–5 in trans. Reactions were
performed by varying the concentration of Ub–Rho110 from 2–20 µM (A and B) or HUBL truncation concentration from
0–25 µM (C and D) with 1 nM USP7CD . Initial AFU/s were measured for each curve, and were converted using the
extinction coefficient of the substrate to v/[E]. Resulting values were plotted as v/[E] in terms of the concentration of the
constant variable. For A. and C., H1–5 was tested. Curves B. and D. are the results of USP7CD with H4–5 in trans.
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β were determined for each fit (Table 4.2). The α– and β–values are factors by which
KA , Km , and kcat change when the substrate is engaged with the enzyme. A large
difference in the Km value for USP7CD with H1–5 present (40 ± 7 µM) is observed in
comparison to USP7CD alone (1.5 ± 0.5 µM) but not with H4–5 and USP7CD (2.6 ±
0.3 µM). This discrepancy is discussed further in Section 4.4.4.
Interestingly, with no substrate present, the global fit to the non–essential activation model reported that the Ka,app value for H1–5 (8.7 ± 0.7 µM) and H4–5 (9 ±
1 µM) are identical. This finding is supported by the SPR findings by Faesen and
coworkers [20]. They determined the dissociation constant for USP7CD and H1–5 as
48.0 ± 9.7 µM, however no interaction could be measured for USP7CD and H1–3.
They therefore concluded that the HUBL domains associate with USP7CD by H4–5
alone [20].
To further validate the findings of Faesen and coworkers isothermal calorimetry
was utilized to measure binding. Three HUBL domains were tested: H1–2, H4–5,
and H1–5. The HUBL truncations were loaded into the syringe and injected into
USP7CD in the ITC cell. For all combinations tested no heat could be detected
above background. This observation suggests one of two possibilities. First, the
interaction between USP7CD and the HUBL truncations is not enthalpically driven
and no measurable heat is released. The second possibility is that the interactions
are too weak to measure. The latter argument is supported by the SPR results of
Faesen and coworkers who observed that the interaction between USP7CD and the
HUBL domains is weak in trans.
H1–5 activation of USP7CD reduces the Km and KA values in the presence of
substrate with an α–value of 0.11 ± 0.02 and increases the kcat value with a β–value
of 6.2 ± 0.9. In contrast, α and β for H4–5 are both greater than one (10 ± 3 and
100 ± 19, respectively), resulting in an increase in Km , KA , and kcat in the presence of
substrate (Table 4.2). This difference in kinetic parameters suggests that with H1–3
present, H1–5 modifies the kinetic parameters differently than that of H4–5 alone.
H4–5 has a substantial increase in kcat , but is hindered by an increase in KA and Km
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without H1–3 present. The larger error associated with the α– and β–values for H4–5
may be a result of weaker activation at lower concentrations of H4–5.

4.4.3

Activation of USP7CD by H4–5 in trans alone is negatively influenced by increasing substrate concentration

To evaluate the appropriateness of applying the non–essential activation model
(Figure 4.2) and equation (Equation (4.1)) to this system the data from each curve displayed in Figure 4.4C and D were fit individually to the Michealis–Menten equation.
The αKA,app and βkcat,app values were determined from each individual concentration
of Ub–Rho110 for both H1–5 and H4–5. These βkcat,app and αKA,app values were then
plotted against the corresponding Ub–Rho110 concentration of the initial individual
curve the values were measured from (Figure 4.5A and B, respectively). The resulting
curves of the βkcat,app for H1–5 and H4–5 are remarkably similar (Figure 4.5A). The
βkcat,app curves of Figure 4.5A were then fit again to the Michealis–Menten equation
to determine a single αKm,app and βkcat,app value which represents the entire data
set. The determined values are presented on the right side of Table 4.2. The αKm,app
values for H1–5 and H4–5 were determined to be 4.9 ± 0.4 µM and 16.0 ± 2.0 µM
respectively. The βkcat,app for H1–5 and H4–5 were determined to be 0.62 ± 0.02 s−1
and 1.08 ± 0.09 s−1 , respectively. The enzymatic efficiency of an enzyme is defined as
how many molecules of substrate can be turned over in a unit of time, kcat,app /Km,app
and is a value that can be used to compare the activity of different enzymes. The
enzymatic efficiency for H1–5 was determined to be 0.13 ± 0.01 x 106 * M −1 * s−1
and 0.07 ± 0.01 x 106 * M −1 * s−1 for H4–5 (Table 4.2). These independently derived
kinetic parameters are similar to the values derived from the global fit to the non–
essential activation model for both H1–5 and H4–5 which provides further support
for the application of the non–essential activation model to this system.
A significant difference between the activation by H1–5 and H4–5 can be observed
in Figure 4.5B. The αKA,app value for H1–5 shows an initial drop from 4 ± 1 µM at

a

90 ± 29
2.0 ± 0.4
10 ± 3
100 ± 19

1.0 ± 0.2
0.6 ± 0.1
0.11 ± 0.02
6.2 ± 0.9

α
β

(s−1 )

βkcat,app

Indicates an average value could not be determined.

(x106 * s−1 * M −1 )

kcat /Km

(µM)

αKA,app

0.08 ± 0.03

26 ± 8

4±1

(µM)

αKm,app

0.15 ± 0.05

9±1

8.7 ± 0.7

(µM)

KA

0.020 ± 0.001

0.1 ± 0.01

(s−1 )

kcat

2.6 ± 0.3

40 ± 7

(µM)

Km

USP7CD +H4–5

USP7CD +H1–5

Non–essential Activation Model Fit

0.13 ± 0.01

0.62 ± 0.02

2.9 ± 0.3

4.9 ± 0.4

USP7CD +H1–5

0.07 ± 0.01

1.08 ± 0.09

N/Aa

16 ± 2

USP7CD +H4–5

Individual Fit

Table 4.2
Steady–State Kinetic Parameters of USP7CD with HUBL Domains in trans as Measured with Ub–Rho110
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0.02 µM Ub–Rho110 to 2.0 ± 0.2 µM at 0.32 µM Ub–Rho110 and averages 2.9 ± 0.3
µM across the concentration range tested. The αKA,app value from the global fit to
the non–essential activation model fit for H1–5 is similar at 1.0 ± 0.2 µM. The αKA,app
value for H4–5, however, varies considerably, ranging from 0.6 ± 0.2 to 23 ± 5 µM
with increasing Ub–Rho110 concentrations. The αKA,app value for H4–5 derived from
the fit to the non–essential activation model is 90 ± 29 µM. These results suggest that
with increasing substrate concentration, the weak interaction of H4–5 with USP7CD ,
as described previously in Section 4.4.2, is exacerbated and suggests H1–3 acts to
stabilize H4–5 for activation of USP7CD in the presence of substrate.

4.4.4

USP7CD is activated predominantly by changes in βkcat,app with respect to HUBL truncation concentration

To further evaluate the requirement of H1–3 in the activation of USP7CD , we
evaluated the effects of increasing HUBL truncation concentration on the kinetic activity of USP7CD by fitting the data from each individual curve in Figure 4.4A and
B to the Michealis–Menten equation. From these fits, individual values for βkcat,app
and αKm,app were determined in terms of the HUBL truncation concentration (Figure 4.6A and B, respectively). The results show that substantially less H1–5 is required to achieve maximum enzymatic activity in this system, while H4–5 does not
reach maximum enzymatic activity within the concentrations tested (Figure 4.6A).
Thus, H1–3 does have a significant role in the enzymatic activity of USP7 and does
not simply serve as a scaffold for USP7 binding partners.
The αKm,app values obtained from the Michealis–Menten fit of Figure 4.4A and B
were plotted in terms of the respective HUBL truncation concentration (Figure 4.6B).
The αKm,app values associated with increasing H4–5 truncation concentration shows
a gradual but slight increase from 2 to 8 µM. A spike in αKm,app is observed for
H1–5 at low concentrations of H1–5 (0.1 to 3.13 µM), which then plateaus at high
concentrations of H1–5 (> 3.13 µM) to ∼8 µM. This spike may shed light on the
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Fig. 4.5.

Modulation of the Steady–State Kinetic Parameters of
USP7CD as a function of Ub–Rho110 Concentration. The individual
curves from Figure 4.4C and D were fit to the Michealis–Menten equation. A.
The βkcat,app values derived from the fits in terms of Ub–Rho110 concentration.
The βkcat,app curves were again fit to the Michealis–Menten equation to derive
an overall αKm,app and βkcat,app value for each truncation. B. The αKA,app
values determined from the individual curves in Figure 4.4C and D in terms of
increasing Ub–Rho110 concentration. Each assay was done in triplicate. Error
bars, Standard Deviation.
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observed discrepancy in the global fit of the data to the non–essential activation model
Km value of 40 ± 7 µM for USP7CD with H1–5 in trans discussed in Section 4.4.2. To
further evaluate the increase in αKm,app observed with H1–5, the βkcat,app /αKm,app
was determined for each HUBL truncation concentration, and plotted as a function of
HUBL truncation concentration (Figure 4.6C). Both H1–5 and H4–5 show a hyperbola
with increasing HUBL truncation concentration. The variation in αKm,app for H1–5
does not greatly influence the overall enzymatic efficiency of the system as a function
of HUBL concentration, and a mechanistic reason for the spike cannot be further
explained at this time. Furthermore, there is only a 2–fold difference between the
enzymatic efficiency of USP7CD by H1–5 and H4–5 with respect to HUBL truncation
concentration, which supports our previous observations in Figure 4.5A that both
H1–5 and H4–5 can activate USP7CD to a similar extent.

4.4.5

Trans activation of USP7CD by HUBL domains persist when evaluated with a more native substrate

The substrate Lys48 di–ubiquitin was utilized to determine if the same activation
trends persisted with a more native substrate. The data is summarized in Figure 4.7.
The results show that USP7FL completely processed the Lys48 di–ubiquitin to mono–
ubiquitin within the two hours, while no cleavage of Lys48 di–ubiquitin by USP7CD
could be visualized. Mono–ubiquitin could be observed with only 2 µM of H1–5 in
trans with USP7CD , while 6 µM of H4–5 was required to observe mono–ubiquitin
in the same amount of time. These results demonstrate that the cleavage of Lys48
di–ubiquitin increases with respect to the concentration of HUBL truncation present
(Figure 4.7). Furthermore, these findings indicated that our experiments utilizing
Ub–Rho110 as a substrate accurately reflect the mechanism of activation for USP7,
and support the findings that H1–3 are required for the activation of USP7CD .
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Fig. 4.6. Modulation of Steady–State Kinetic Parameters of USP7CD
as a function of HUBL Truncation Concentration. The individual curves
from Figure 4.4A and B were fit to the Michealis–Menten equation. A. From
this fit, βkcat,app values in terms of increasing concentrations of H1-5 and H4–5
were determined. B. The variation in the αKm,app values in terms of increasing
H1–5 and H4–5 concentrations. C. Evaluation of the turnover of substrate by
both systems in terms of HUBL truncation concentration as calculated from the
fits of the individual curves from Figure 4.4A and B to the Michealis–Menten
equation
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Fig. 4.7. Cleavage of Di–Ubiquitin Substrate Lys48 by USP7CD with
HUBL Truncations in trans. Survey of the hydrolysis of 0.5 µg of di–
ubiquitin substrate Lys48 by 50 nM of USP7FL (Lane 2), USP7CD (Lane 3),
and USP7CD in trans with noted concentrations of either H1–5 (Lanes 4–6) or
H4–5 (Lanes 7–9). Concentration of HUBL truncations varied as stated from
2 to 20 µM.

4.4.6

H1–3 can disrupt USP7FL and USP7CD –H4–5 activity

To further evaluate the role of H1–3 in the activation of USP7CD , HUBL truncations were added to USP7FL and Ub–Rho110. The percent inhibition was calculated
from the measured activity (Equation (4.3)), and plotted in terms of the respective
concentration of HUBL truncation (Figure 4.8A). When H4–5 was added to USP7FL
it appeared to have no effect on the system, as is observed by the negative percent
inhibition values. HUBL truncations H1–2 and H1–3 strongly interfered with the native activity of USP7FL and had IC50 values of 45 ± 3 µM and 9 ± 1 µM respectively.
H1–5 showed weaker interference with a calculated IC50 value of 201 ± 40 µM. The
larger IC50 value associated with H1–5 may be a result of HUBL domains 4 and 5
being present within the truncation and being able to partially reactivate the system
upon disruption.
We next attempted to disrupt USP7CD –H4–5 with H1–3 and H4–5. Interestingly,
we saw inhibition in both systems. Disruption by H1–3 resulted in an IC50 value of
46 ± 3 µM which is slightly larger than that observed with USP7FL (Figure 4.8B).
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Unlike USP7FL , the activity of USP7CD –H4–5 could be weakly disrupted by H4–5
with an IC50 value of 190 ± 35 µM (Figure 4.8C).
To evaluate if H1–3 interacts directly with H4–5 they were evaluated by size exclusion chromatography (SEC). First H1–3 was injected onto a 24 mL Sepharose 6 (GE
Healthcare) chromatography column, and a peak eluted at 17.33 mL (Figure 4.9A,
green). Second, H4–5 was injected onto the column and a peak eluted at 18.18 mL
(Figure 4.9A, purple). Finally, both truncations were combined at a concentration
of 65 µM in a 1:1 molar ratio to evaluate if they formed a complex (Figure 4.9B).
Two peaks were apparent in the mixed injection (Figure 4.9B), first at 17.3 mL and
second at 18.2 mL. Based on the results, no direct interaction appears to take place
between H1–3 and H4–5. Together, these results further support a model where H1–3
is required to stabilize H4–5’s interaction with USP7CD , however it remains unclear
how H1–3 dictates this stabilization. Furthermore, without H1–3 present, H4–5 is
able to disrupt activity the native H4–5 in USP7CD , an observation which was not
observed with USP7FL .

Table 4.3
Percent Interference of USP7FL by Various HUBL Truncations
HUBL

IC50

Maximum

Truncation

(µM)

% Inhibition

H1–5

201 ± 40

125 ± 14

H4–5

14 ± 14

-19 ± 5

H1–2

45 ± 3

100 ± 2

H1–3

9±1

81 ± 3

Fig. 4.8. Interference of USP7FL Activity by HUBL Domains in trans A. The percent inhibition of the activity
of USP7FL as a result of HUBL truncations interference. Blue circles: H1–5. Red squares: H4–5. Green triangles: H1–2.
Grey inverted triangles: H1–3. B. The percent inhibition of the activity of USP7CD –H4–5 with H1–3. C. The percent
inhibition of the activity of USP7CD –H4–5 with H4–5. Error Bars, SD.
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Fig. 4.9. Evaluation of direct interaction between H1–3 and H4–5
by SEC. H1–3 and H4–5 were run over a Sepharose 6 (GE Healthcare) size
exclusion chromatography column. A. Chromatography curves of H1–3 and
H4–5 run individually at a concentration of 65 µM. H1–3, green. H4–5, purple.
B. H1–3 and H4–5 were combined at a concentration of 65 µM each in a 1:1
molar ratio. Resulting curve in orange.
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4.5

Discussion
Several members of the USP family have been described to have at least one if

not multiple UBL domains; however very little is known about the function of these
UBL domains within the USPs. One of the most well studied functions of an UBL is
within USP14. The UBL domain in USP14 appears to play an important role in the
association of USP14 to the proteasome. This association results in the alleviation of
the steric hindrance of the active site by the blocking loops [19]. In the case of USP7,
previous work has shown that removal of the TRAF domain from USP7FL does not
affect activity, but removal of the HUBL domains reduces activity substantially [34].
Structural and biochemical studies have described the importance of HUBL domains
4 and 5 in the activity of USP7 as well as elucidated a binding pocket for the C–
terminus peptide of HUBL 5 within the catalytic domain of USP7 [20, 64]. While
Faesen and coworkers did not find evidence for the importance of H1–3, the work
presented here shows that H1–3 are required to regulate the activation by H4–5 to
achieve the native form of intramolecular activation of USP7.
Kinetic analysis of USP7CD and USP7FL with Ub–Rho110 found that both have
similar Km values, but show great variation in their ability to process the substrate,
as USP7FL is 30–fold more efficient than USP7CD . This supports the findings that
the HUBL domains are required for full intramolecular activation of USP7 [20, 34].
Investigation of the activity of USP7CD with H1–5 or H4–5 in trans exposed distinct
differences in their ability to activate USP7CD . These differences were also observed
with Lys48 di–ubiquitin substrate, which more closely resembles the native substrate
of USP7. The kinetic data was fit to the non–essential activation model and kinetic
parameters α, β, KA , Km , kcat were determined. The derived α–value for H4–5
activation of USP7CD was greater than one which indicates an increase in KA and Km
in the presence of substrate. The opposite is true for H1–5 which has an α–value of less
than one. Previous reports have described the interaction between H4–5 and USP7CD
as easily disrupted by a single point mutation in the C–terminus loop of H4–5 [20,64].
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The continuous increase observed in the αKA,app value for H4–5 with increasing Ub–
Rho110 concentration indicates that the presence of substrate further weakens the
interaction of H4–5 with USP7CD . With no substrate present, the KA value for both
truncations is identical. These differences in α–values strongly suggest that H1–3 has
a role in stabilizing the interaction between H4–5 with USP7CD , specifically in the
presence of substrate.
The derived values of the kinetic parameter β suggests that the role of H1–3 exceeds that of just stabilizing the interaction between H4–5 and USP7CD in the presence
of substrate. The β–value of H4–5 is 16–fold higher than that of H1–5. It appears
that in the presence of H1–3, USP7CD cannot turnover substrate as efficiently as it
can with just H4–5 alone. This suggests that H1–3 may attenuate USP7 activation
by H4–5 in the presence of substrate. This hypothesis is supported by the observation
that when introduced to USP7FL , H1–3 can disrupt activity with an IC50 value of 9
± 1 µM, the lowest IC50 value of the HUBL truncations tested. From these results,
we propose that H1–3 plays the role of a rheostat in this system by regulating the
activation levels USP7FL experiences by H4–5.
When comparing the enzymatic efficiencies of USP7 by the two truncations, it
appears that the activation by H4–5 is not drastically different than that of H1–5.
Only by careful kinetic characterization and interpretation of the α– and β–values
associated with the non–essential activation model described above do we gain an
understanding for how this system is controlled. When considering the α– and β–
values of the H1–5 system separately from those values for the H4–5 system it becomes
clear why there is only a 2–fold difference in enzymatic efficiency. The interaction
between H4–5 and USP7CD is weakened in the presence of substrate, as is seen by the
large α–value. However, the β–value for H4–5 is significantly larger than that with
H1–5 activation and therefore this system is able to overcome the effects caused by
the weakened interaction in the presence of substrate. The α– and β–values for H1–5
are as expected for an activation system, the α < 1 strengthens the interaction of the
USP7CD –H1–5–Ubiquitin complex (Figure 4.2) while β > 1 increases the turnover of
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the substrate. It is because of the large β value associated with the H4–5 activation
of USP7CD that we do not see more drastic loss of enzymatic efficiency than we do.
It is understandable that without such careful analysis, the importance of H1–3 may
be overlooked in the activation of USP7.
Further evidence for the importance of H1–3 regulation was observed by differences
in the interference caused by introducing H4–5 to USP7CD –H4–5 in trans as compared
to USP7FL . Interestingly, without an internal H1–3 present H4–5 in trans was able to
disrupt the activation provided by the tethered H4–5 in the USP7CD –H4–5 construct.
While the H4–5 in trans would still activate USP7CD –H4–5, the activation level is
significantly lessened without the tether and appears as inhibition within this system.
When this same experiment was performed with USP7FL , H4–5 was unable to disrupt
activity and did not appear to have an effect on USP7FL . Without H1–3 present in
the USP7CD –H4–5 construct, the regulatory role of H1–3 as defined in this paper was
lost, and the burden of the large α–value associated with H4–5 in trans is eliminated.
These results clearly support the proposed regulatory role of H1–3 has on H4–5 in
the activation of USP7.
Currently there are two accepted orientations of the HUBL domains with respect
to one another as determined by X–ray crystal structures [20,37,39]. The full structure
of the HUBL domains shows the domains in an elongaged 2–1–2 fashion while the
structures of HUBL domains 1–3 (with or without the catalytic domain) show a
compact structure due to a hinge between HUBL domains 2 and 3. From these
structures it was hypothesized that the HUBL domains fold back toward the catalytic
domain for proper alignment for catalysis. The kinetic data discussed here not only
supports this hypothesis, but further suggests that the compact state of the HUBL
domains is essential to allow for intramolecular interactions between the domains
which dictates USP7 activation, a finding that could not be elucidated from the
available structures alone.
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The X–ray structure of the catalytic domain with HUBL domains 1–3 displays the
importance of the α–helix of the catalytic domain (residues 535–560) for the proper
positioning of the HUBL domains with respect to the catalytic domain [63].
Utilizing this structure, as well as biochemical studies, Kim and coworkers developed a model for the regulatory function of the tether in regards to its rigidity, length,
and charge localization to spatially align the HUBL domains to the catalytic domain.
They propose that the α–helix tether positions the HUBL domains at the proper distance from the catalytic domain so that all five HUBL domains are required to fold
back comfortably, without steric hindrance, toward the catalytic domain to properly
align the C–terminal peptide of HUBL 5 for activation [63]. Support for the proper
spatial alignment of the C–terminal peptide of HUBL 5 was expressed with kinetic
studies performed Rougé and coworkers where they defined the appropriate linker
length for activation of USP7CD by just the C–terminal peptide. When they created
a construct of USP7CD tethered to the C–terminal peptide of HUBL 5 with a 10 or
20 amino acid linker, the kcat values measured were within 2–fold of USP7FL [64]. If
they shortened the linker, the kcat values increased. These results, however, do not
explain the similarity of the kcat values determined with our USP7CD –H4–5 construct
in comparison to the kcat values determined with USP7FL .
Figure 4.10A summarizes what is known of the different states USP7 can assume.
Under basal conditions in the cell, the HUBL domains exist in equilibrium between
a not–engaged (top) and engaged (bottom) state with the catalytic domain. When
the HUBL domains assume the engaged state they interact with the catalytic domain
causing USP7 to enter an activated state which results in an increase in kcat . With
the available X–ray crystal structures, we have snapshots of the apo enzyme without
HUBL domain engagement (PDB: 4M5W, 1NB8) [15,16], apo enzyme with potential
HUBL domain engagement (Kim et al, and PDB 5J7T) [63, 64], and the ubiquitin
bound catalytic domain without HUBL engagement (PDB: 1NBF) [16]. Furthermore,
we have now have an idea of what HUBL engagement with the ubiquitin bound
catalytic domain may look like with the C–terminal peptide of HUBL 5 bound in an
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activation cleft of USP7CD [64]. The catalytic triad is misaligned in all structures
lacking ubiquitin and is aligned in all structures containing ubiquitin. Until recently,
how the HUBL domains 4–5 activate USP7 was unclear. It had previously been
proposed that this activation was a result of an interaction of the C-terminal peptide
of the HUBL domain 5 with the switching loop of the catalytic domain [20]. However,
Rougé and coworkers recently published two X–ray crystal structures suggesting that
upon ubiquitin binding to the catalytic domain, an activation cleft opens [64]. This
within this activation cleft, the C–terminal peptide of HUBL 5 was bound. This
suggests that the activation observed with H4–5 is a result of stabilization of the
ubiquitin bound construct and is indicative of an induced fit model [64].
GMPS is an allosteric activator of USP7. When the cell experiences genotoxic
stress, GMPS is translocated to the nucleus and directly interacts with USP7 by binding to the acidic pocket of HUBL domain 2 [37,39]. Through this interaction, GMPS
is able to allosterically activate USP7 by further increasing βkcat,app to over 5–fold
what is observed by the intramolecular activation of the HUBL domains alone [20].
Based on the research presented here, this finding supports our hypothesis that H1–3
regulates USP7 catalytic activity by maintaining a lower β–value than what is seen
with just H4–5 with USP7CD in trans. The binding of GMPS to H1–3 may alleviate
the regulation imposed by H1–3, allowing for an increase in the β–value and higher activity of USP7. The physiological ramifications of this activation in the cells response
to stress supports this hypothesis. More p53 would be stabilized in a less amount
of time leading to a stronger and faster downstream response. Further analysis will
need to be done to determine the exact mechanism by which H1–3 regulates H4–5 in
the intramolecular activation of USP7.
By combining the kinetic results presented here with the available X–ray crystal
structures of the HUBL domain orientations, we propose the following rheostat model
for the intramolecular activation of USP7 by its HUBL domains (Figure 1.4B) [20,
39, 63]. In the not-engaged state (1), the HUBL domains do not associate with
the catalytic domain, and, as such, the activity is 30–fold less than the engaged
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state. When USP7 assumes the engaged state (2) the HUBL domains 1–3 act as a
rheostat to dial up the activity by stabilizing and regulating the interaction of HUBL
domains 4–5 with the catalytic domain. While H4–5 have the potential to activate
USP7 further, H1–3 act as a regulator, and hold this activity in check. When the
cell experiences genotoxic stress, the allosteric activator, GMPS, translocates to the
nucleus and activates USP7 by interacting with HUBL domains 1–3 (3) to alleviate
the regulation of H1–3 on H4–5 while maintaining stabilization with the catalytic
domain to increase activity levels over 5–fold than without GMPS present. This
model further describes the importance of H1–3 in the intramolecular activation of
USP7 and catalysis.
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Fig. 4.10. Tethered–Rheostat Model for the Intramolecular Activation of USP7. HUBL domains 1–3 act as a rheostat to dial the activity USP7
experiences to more or less depending on the state of the cell. A. USP7CD
(pink) exists in an equilibrium between not–engaged (Top Row) and engaged
(Bottom Row) HUBL domains. In the not–engaged state, the HUBL domains
do not influence activity and the kcat value is minimal. In the engaged state,
H1–3 regulate the interaction of H4–5 with the catalytic domain to regulate the
activity of USP7 through manipulation of the kinetic parameters to increase
the kcat value by the β–value. B. USP7 exists in three states, (1) HUBL domains not engaged, (2) HUBL domains engaged, and (3) USP7 in complex with
GMPS. When the HUBL domains are not engaged (1) with the catalytic domain the activity is significantly lower than when they engage with the catalytic
domain (2) as shown by the relative activity. Based on the data presented here,
we propose that H1–3 regulate and stabilize the interaction of H4–5 with the
catalytic domain. However, H1–3 also regulates the amount of activity USP17
experiences. When HUBL domain 2 binds GMPS (3) the interaction alleviates
the negative regulation imposed on H4–5 by H1–3 and allows for an elevated
activity state. In this way, H1–3 act as a rheostat to regulate USP7’s activity.
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CHAPTER 5. HIGH-THROUGHPUT SCREENING AND HIT COMPOUND
EVALUATION FOR USP17
5.1

Introduction
As described in Chapter 2, USP17 regulates cell–cycle progression by the deubiq-

uitination of the Ras and CDC25A pathways. When the balance of either of these
pathways is perturbed, cell proliferation and hence cancer can result. The persistent overexpression of USP17 has been attributed to promotion of prostate, breast,
hematopoietic, and non–small cell lung cancers [27, 29, 46]. Previous work has validated USP17 as a target for the development of anti–cancer theraputics since knocking down overexpressed USP17 by shRNA leads to a reduction in the size of breast
cancer xenographs [29]. The expression and purification methodology for obtaining
high yields of USP17 described in Chapter 2 allowed for the development of high–
throughput screening (HTS) assays for the identification of small molecule inhibitors
towards USP17 which is described herein.
This chapter describes the development and optimization of a high–throughput
screening assay for USP17. The assay was utilized to screen 25,000 compounds from
the ChemBridge library composed of drug–like scaffolds. The identified scaffolds were
used for development of structure activity relationship described within.
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5.2

Experimental Procedures

5.2.1

High-throughput screening (HTS) of a diverse 20K library

HTS Assay Design
The purchased library used to screen USP17 contained 25,000 compounds containing drug–like scaffolds that were cherry–picked from the entire ChemBridge Corporation collection of compound libraries. The compounds are stored at a concentration
of 10 mM in 100% dimethyl sulfoxide (DMSO) at -20 ◦ C. The kinetic assay described
in Section 2.3.12 was redesigned as an end–point assay, and scaled down to a final volume of 5 µL for use in 1536–well plates. The screen was automated with the use of a
ThermoScientific Multidrop Combi reagent dispenser (for addition of the enzyme and
substrate) and a BiomekFX liquid handling system (for addition of the compounds).
To perform the screen, 4 µL of 1.25 nM USP17 (a final concentration of 1 nM) in
Screening Buffer (50 mM CHES pH 9.5, 5 mM DTT, 0.1 mg/mL BSA, and 0.01 %
Trition X–100) was dispensed into a Nunc 1536–well High Base, black polystyrene
microplate. The compound was added in a volume of 20 nL dispensed with a VP
Scientific 384–well pin–tool attached to a BiomekFX liquid handling system (a final
concentration of 10 µM). The reaction was initiated with 1 µL of 1µM Ub–Rho110
suspended in Screening Substrate Buffer (50 mM CHES pH 9.5, 1 mM EDTA, 100 mM
NaCl, 0.05% CHAPS) to a final concentration of 200 nM, and allowed to incubated
for 20 minutes. After incubation, 1 µL of 0.5 M Acetic Acid (a final concentration of
83 µM) was added to quench the reaction. The end–point fluorescence was then read
using a Beckman–Coulter DTX880 plate reader at an excitation λ of 485 nm and
emission λ of 535 nm. The screen was performed in duplicate using separate 1536
well plates at room temperature. The screen set up is depicted in Figure 5.1. Each
plate contained two columns (64 wells) of USP17 without compound present and two
columns of substrate alone for determination of Z’ –factors.
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Fig. 5.1. HTS workflow using 1536–well microplate format. For the
USP17 screen, each plate contained 128 control wells, as depicted with blue
and red shading, and 1,408 sample wells. The assay was performed in 3 main
steps. (1) the enzyme, compound, and substrate were added to the plate. (2)
the plate is incubated for 20 minutes and quenched with acetic acid. (3) the
fluorescence intensity was measured.

Z –factor and Z’ –factor Determination
The Z –factor is a simple and dimensionless parameter for evaluating the quality
of an HTS screen. It is calculated using Equation (5.1) to quantify the ratio between
the separation band (the signal between the sample reading and the control reading)
and the dynamic range (the absolute value of difference between the sample signal, µs ,
and the control signal, µc means) as depicted in Figure 5.2. The separation band is
the sum of three standard deviations of the sample (3σs ) and the control (3σc ). A Z –
factor value of ≥ 0.5 indicates a large separation between the sample and separation
bands indicating the assay is of high quality.

Z=1−

(3σs + 3σc )
|µs − µc |

(5.1)

The values corresponding to sample are defined as the signal from the enzyme
in the presence of a compound and the values defined as the control are calculated
from the signal of the enzyme without inhibitors present. The Z –factor is typically
calculated using a well–characterized inhibitor of the enzyme and the uninhibited
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Fig. 5.2. Illustration of Z –factor determination. Depiction of the data
variability band measurement for the control and the sample as well as the 3σ
and µ values for the control and the sample. The separation band measurement
is also depicted. These measurements are used to determine the Z – and Z’ –
factors for HTS. Figure adapted from [66].

control, however in the case of USP17 no well–characterized inhibitor is known [66].
Therefore the Z’ –factor was calculated using Equation (5.2) using only the control
data of the signal of the reaction with enzyme (3σc+ and µc+ ) and without enzyme
(3σc− and µc− ) present [66].

Z’ = 1 −

5.2.2

(3σc+ + 3σc- )
|µc+ − µc- |

(5.2)

Hit–2–Lead Follow–up Analysis

Preparation of Hit–2–Lead compounds
Three promising scaffolds were identified from the screening (Figure 5.3) and 13
compounds containing these scaffolds were ordered as their dried powder from ChemBridge Hit–2–Lead Online Chemical Store for further analysis (Figure 5.4). Each
compound was dissolved in 100% DMSO to a stock concentration of 40 mM. Com-
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pounds 8 and 10 were not soluble at 40 mM and therefore were diluted to 10 mM in
DMSO.

Fig. 5.3. USP17 HTS Summary. Three compound scaffolds were identified
from the original HTS, and the follow–up screen with the Diverset ChemBridge
library that showed promising structure activity relationships, as described.
The purchased value is the number of compounds from each scaffold that were
purchased from Hit–2–Lead. The validated value is the number of compounds
that IC50 values could be measured for. The validated hits are shown along
with their corresponding IC50 value.

% Inhibition of Hit–2–Lead compounds
The % inhibition of each compound was determined prior to determining the IC50
values to conserve substrate. The final concentration of substrate was held constant
at 100 nM and the final enzyme concentration was held at a final concentration of 1
nM, which is identical to that of the original screen. From the 40 mM stock, each
compound was diluted to a working concentration of 5 mM in 100% DMSO. The
assay was performed as follows: 1 µL of the working stock of compound was added
to a Costar 96 half–volume black plate, and mixed with 15 µL USP17. Plates were
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Fig. 5.4. Hit–2–Lead Compound Summary. Compounds are labeled numerically with identifying scaffold. The % inhibition was tested for all 13 compounds at 100 µM. IC50 measurements were attempted for 8 of the compounds,
of which 2 were successful (green boxes).
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allowed to incubate for five minutes at room temperature. To initiate the reaction,
14 µL of Ub–Rho110 was added. Each assay was measured in triplicate. A negative
control of Ub–Rho110 alone was performed to evaluate the background fluoresence.
All reactions contained a final concentration of 2% DMSO. The enzymatic activity
was measured as described in Section 2.3.12, and the % inhibition was calculated as
follows:


% Inhibition = 1 −

Rateinhibited − Rateneg
Rateuninhibited − Rateneg


 × 100

(5.3)

In Equation (5.3), Rateinhibited is the measured initial slope of the progress curve
of USP17 in the presence of inhibitor, while Rateuninhibited is the measured initial
slope of the progress curve of USP17 in the absence of inhibitor. Rateneg is the slope
of the background fluorescence with respect to time in the absence of enzyme.

Determination of IC50 values
Only 8 of the 13 Hit–2–Lead compounds showed measurable inhibition of USP17
at 100 µM, therefore, these compounds were further evaluated to determine their
IC50 values. The IC50 value refers to the concentration of compound required to
reach half–maximal inhibition of the enzyme. To determine the IC50 values, eleven
serial dilutions of each compound of interest were prepared from the 40 mM stock to
working stock concentrations of 10 mM to 20 µM in 100% DMSO. 1 µL of working
stocks of compound were added to a Costar 96 half–volume black plate and 15 µL of
USP17 (a final concentration of 1 nM) was added to each well. The plate was mixed
and incubated at room temperature for five minutes. To initiate the reaction, 14 µL
of Ub–Rho110 (a final concentration of 200 nM) was added to each well. The initial
slope of the progress curves were measured, and the % inhibition was calculated with
Equation (5.3). The resulting % inhibition was plotted as a function of inhibitor
concentration. The IC50 was determined from the fit of each curve to Equation (5.4)
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using non–linear regression analysis with the Enzyme Kinetics Module in the program
SigmaPlot (v13:Systat Software Inc.).
Max %Inhibition ∗ [ Inhibitor]
% Inhibition =

[Inhibitor] + IC50

(5.4)

The hill equation was used to determine if cooperativity plays a role in the inhibition of USP17 by compound 8. The Hill equation is as follows:

V =

Vmax ∗ [S]n
Km n + [S]n

(5.5)

where V is the reaction velocity and Vmax is the maximum reaction velocity. [S] is
the substrate (Ub–Rho110) concentration and Km is the Michealis–Menten coefficient.
n is the hill coefficient. A n value of one indicates no cooperativity, > 1 indicates
positive cooperativity, and < 1 indicates negative cooperativity.

5.3

Results

5.3.1

High–throughput screening optimization

The kinetic assay previously described for USP17 (Chapter 2, Section 2.3.12)
was adapted to develop a 5 µL end–point assay for use with 1536–well plates. This
optimization reduces the amount of enzyme and substrate required, as well as the
length of time required to complete the entire screen. Variables that were optimized
were enzyme and substrate concentrations, length of reaction time, and Z’ –factors.
Since the screening was performed in collaboration with the Biomolecular Screening
and Drug Discovery Facility in the Purdue Discovery Park, all optimizations were done
with their equipment. The goal of optimizing the enzyme and substrate concentration
was two–fold. First, by reducing the amount of enzyme and substrate required the
cost of the total screen would be significantly reduced. Second, manipulation of the
enzyme and substrate concentrations varied the length of time, the reaction could
proceed prior to quenching and reading the resulting fluorescence. Optimization of
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this time period allowed for numerous plates to be run simultaneously, decreasing the
time required to complete the entire screen. The determined optimal concentrations
were 1 nM USP17 and 100 nM Ub–Rho110. This assay composition allowed the
reaction to run for 20 minutes prior to adding a final concentration of 80 µM Acetic
Acid to quench the reaction.
Prior to performing the entire screen, a single plate was tested in triplicate, and
a Z’ –factor of 0.8 was determined. After the first day of screening, two plates were
evaluated and a Z’ –factor of 0.5–0.6 was calculated. While still within the acceptable
range, this drop in Z’ –factor was cause for concern, and led to the reevaluation of how
the screen was designed. Many variables were reanalyzed to attempt to increase the
Z’ –factor including making fresh reagents daily, sterile filtering all reagents, timing
of the reaction, and washing the dispenser lines between plates to ensure accurate
dispensing. Unfortunately, none of these adjustments resulted in an increase in the
Z’ –factor, therefore USP17 was screened as described above. As a Z’ –factor of 0.5–0.6
is still within the acceptable range which indicates a strong assay, the entire library
(a total of 41 plates) was screened over three days time. The resulting Z’ –factors
varied between 0.53 and 0.60 throughout the screen.

5.3.2

High–throughput screening evaluation and development of structure activity relationships

Figure 5.5 displays the percent inhibition mean and standard deviation calculated
for the entire screen. Of the 25,000 compounds, 48 compounds consistently had
percent inhibition values ≥ -1000% which may indicate that those compounds may
activate the enzyme, but it is more likely that the compounds are auto–fluorescent.
The percent inhibition cut–off was set to 38% to maintain a hit rate of less than
0.1%. With this inhibition threshold, 15 compounds were identified as potential hits.
These identified hits fell into four classes: indole–containing (Figure 5.3, scaffold 1),
indole like, quinoxiline substructure (Figure 5.3, scaffold 2), and nitroso containing
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structures. The indole containing class had seven compounds, the indole like class
had two compounds, the quinoxiline substructure class only had one compound, and
the nitroso containing class had five compounds. Structure Activity Relationships
(SARs) were determined for the indole–containing and the indole like compounds. To
expand on the indole-containing and indole like SAR, as well as develop an SAR for
the quinoxiline substructure, five plates of the ChemBridge Diverset library known to
contain compounds of similar scaffolds based on substructure analysis, were screened
in triplicate identically to the original screen. The nitroso containing compounds were
not followed up with at this time due to toxicity commonly associated with these type
of compounds. The results of the secondary screen supported the primary screen, and
expanded the SAR of the indole–containing and quinoxiline substructure compounds.
From this secondary screen an indazole–containing scaffold was identified, and was
pursued further by ordering a series of compounds from the ChemBridge Hit–2–Lead
library. The three promising scaffolds are displayed in Figure 5.3.

Fig. 5.5. HTS results for primary screen for USP17 inhibition. Distribution of the % inhibition data from the USP17 HTS screen. Red line represents
the 38 % cut–off for inhibition. Grey shaded region represents compounds that
showed increased fluorescence in the screen.
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5.3.3

Follow–up Hit–2–Lead compounds for further development of SAR

Virtual screening of the identified hits by Dr. Laura Kingsley aided in the selection
of compounds to be purchased to further develop the SAR of the indole–containing
(scaffold 1), quinoxiline substructure (scaffold 2), and the indazole (scaffold 3) compounds. A total of 13 compounds were purchased ChemBridge Hit–2–Lead library
(Figure 5.3), six containing scaffold 1, four containing scaffold 2, and three containing scaffold 3. The compounds were dissolved in 100% DMSO to 40 mM and the
percent inhibition at 100 µM was determined for each compound (Figure 5.6). Compounds that showed measurable inhibition (1, 2, 3, 6, 8, 9, 10, 11) were evaluated
to determine IC50 values. Of these eight compounds, only two (compounds 1 and
8) had measurable IC50 values (i.e. a dose–response curve was apparent and could
be fit to Equation (5.4), Figure 5.7 and Figure 5.8). Compound 1 was part of the
scaffold 3 group, and had an IC50 value of 22 ± 4 µM with a maximum % inhibition
value of 66 ± 4 %. Compound 8 was part of the scaffold 1 group, and had an IC50
value of 144 ± 54 µM with a maximum % inhibition value of 144 ± 28 %. The IC50
curve for compound 8 appears to be sigmoidal in nature, and was refit using the
Enzyme Kinetics Module of SigmaPlot (v13: Systat Software Inc.) to the Hill form
of the Michealis–Menten equation (Equation (5.5)), and is displayed in Figure 5.8B.
The determined Hill coefficient was n = 1.4 ± 0.4. With the large error associated
with the hill coefficient, cooperativity of compound 8 cannot be determined by this
analysis.

5.4

Discussion
The ChemBridge cherry–pick library was the first library to be screened because

of the high number of deubiquitinating enzymes in the Mesecar Lab that had previously been screened against this library, including USP7 (Chapter 6). These previous
screens provided a wealth of knowledge regarding promiscuous inhibitors that would
save time and money in the identification of USP17 specific inhibitors. After ruling
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Fig. 5.6. % Inhibition of Hit–2–Lead compounds. Bar graph of the
% inhibition of the 13 Hit–2–Lead compounds at 100 µM with 1 nM USP17
and 200 nM Ub–Rho110. Compounds are labeled numerically with identifying
scaffold. Asterisks denote compounds with determined IC50 values. Error bars,
SD.

Fig. 5.7. Compound 1 IC50 curves for USP17. IC50 values were determined from dose–dependent % inhibition of USP17 after five minute incubation
with compound 1 at room temperature. Error bars, SD.
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Fig. 5.8. Compound 8 IC50 curves for USP17. IC50 values were determined from dose–dependent % inhibition of USP17 after five minute incubation
with compound 8 at room temperature. A. IC50 curve fit to Equation (5.4). B.
Cooperativity analysis by fitting the IC50 curve to Equation (5.5) Error bars,
SD.

out promiscuous compounds and compounds containing reactive nitroso groups, 15
hits remained. The hits could be classified into three scaffolds: indole-like, quinoxiline
substructure, and indazole containing compounds (Figure 5.3). Thirteen compounds
were ordered from the ChemBridge Hit–2–Lead library to further develop SAR (Figure 5.4), however only two of these compounds had measurable IC50 values towards
USP17 (Figure 5.7 and Figure 5.8).
Compound 1 is of the indazole scaffold group and had a reasonable IC50 value of 22
± 4 µM. The maximum % inhibition value of compound 1 was 66 ± 4 %, suggesting
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that compound 1 may be a partial inhibitor. These values suggest that compound 1
would be promising to optimize further to increase its potency, and further develop
the SAR with USP17.
Compound 8 is of the indole scaffold group, and had a weaker IC50 value compared
to compound 1 at 143 ± 53 µM, but it demonstrated a higher maximum % inhibition
than compound 1 at 144 ± 28 %. However, this higher maximum % value may be to
due to the large amount of error seen associated with the IC50 curve. Furthermore,
the IC50 curve of compound 8 appears to be sigmodial in nature which may indicated
cooperativity. However, when the IC50 curve of compound 8 was fit the Equation (5.5)
the Hill coefficent was 1.4 ± 0.4, so cooperativity within the system could not be
determined.
It is unfortunate that we were only able to validate two compounds from this initial
round of screening. Furthermore, concerns regarding the screen itself and the lower
Z’ –factors discussed in Section 5.3.2 suggest more work needs to be done. Taking
this in mind, further optimization of the screen design is necessary to improve the
Z’ –factors. Furthermore, this screen took place prior to the pH evaluation of USP17
described in Chapter 2. The results from that experiment suggest that USP17 is most
active between pH 7 and 9, therefore the Screening Buffers utilized here should be
eliminated and the typical Assay Buffer described in Section 2.3.12 should be utilized
for future screens. Finally, it would be ideal to branch out and screen USP17 against
different libraries available within the Biomolecular Screening and Drug Discovery
facility.
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CHAPTER 6. IDENTIFICATION, OPTIMIZATION, AND MECHANISTIC
EVALUATION OF A NOVEL ALLOSTERIC INHIBITOR OF USP7
6.1

Introduction
Deubiquitinating enzymes (DUBs) are involved in many different signaling path-

ways within the cell [13]. Tight regulation of DUB expression is required for normal cell progression as a large number of the 100+ DUB family members regulate
cancer–associated pathways [13]. A common characteristic in many cancers is the
upregulation of specific DUBs, and the subsequent downstream perturbation of their
corresponding signaling pathways. Therefore, DUBs whose overexpression has been
well–characterized in cancer may be are ideal targets for the development of small
molecule inhibitors for cancer treatment [13].
Targeting an individual member of the DUB protease family was originally assumed to not be feasible due to the well–conserved cysteine and histidine boxes and
fold of the catalytic domain described in Chapter 1. This is a similar thought process
to what previously slowed drug discovery for the kinase enzyme family as well. However, the development and approval of the tyrosine kinase inhibitor, imatinib, for the
treatment of BCR–ABL associated cancers in 2001 changed this way of thinking [67].
Since the approval of imatinib, 28 more specific kinase inhibitors have been approved
by the FDA, the bulk of which were approved between 2012 and 2015 [67]. With
such a high level of success targeting specific members of the kinase family, targeting
specific members of the USP family may be more feasible than originally thought.
USP7 is responsible for maintaining the careful balance between MDM2 and p53
levels in the regulation of cell survival, as described in Chapter 4. Disruption of
the p53 signaling pathway is responsible for roughly 50% of human cancers due to
mutation or inactivation of p53 [38]. By deubiquitinating MDM2 and p53, as well as
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other known USP7 substrates, such as tumor suppressors PTEN and FOXO, DNA
regulators DNMT1 and UHRF1, and viral E3 ligase ICP0, USP7 plays a role in
pathways involved in viral infection, cell signaling, proliferation, and apoptosis [35–
37, 39, 59]. Therefore, tight regulation of USP7 activity is essential to maintaining
proper cell signaling, and the up–regulation of USP7 appears to be associated with
the progression of many cancers [35, 36, 40–43, 56].
Two research groups have identified small molecule compounds that show some
selectivity towards the inhibition of USP7 [45,60]. Chauhan and coworkers have identified a compound series that inhibits cell growth and induces apoptosis in multiple
myeloma cell lines by inhibiting USP7 [45]. Colland and coworkers have developed
a specific inhibitor of USP7 that induces apoptosis, and shows promise as part of
a combinatorial therapy [60]. However, both of these compounds are presumed to
target the conserved catalytic domain of USP7 and may have off target effects that
have yet to be elucidated.
A High–Throughput Screen performed previously within the Mesecar Lab identified a small molecule inhibitor of USP7. This compound was unable to inhibit the
catalytic domain alone, but was able to inhibit the full–length enzyme. The work
described within this chapter involves the characterization and synthetic optimization of the original hit compound as well as the identification of the required domains
within USP7 that are necessary for inhibition.

6.2

Experimental Procedures
The USP7FL enzyme and the truncations utilized in this chapter were expressed

and purified as described in Chapter 3.
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6.2.1

High–Throughput Screening (HTS) Assay

Disclaimer: This section was performed in collaboration with Dr. Katie Molland,
by a previous post–doc in the Mesecar lab. The data included within this section is
the extent of what was provided once the project was passed over.
The activity assay described in Section 3.2.8 was optimized for use as a 5 µL
reaction with final concentrations of 2.5 nM USP7 and 170 nM Ub–Rho110. HTS
was performed in Nunc 1536–well High Base, black polystyrene microplates. USP7
was diluted in HTS Buffer (50 mM Tris pH 7.5, 5 mM DTT, and 0.1 mg/mL BSA)
and Ub–Rho110 was diluted in the standard Substrate Buffer (50 mM Tris pH 7.5, 1
mM EDTA, 100 mM NaCl, and 0.05% CHAPS). The assay was performed as an end
point assay by quenching the reaction with 0.5 M acetic acid. USP7 was screened
against the 25,000 ChemBridge library that was cherry–picked to include compounds
composed of drug–like scaffolds, and was also used to screen for USP17 inhibitors as
described in Chapter 5. The screen was automated with the use of a ThermoScientific
Multidrop Combi reagent dispenser (for addition of the enzyme and substrate) and
a BiomekFX liquid handling system (for addition of the compounds). The general
scheme of the screen is depicted in Figure 5.1. The screen was performed as follows:
4 µL of 3.13 µM USP7 was dispensed into the plate followed by 20 nL from the 10
mM stocks of the compounds dispensed by a VP Scientific 384–well pin–tool attached
to a BiomekFX liquid handling system. The reaction was initiated with 1 µL of 850
nM working concentration of Ub–Rho110, and allowed to incubate for 20 minutes,
at which point 1 µL of 0.5 M Acetic Acid was added to quench the reaction. The
end–point fluorescence was then read using a Beckman–Coulter DTX880 plate reader
at an excitation λ of 485 nm and emission λ of 528 nm. Each plate contained two
columns (64 wells) of USP7 without compound present and two columns of substrate
alone. The entire screen was performed in singlet at room temperature.
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6.2.2

Structure Activity Relationships (SAR) Determination

Preparation of Compounds for SAR Determination
All compounds utilized for the development of the SAR surrounding hit compound
4 (see below) were synthesized at Purdue University by Dr. Antonella Pepe in collaboration with the Computational and Medicinal Chemistry Shared Resource through
the Purdue Center for Cancer Research. A total of 23 compounds were synthesized
and tested for inhibition of USP7FL (Figure 6.1). The lyophilized compounds were
resuspended in 100% DMSO to a stock concentration of 40 mM and stored at -20 ◦ C.
The methods used to synthesize these compounds will be published elsewhere.

Inhibition of SAR compounds
The percent inhibition of USP7 at 100 µM of each compound was determined prior
to the determination of IC50 values to conserve substrate. The final concentration
of substrate was held constant at 200 nM and USP7FL was held constant at a final
concentration of 1 nM. From the 40 mM stock, each compound was diluted to a
working concentration of 3 mM in 100% DMSO. The assay was performed as follows:
1 µL of the working stock of compound was added to a Costar 96 half–volume black
plate to which 15 µL of USP7FL was added. Plates were gently mixed and incubated at
room temperature for five minutes. To initiate the reaction, 14 µL of Ub–Rho110 was
added. Each assay was measured in triplicate. A negative control of Ub–Rho110 alone
was measured to evaluate the background rate. Control reactions of USP7FL without
compound (DMSO only) were included to measure the rate of the uninhibited USP7
reaction. All reactions contained a final concentration of 3% DMSO. The activity of
USP7 was measured as described in Chapter 3 and the % inhibition was calculated
using Equation (5.3).
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Fig. 6.1. Compounds Used to Determine SARs with USP7. Chemical
structures of the 23 compounds synthesized to develop the structure activity
relationship with USP7 are shown. Each of these compounds was resuspended
in 100% DMSO to a stock concentration of 40 mM and then stored at -20 ◦ C.
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Determination of IC50 values
IC50 values were determined for compounds that showed % Inhibition values ≥ 40
%. To determine the IC50 values, 11 two–fold serial dilutions of each compound were
prepared from the 40 mM stock to working stock concentrations of 6 mM to 0.006 mM
in 100% DMSO. The working stocks were added to a Costar 96 half–volume black
plate (1 µL) and a final concentration of 1 nM USP7FL in Assay Buffer (15 µL of
working stock) was added to each well. The plate was gently mixed and incubated at
room temperature for five minutes. To initiate the reaction, a final concentration of
200 nM Ub–Rho110 (14 µL of working stock) was added to each well. The background
rate was measured by omitting the enzyme from the reaction. The initial slopes of
the progress curves were measured, and the % inhibition was calculated with Equation (5.3). The resulting percentages were plotted in terms of inhibitor concentration.
The IC50 value was determined from each curve by fitting the data to Equation (5.4)
using non–linear regression analysis with SigmaPlot (v13:Systat Software Inc.). For
compounds 4, 15, and 32, an IC50 value was determined using the same procedure
for USP7 truncations USP7CD , USP7CD –H1–5, USP7CD –H4–5 and TRAF–USP7CD .
The final concentrations of each were 200 nM for USP7CD and TRAF–USP7CD , and
1 nM for USP7CD –H1–5 and USP7CD –H4–5.

6.2.3

Di–Ubiquitin Chain Cleavage Inhibition Assay

Inhibition of USP7FL by compound 4 was evaluated with a more native substrate,
Lys48 di–ubiquitin (Boston Biochem). This substrate is a more ”native” substrate
because it contains an iso–peptdie linkage that is normally hydrolyzed by USPs. The
reaction was performed with four concentrations of compound 4: 1.9, 3.9, 39, and
100 µM. Each reaction contained 5 nM USP7FL and 4.2 µM Lys48 di–ubiquitin. A
negative control was included that lacked USP7FL . The positive control contained
uninhibited USP7FL and Lys48 di–ubiquitin. USP7FL and the compounds were mixed,
and incubated at room temperature for 10 minutes prior to initiating the reaction with
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the Lys48 di–ubiquitin substrate. All reactions were performed at 25 ◦ C in Assay
Buffer (Section 2.3.12) for 18 hours. Reactions were quenched with the addition
of NuPAGE LDS sample buffer (Invitrogen) supplemented with 5 mM fresh DTT.
Samples were analyzed by SDS-PAGE using NuPAGE Novex 4-12% BisTris mini
gels (Invitrogen), and quantitatively analyzed using the software AlphaView from
ProteinSimple.

6.2.4

Mode of Inhibition Determination

The mode by which compounds 4, 15, and 32 inhibit USP7FL was evaluated
by varying the compound concentration with fixed–variable concentrations of Ub–
Rho110 substrate. Eight two–fold serial dilutions of Ub–Rho110 were made in Substrate Buffer to obtain a working concentration range of 0.08 µM to 10.7 µM. Five
two–fold serial dilutions of each compound were made in 100% DMSO to obtain a
working concentration range from 46.8 µM to 750 µM. USP7FL was diluted in Assay Buffer to a working concentration of 2 nM. Each assay was performed in 30 µL
reaction volumes, in triplicate, in Corning 96 half–well black plates. First, 1 µL of
the compound and 15 µL of USP7FL was added to each well, and incubated for five
minutes with gentle shaking. To initiate the reaction, 14 µL of Ub–Rho110 was added
to the wells, mixed for 10 seconds, and the plate was read for 30 minutes with an
excitation λ of 485 nm and emission λ of 528 nm at 25 ◦ C. The uninhibited control
contained 1 µL of DMSO, 14 µL of Ub–Rho110, and 15 µL of USP7FL while the negative control lacked enzyme. The final concentrations of each component is as follows:
Ub–Rho110 ranged from 0.04 µM to 5 µM, compounds ranged from 1.56 µM to 25
µM and the USP7FL concentration was held constant at 1 nM. The initial rates were
determined and converted to v/[E] using the extinction coefficient of the substrate as
determined and described in Section 2.3.12. The resulting v/[E] values were plotted
as a function of Ub–Rho110 concentration, and the data were fit to four different
equations representing Competitive, Non–Competitive, Uncompetitive, and Mixed
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inhibition. These equations are standard within the kinetics module of SigmaPlot
(v13: Systat Software Inc.). Statistical analysis was performed by comparison of the
AICC values that were determined from the fits to all four models for each compound
tested. The Non–Competitive inhibition equation,
v
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was found to best–fit the data.

6.2.5

Determination of the Steady–State Kinetic Parameters of the TRAF–
USP7CD Construct

The steady–state kinetic paramters, Km and kcat of the TRAF–USP7CD truncation
were determined using Ub–Rho110 as a substrate. The enzyme was diluted to a
working concentration of 400 nM in Assay Buffer. Twelve, two–fold serial dilutions of
Ub–Rho110 were made ranging from 40 µM to 0.04 µM in Substrate Buffer. Assays
were performed in 30 µL reaction volumes and in triplicate. The background rates
were measured by pipetting 15 µL of Ub–Rho110 at each concentration into a 96–
well Corning Costar black half–volume plate, and measuring the rate of change in
fluorescence with a BioTek Synergy H1 plate reader. Fluorescence measurements
were made every 10 seconds at an excitation λ of 360 nm and emission λ of 460 nm
over a time period of two minutes and at 25 ◦ C. Following the measurement of the
background rate, 15 µL of the working stock of TRAF–USP7CD was added to the
plate, the plate was mixed for 10 seconds, and the assay was measured under the
same conditions for 30 minutes total. The final concentration of TRAF–USP7CD was
200 nM and the final concentration range for Ub–Rho110 ranged from 20 µM to 0.01
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µM. The initial slope of each reaction in artificial fluorescence units (AFU) per unit
time (AFU/sec) was converted to the amount of product produced per unit time
(µM/sec) using the extinction coefficient of the substrate. This value of µM/sec was
then converted to the rate of reaction in terms of enzyme concentration (V/[E]) by
dividing by the enzyme concentration. The data were then analyzed with the kinetics
module of SigmaPlot (v13: Systat Software Inc.) by fitting the resulting curves to
the Michealis–Menten equation (Equation (2.1)) to determine the kcat and Km .

6.2.6

Isothermal Calorimetry (ITC) Analysis of Compound Binding

Compound 32 was used for separate ITC analysis with USP7CD and H1–5 truncations. Measurements were taken using a Malvern MicroCal ITC200 instrument.
Initial tests were performed to determine the highest concentration at which compound 32 remained soluble in Analytical Buffer (50 mM HEPES pH 7.5, 3 mM
TCEP, and 100 mM NaCl). The 40 mM stock of compound 32 in 100% DMSO was
serially diluted in two–fold increments in Analytical Buffer from 200 µM down to
6.25 µM while maintaining 3, 2, 1, 0.5, or 0.25% DMSO. The A600 of each sample
was measured in comparison to a blank well containing Analytical Buffer and the
appropriate percentage of DMSO to determine which well had the least amount of
precipitant. The highest concentration of compound 32 at the lowest percentage of
DMSO that was found to lack measurable precipitation was determined to be 25 µM
and 0.5% DMSO. Due to the lack of solubility of the compound, reverse ITC was
performed by diluting the protein into the compound. H1–5 and USP7CD truncations
were dialyzed into Analytical Buffer overnight at 4 ◦ C. The following morning, the
samples were concentrated to 515 µM (32 mg/mL) for H1–5 and 736 µM (30 mg/mL)
for USP7CD using spin concentrators with 10,000 MWCO and diluted in Analytical
Buffer containing 0.05% DMSO. Both truncations were over 20 times greater in concentration than that of compound 32. A volume of 200 µL of 25 µM compound 32
was added to the cell and the syringe volume of USP7 truncation was 40 µL. The
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initial injection volume was 0.4 µL to remove any bubbles from within the system,
and the remaining injections contained 1.8 µL of the USP7 truncation for a total of 22
injections. A three minute delay was programmed between each injection to allow the
signal to return to baseline. All reactions were run at 25 ◦ C. The spin speed was set
to 1000 rpm with a filter period of five minutes. For each truncation, blank injections
were run utilizing the same protocol by injecting the USP7 truncation into Analytical
buffer containing 0.5% DMSO. Data was exported into NitPic and the heat from the
blank runs were subtracted. The results were analyzed for any measurable heat.

6.3

Results

6.3.1

HTS Hit Identification and Validation

HTS was performed with USP7FL against the cherry-picked Chembridge library
containing 25,000 compounds of drug–like scaffolds utilizing Ub–Rho110 as the substrate. The Z’ -factor’s for the screen were calculated as described in Section 5.2.1
and they ranged from 0.75-0.81. A summary of the screen is depicted in Figure 6.2.
The percent inhibition threshold was set to 40% to maintain a hit rate of less than
0.1%. Virtual screening to evaluate the chemical properties of each hit, and identify
other potential protein targets was performed by Dr. Sergey Savinov. With this inhibition threshold and virtual screening by Dr. Sergey Savinov, 12 compounds were
identified as potential hits. Of the 12 compounds, nine were commercially available.
From these nine compounds, only four had measurable inhibition towards USP7FL .
The best of which was compound 4 (Figure 6.3A) which has an IC50 value in the
single digit micromolar range, 4.1 ± 0.5 µM and maximum % inhibition of 98 ± 4 %
(Figure 6.3B).
Inhibition of USP7FL by compound 4 was further evaluated with the more physiological substrate Lys48 di–ubiquitin. Without compound 4 present in the reaction
mixture, roughly 75% of the di–ubiquitin substrate is cleaved (Figure 6.3C lane 2).
With increasing concentrations of compound 4, a steady decrease in the amount of
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mono–ubiquitin formed can be observed (Figure 6.3C lanes 3–6). These results indicate that compound 4, is a bona fide inhibitor of USP7FL and that Ub–Rho110 and
Lys48 di–ubiquitin can be used as substrates to determine inhibition.

Fig. 6.2. HTS Hit Validation. A. A cherry–picked ChemBridge library
of 25,000 compounds composed of drug–like scaffolds was screened. Tweleve
hits were identified to have 40% inhibition or more. Of the 12 identified compounds, nine were commercially available and further analyzed. Of these nine,
four had measurable and reproducible inhibition. SAR was developed using 23
compounds, of which a panel of three was used for the characterization of the
inhibition of USP7, compound 4, 15, and 32.

Specificity of compound 4 for USP7FL
A small panel of DUB enzymes were tested for inhibition by compound 4 to
assess its selectivity for USP7. Both the IC50 values and maximum % inhibition were
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Fig. 6.3. Kinetic Analysis of HTS Hit Compound 4. A. Chemical
structure of HTS hit, compound 4. B. IC50 analysis of compound 4 with 1 nM
USP7FL and 200 nM Ub–Rho110. C. Cleavage of Lys48 di–ubiquitin substrate
in the presence of increasing concentrations of compound 4, as shown. Error
bars, SD.

analyzed for compound 4 with two members of the USP family, USP17 and USP28, as
well as 2 members of the viral DUB family, SARS–PLpro and MHV–PLP2. The IC50
values for compound 4 with these enzymes were all >100 µM with low maximum %
inhibition values. The results of this small panel suggest that compound 4 is selective
towards USP7, however it would be desirable to test compound 4 against a larger
panel of DUBs.

6.3.2

Structure Activity Relationships with the Compound 4 Scaffold

A summary of the compounds analyzed and their corresponding IC50 and % inhibition values is shown in Figure 6.4.
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Compounds must maintain both R1 and R2 substituents on the phenyl ring
The initial round of synthesis focused on determining the importance of the meta–
bromine group at R1 and para–methoxy group at R2 on the phenyl ring of compound
4. Replacing either the meta–bromine or the para–methoxy groups with hydrogen
(compounds 5 and 6) abolished inhibitory activity. Furthermore, replacing the meta–
bromine group with hydrogen and reducing the size of the para–methoxy group to
either a hydroxyl group (compound 9) or a methyl group (compound 10) also abolished inhibitory activity.

SAR reveals that inhibition of USP7FL depends on size and electronegativity of the halogen substituent
The next few rounds of synthesis analyzed the importance in the size and electronegativity of the meta–bromine substituent at R1 . When the bromine substituent
was replaced with a fluorine (compound 70) or chlorine (compound 14), smaller and
more electronegative substituents, the IC50 values increased (IC50 = 7 ± 2 µM for
both). However, if the bromine substituent was replaced with iodine (compound 15),
a larger less electronegative substituent, the IC50 value decreased (IC50 = 1.8 ± 0.1
µM) indicating tighter binding. Interestingly, when the bromine was replaced with
trifluoromethyl (compound 32), a larger more electronegative substituent, the IC50
value decreased further into the nanomolar range (IC50 = 0.75 ± 0.06 µM). Figure 6.5
displays the IC50 curves for compounds 4, 14, 15, and 32. Furthermore, when the
R1 bromine was replaced with a trifluoromethyl group and the R2 group was replaced
with a hydroxyl group (compound 71) an increase in IC50 value was again observed,
emphasizing the importance of the methoxy group at the R2 position.
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Fig. 6.4. SAR Trends Varying in the Phenyl Ring Substituents R1
and R2 The effects of varying the subsituents of the phenyl ring of compound
4 on the inhibition of USP7FL .

6.3.3

Mode of inhibition of most potent compounds (4, 15, and 32)

The mode of inhibition was determined to be that of Partial Non–Competitive
inhibition for this compound series (4, 15, and 32, Figure 6.6 A). The scheme for
Non–Competitive inhibition is shown in Figure 6.7 where the KI value is the measure
of affinity of the compound for both the free enzyme (E) and the enzyme–substrate
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Fig. 6.5. IC50 of Halogen SAR Trend. IC50 curves of USP7FL with compounds 14, 4, 15, and 32. Assays were composed of 1 nM USP7FL , 200 nM
Ub–Rho110, and 11 serial dilutions of the compounds ranging from 0.01–25
µM.

complex (ES). As these compounds do not inhibit 100% of the activity of the enzyme,
a β value other than one exists which reflects the magnitude by which the kcat value
is decreased as compared to the uninhibited enzyme. The KI and β values for each
compound are shown in Table 6.1. The data revealed that the maximum % inhibition
increases from compound 4 to 32, a trend that is reflected in the calculated β values.
With Non–Competitive inhibitors the IC50 should be equal to the KI value. While the
increase in potency observed with the IC50 values are reflected in the KI values, they
are not equal, but the same increase in potency from compound 4 to 32 is observed.
The significant decrease in the kcat values observed with increasing concentration of
the compounds, and lack of large variation in the Km values (Figure 6.6 B) suggest all
three compounds are V–type allosteric inhibitors (inhibit by decreasing the kcat ) and
not K–type inhibitors (inhibit by increasing the Km ) of USP7. A typical definition
of a Non–Competitive inhibitor is that the inhibitor binds to a separate site on an
enzyme that is distinct from the active site such that the inhibitor does not alter the
binding affinity of the substrate to the enzyme. Rather the inhibitor decreases the
rate of catalysis of the enzyme.

Fig. 6.6. Mode of Inhibition of compounds 4, 16, and 32. A. The mode of inhibition was determined for
compounds 4, 15 and 32 with USP7FL . Assays were performed by varying the concentration of Ub–Rho110 from 0.04–5
µM with fixed–variable concentrations of the compounds from 1.56–25 µM. An uninhibited USP7FL control was also
measured. Initial RFU/min were measured for each curve and were converted using the determined extinction coefficient
of Ub–Rho110 to V/[E]. Resulting values were plotted against the concentration of Ub–Rho110. B. Each curve in A. was
fit to the Michealis–Menten equation to determine the kcat and Km values. The resulting values were plotted in terms of
the compound concentration. Error bars, SD.
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Fig. 6.7. Scheme for Partial Non–Competitive Inhibition. Expansion
of the typical Non–Competitive enzyme kinetic scheme to include partial inhibition. The Partial Non–Competitive inhibition model includes the kinetic
parameter, KI , and the kinetic modulator parameter β, which modulates kcat .

Table 6.1
Partial Non–Competitive inhibition parameters for compounds 4, 15,
and 32

6.3.4

Compound

β

KI

4

0.209 ± 0.007

4.3 ± 0.2

15

0.150 ± 0.006

2.48 ± 0.09

32

0.072 ± 0.005

1.60 ± 0.06

IC50 panel of compound 4, 15, and 32 with USP7 truncations

In an effort to determine where the alternative binding site on the enzyme for
the Partial Non–Competitive inhibitors is, IC50 values were determined for all three
compounds against four different truncations of USP7: USP7CD , USP7CD –H1–5,
USP7CD –H4–5, and TRAF–USP7CD (Figure 6.8). In conjunction with the mode
of inhibition analysis, the lack of inhibition of the USP7CD (Figure 6.8) suggests that
these compounds do not bind to the conserved catalytic domain. Rather, these compounds require the other domains of USP7 to produce inhibition. Interestingly, the
IC50 values could only be measured for USP7CD –H1–5(Figure 6.8: compound 4 = 11

167
± 5 µM, compound 15 = 6 ± 2 µM and compound 32 = 3 ± 2 µM). These IC50
values are significantly larger than those measured for USP7FL suggesting that the
TRAF domain is also required (Figure 6.4). Taken together, these results suggest
that the HUBL domains are essential for inhibition, specifically HUBL domains 1,
2, and 3 as no inhibition could be measured with USP7CD –H4–5. Furthermore, the
TRAF domain appears to be important but not absolutely essential for inhibition.

6.3.5

Role of the TRAF domain in inhibition of USP7FL by compounds 4,
15, and 32

To further investigate the role of the TRAF domain in the inhibition of USP7,
the steady–state kinetic parameters, Km and kcat , values were determined for TRAF–
USP7CD using Ub–Rho110. THe values were found to be 25 ± 1 µM and 0.174 ± 0.005
s−1 respectively. The kcat value of TRAF–USP7CD is roughly 4 fold higher than the
kcat value of USP7CD and is 7 fold lower than the kcat value of USP7FL . Interestingly,
a large difference is observed between the Km values, where the TRAF–USP7CD Km
value is ∼ 16 fold higher than that of the Km value for both USP7FL and USP7CD .

6.3.6

Isothermal Calorimetry Analysis of Compound 32

Isothermal calorimetry (ITC) was utilized to further evaluate the required domains
of USP7 for inhibition by these compounds. The most potent inhibitor, compound 32,
was utilized. However, due to solubility issues, the ITC experiments were performed
in reverse by diluting a high concentration of USP7 truncation into compound 32.
H1–5 and USP7CD truncations were injected into 25 µM of compound 32 at 515 µM
and 736 µM, respectively. The background heat was measured by injecting the USP7
truncation into Analytic Buffer containing 0.5% DMSO. Neither H1–5 or USP7CD
injections generated heat greater than the background levels. These results may suggest one of two results. First, the interaction between compound 32 and USP7 is not

domains of USP7. N–terminal TRAF domain (grey), catalytic domain (pink), five ubiquitin–like domains (rainbow).
IC50 curves for compound 4 (green circles), 15 (red squares), and 32 (blue triangles) were determined with 200 nM
Ub–Rho110. Compound concentration ranged from 0.01 to 25 µM. Enzyme concentrations were held constant at 1
nM for USP7FL , USP7CD –H1–5, and USP7CD –H4–5 and 200 nM for USP7CD and TRAF–USP7CD . IC50 curves of B.
USP7FL , C. USP7CD , D. USP7CD –H1–5, E. USP7CD –H4–5, F. TRAF–USP7CD . Data in panels B and D were fit to
Equation (5.4) to determine IC50 values. Error bars, SD.

Fig. 6.8. Inhibition of Different USP7 Truncations by Designed Compounds. A. Schematic of the 7 different
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Fig. 6.9. Interaction of Ub–Rho110 with TRAF–USP7CD . The rates of
hydrolysis of Ub–Rho110 by the TRAF–USP7CD are shown and are normalized
to the total TRAF–USP7CD concentration. TRAF–USP7CD concentration is
200 nM. Ub–Rho110 concentrations varied from 0.02 µM to 20 µM. Data were
performed in triplicate.

enthalpically driven. Second, compound 32 cannot bind the individual truncations,
and requires an interface to be formed between the domains for binding.

6.4

Discussion
The goal of developing inhibitors towards specific members of the USP family

mirrors that of the protein kinase family of enzymes. It was long assumed that targeting a specific protein kinase within the family that shares high similarity in both
structure and sequence was an impossible task. However, in 2001 the first specific
kinase inhibitor, imatinib, was FDA approved for targeting BCR–ABL cancers [67].
The impact of this accomplishment has been widespread since 2001, 27 more drugs
that target specific protein kinases (i.e. EGRF, Src, B–raf, etc) have entered the market [67]. Furthermore, this success broadened our horizons with regards to targeting
specific enzymes within a large family, including the USPs which share a conserved
catalytic domain.

170
Two groups have successfully identified small molecule inhibitors that are presumably specific against USP7 and these compounds have shown efficacy in cell culture
[45, 60]. However, both of these molecules target the conserved catalytic domain and
while both molecules have been shown to be specific towards USP7 in vitro, off target
effects may yet arise when further tested in vivo.
Several groups have reported significantly lower activity of USP7CD than USP7FL [20,
34]. In our hands, the difference in activity between USP7CD and USP7FL was 30 fold.
Faesen and coworkers elucidated the requirement of HUBL domains 4 and 5 in the
intramolecular activation of USP7 by a proposed interaction between the C–terminal
loop of HUBL 5 and the switching loop within USP7CD . However, the involvement
of HUBL domains 1, 2, or 3 in the intramolecular activation was not defined. The
work described in Chapter 4 elucidates the role of HUBL domains 1, 2, and 3 in the
intramolecular activation of USP7 as required for the regulation of HUBL domains
4 and 5. Furthermore, it has been observed that the TRAF domain does not have
a role in the intramolecular activation of USP7 and is dispensable for activity [20].
Understanding how USP7 activity is internally regulated by the HUBL domains has
aided in the development of USP7 inhibitors discussed within this chapter.
Compound 4 (Figure 6.3 A) was identified from the HTS screen and it has an
IC50 value of 4.1 µM. Compound 4 was found to be specific towards USP7 using a
small panel of DUB enzymes. Modifications to the meta–bromine and para–methoxy
substituents of the phenyl ring elucidated the requirement for both substituents to
be present for inhibition. When the para–methoxy group was reduced in size or
electronegativity, inhibition was lost. Potency was increased with an increase in size
and electronegativity at the meta position. While these results strongly suggest that
the pocket the phenyl group occupies is large and prefers a highly electronegative
group, without a structure of USP7 bound to these compounds, we cannot further
discuss the importance of these elucidated features from a structural standpoint.
The compounds developed in this work were determined to inhibit USP7 by a
Partial Non–Competitive mode of inhibition (Figure 6.6) which suggests that they
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do not bind to the conserved catalytic active site. Upon further analysis, it was
discovered that the inhibitors could not inhibit USP7CD alone. Strikingly, when
the compounds were tested against USP7CD –H1–5 and USP7CD –H4–5, it was found
that HUBL domains 1–3 were essential for inhibition. These observations suggest
that these compounds may bind to an interface on HUBL domains 1–3 and thereby
disrupts the stabilizing influence these domains have on the intramolecular activation
of USP7 by HUBL domains 4 and 5 (Chapter 4).
Interestingly, the IC50 values determined with USP7CD –H1–5 were significantly
weaker than the values determined with USP7FL , however no inhibition could be
measured with the TRAF–USP7CD construct. These results suggest that the TRAF
domain may have a role in the activity of USP7 after all, and that the TRAF domain acts in concert with HUBL domains 1–5 to produce maximum inhibition. We
hypothesize that the significantly higher Km value associated with TRAF–USP7CD
indicates that the TRAF domain may bind Ub–Rho110, and may require the HUBL
domains for proper positioning with the catalytic domain. Without the HUBL domains, the binding of Ub–Rho110 increases the Km value by reducing the amount
of free substrate that can enter the active site. An interaction between the TRAF
domain and the HUBL domains has yet to be described, however the results presented here suggest further investigation is necessary. The increase in the kcat value
from USP7CD alone suggests that the TRAF domain, when aligned correctly aids in
stabilizing Ub–Rho110 with the catalytic domain.
USP7 is an important drug target for many types of cancers due to its upregulation and the signaling pathways its involved in. The compounds described
here appear to require the HUBL domains and the TRAF domain for full inhibition.
Furthermore, these results suggest that the compounds disrupt the intramolecular
activation of USP7, imposed by the HUBL and TRAF domains. By targeting the
interactions of all the domains within USP7 and their function in the intramolecular
activation of USP7 these compounds show great promise for further development as
USP7 specific inhibitors. This unique approach would allow for reduced activity of

172
USP7 but not complete inhibition, which could lessen the effects of full inhibition
of USP7 on other important pathways in the cell. Furthermore, drugs developed to
target the HUBL domains would be more specific to USP7 due to the unique architecture of the USP7 domains, as opposed to targeting the highly-conserved structure
of the catalytic domain.
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CHAPTER 7. SUMMARY
Many members of the Ubiquitin Specific Protease (USP) family play a role in the
regulation of cell–cycle progression. As a result, their observed upregulation in many
disease states, predominantly cancer, suggests that individual members of this family
of enzymes would make ideal drug targets for anti–cancer therapeutic development.
The USP family members are composed of a conserved catalytic domain which is
flanked by a variety of domains important for substrate recognition, regulation, and
catalysis. It is the composition of these flanking domains that make each USP unique.
While the conserved catalytic domain of the USPs share high structural similarities,
two regions within the catalytic domain share high sequence similarity as well, the Cys
and His boxes. The catalytic triad is composed of a cysteine, histidine, and aspartate
residues and are contained with these sequence conserved boxes. These similarities
make the task of inhibiting specific members of the USP family substantially more
difficult. Therefore, thorough enzymatic and biochemical characterization of the USP
of interest is required, specifically the characterization of the role of the flanking
domains that make each USP unique. Along these lines, we report here the enzymatic
and biochemical characterization of two USP family members, USP17 and USP7 are
reported in this dissertation.
USP17 is an important anti–cancer target for its role in perturbing both the
Ras and CDC25A signaling pathways in breast and prostate cancers. As such, the
expression, refolding, and purification of USP17 was pursued and achieved. Due to its
insolubility when expressed in E. coli expression systems, the recombinant expression
and purification of USP17 had not previously been reported. Furthermore, while
numerous USPs have successfully been expressed and purified using the baculovirus
expression system, it was found that expression of USP17 within the baculovirus
system results in its significant degradation and low yields. A methodology for the
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refolding of USP17 from E. coli inclusion body was developed and results in ∼4 mg/L
of pure USP17.
Having the ability to purify milligram quantities of USP17 allowed for the enzymatic and biochemical characterization of USP17. The enzymatic characterization of USP17 included defining the steady–state kinetic parameters, kcat and Km ,
with fluorogenic substrates Ub–Rho110 and Ub–AMC and determination of USP17’s
ubiquitin–chain linkage specificity. Comparison of the determined steady–state kinetic values with the values of other characterized USPs, it was discovered that
USP17 has significantly higher enzymatic activity than many members of the USP
family. Furthermore, as is common with USPs, USP17 is very promiscuous with
respect to ubiquitin–chain linkage recognition, and could cleave all seven lysine linkages to a certain extent but could not cleave linear ubiquitin chains. Biochemical
characterization of USP17 included determination of the oligomeric state, stability,
and preferred pH range for activity. The oligomeric state of USP17 was determined
using 3 different techniques: Analytical Size Exclusion Chromatography, Analytical
Ultracentrifugation, and Dynamic Light Scattering. Combining the results of these
techniques suggests that USP17 is a monomer in solution. The preferred pH range
for optimal USP17 activity was between pH 7 and 9. As this is the first report of
the enzymatic and biochemical characterization of USP17, this work focused on the
conserved catalytic domain of USP17, however to develop specific inhibitors towards
USP17, a deeper understanding of the C–terminus hyaluronan binding motifs is required.
The USP17 kinetic assay utilizing Ub–Rho110 was optimized for high throughput–
screening (HTS) conditions, and a cherry–picked ChemBridge library composed of
25,000 drug–like scaffolds was screened. From this screen and the secondary screening of the DiverSet ChemBridge library, four promising scaffolds were identified. A
structure activity relationship (SAR) was developed from the analysis of the compounds within the screens containing one of the four scaffolds. Thirteen compounds
containing the identified scaffolds from the ChemBridge Hit–2–Lead library were or-
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dered to further develop the SAR, and evaluated for % inhibition and IC50 values.
Only two of the 13 compounds had measurable IC50 values, one of which is ideal to
pursue further. The low hit rate of this screen suggests further optimization of the
HTS assay, and future screening of more diverse libraries.
USP7/HAUSP is a highly characterized USP that was originally identified for
its role in herpesvirus infection, and has since been defined to regulate many tumor
suppressor related pathways, including the p53/MDM2 pathway. The upregulation
of USP7 is described in a variety of cancers, including prostate, breast, glioma, lung,
multiple myeloma, colon, and neuroblastoma [35,36,40–43,56]. The catalytic domain
of USP7 has significantly lower activity than the full–length enzyme, and requires
intramolecular activation by the C–terminal ubiquitin–like domains (HUBL) 4 and 5.
The role of HUBL domains 1–3 in this intramolecular activation, however, was previously ill defined. Through kinetic and biochemical characterization of USP7, a model
displaying the significance of HUBL domains 1–3 in the intramolecular activation of
USP7 was developed and the role of HUBL domains 1–3 in inhibition by identified
compounds was established.
To evaluate the role of the HUBL domains in the intramolecular activation of
USP7, nine different USP7 constructs were expressed and purified: USP7FL , USP7CD ,
USP7CD –H1–5, USP7CD –H4–5, TRAF–USP7CD , H1–5, H4–5, H1–2, and H1–3. With
the exception of USP7FL which was prepared from the baculovirus expression system,
each truncation was expressed from E. coli and purified using three sequential chromotographic steps. All truncations were purified in milligram quantities of ≥ 98%
purity.
Using the fluorgenic substrate, Ub–Rho110, the steady–state kinetic parameters
for the active constructs (USP7FL , USP7CD , USP7CD –H4–5, and TRAF–USP7CD )
were determined. The results validated the requirement of HUBL domains 4 and 5
to achieve full activity of USP7. Interestingly, the parameters associated with the
TRAF–USP7CD truncation suggests that the TRAF domain interacts with the Ub–
Rho110 substrate, a result previously not observed. Further kinetic approaches, as
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well as other biochemical and biophysical experiments allowed the assignments of the
role of then HUBL domains 1–3 in the intramolecular activation of USP7. Based
on our results, we propose a novel rheostat model for the regulation of USP7 by
HUBL domains 1–3. HUBL domains 1–3 serve to adjust the level of activity USP7
experiences by stabilizing and regulating the interaction of HUBL domain’s 4 and 5
with the catalytic domain.
A promising small molecule inhibitor of USP7 was identified using USP7FL by
HTS. In collaboration with the Computational and Medicinal Chemistry core of the
Purdue Center for Cancer Research, several rounds of synthesis allowed for the develop
a strong SAR surrounding the halogen substituent of the scaffold. The different active
truncations of USP7 were tested for inhibition by these compounds, and it was found
that no inhibition could be measured without HUBL domains 1–3 present. Fitting
with this finding, the mode of inhibition of these compounds was determined to be
Non–Competitive, suggesting these inhibitors act via an allosteric mechanism. The
allosteric inhibitors identified by this dissertation work are the first of their kind,
and will provide a novel chemical tool to the scientific community. Many attempts
were made to determine where these compounds bind to USP7 using both kinetic
and biophysical (ITC) approaches, however no conclusive results were obtained. It
is hypothesized that these compounds bind to an interface formed between HUBL
domains 1–3 and the catalytic domain, and, without both components, binding does
not occur. Future work on this project will be both structural and biophysical in
nature to determine where these compounds bind to USP7 and how these compounds
inhibit USP7 activity.
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APPENDIX A.
A.1
A.1.1

USP17 Nucleotide Sequences
USP17 Sf9 Optimized Nucleotide Sequence

GGATCCATGGAAGACGATTCTCTGTACCTCCGCGGTGAGTGGCAATT
CAATCACTTTTCCAAGCTGACCTCTTCCCGCCCTGATGCCGCTTTTGCTG
AAATCCAGCGCACCAGTCTCCCTGAAAAGAGCCCCCTCTCCTGCGAAAC
CAGAGTCGACCTGTGTGACGATCTGGCTCCCGTTGCTCGTCAACTCGCC
CCACGTGAGAAACTGCCACTCTCTAGCCGTCGTCCTGCTGCCGTCGGAG
CTGGACTGCAAAATATGGGCAACACTTGTTACGTCAACGCCTCCCTGCA
GTGCCTCACTTACACCCCACCATTGGCTAACTACATGCTGTCTCGTGAA
CACTCACAAACTTGCCACCGCCACAAGGGCTGTATGCTCTGCACTATGC
AAGCCCATATCACTCGCGCCCTCCACAACCCAGGCCACGTGATTCAGCC
TAGCCAAGCCTTGGCTGCCGGATTCCATCGCGGTAAACAGGAAGATGCT
CACGAGTTCCTGATGTTCACAGTGGACGCTATGAAGAAGGCCTGCTTGC
CAGGACACAAGCAGGTCGATCACCACTCCAAGGATACTACCCTGATCCA
CCAAATCTTCGGTGGTTACTGGCGTTCCCAGATCAAGTGCCTGCACTGT
CACGGTATTTCAGACACCTTCGACCCATACCTCGACATCGCCCTGGACA
TCCAGGCTGCCCAGAGTGTGCAGCAGGCTTTGGAACAGCTGGTTAAGCC
AGAAGAACTGAACGGCGAGAACGCCTACCATTGTGGCGTGTGTCTGCAA
AGGGCTCCCGCTTCCAAGACACTGACATTGCATACTAGCGCCAAGGTCC
TCATCCTCGTCTTGAAGCGTTTCTCTGACGTCACCGGTAACAAGATCGC
TAAGAACGTGCAGTACCCTGAGTGTTTGGACATGCAACCCTACATGTCC
CAGCCCAACACTGGACCCTTGGTTTACGTCTTGTATGCCGTCCTGGTGC
ATGCTGGTTGGTCATGTCACAACGGACACTACTTTAGCTACGTTAAAGC

184
CCAAGAGGGCCAGTGGTACAAGATGGACGACGCCGAGGTTACCGCCTCC
AGCATTACAAGCGTTCTCAGCCAACAGGCCTACGTGCTCTTCTATATCC
AGAAATCAGAGTGGGAAAGGCACTCTGAGAGCGTTAGTAGGGGTCGTG
AGCCTCGTGCTCTCGGCGCTGAGGACACCGACCGCAGAGCTACACAAGG
AGAACTCAAACGTGACCACCCCTGTTTGCAAGCTCCAGAACTGGATGAA
CACCTGGTTGAAAGGGCCACACAAGAGTCAACACTCGATCACTGGAAGT
TCCTCCAGGAGCAAAATAAGACAAAACCTGAGTTCAACGTGCGCAAGGT
GGAAGGCACCCTGCCCCCTGACGTGCTGGTTATCCACCAGTCCAAGTAC
AAGTGCGGAATGAAGAACCACCACCCTGAGCAGCAATCTTCCCTGTTGA
ACCTCAGCAGCTCAACACCTACTCACCAGGAGTCAATGAACACTGGTAC
ACTCGCCTCTCTGAGGGGTCGCGCCAGAAGGAGTAAGGGCAAGAATAAG
CATTCAAAGCGCGCTCTGCTGGTGTGCCAGTAAGAATTC

A.1.2

USP17 E. coli Optimized Nucleotide Sequence

ATGGAAGACGATAGCCTGTACCTGCGTGGCGAATGGCAGTTCAATCA
CTTTAGCAAACTGACCTCAAGCCGCCCGGATGCAGCGTTCGCGGAAATT
CAGCGTACCAGTCTGCCGGAAAAAAGCCCGCTGTCTTGCGAAACGCGCG
TCGATCTGTGTGATGACCTGGCACCGGTGGCACGTCAGCTGGCACCGCG
CGAAAAACTGCCGCTGAGCTCTCGTCGCCCGGCAGCAGTGGGTGCAGGT
CTGCAGAACATGGGCAATACCTGCTATGTTAACGCATCTCTGCAATGTC
TGACCTATACGCCGCCGCTGGCTAATTACATGCTGTCACGTGAACATTC
GCAGACCTGCCATCGCCACAAAGGCTGCATGCTGTGTACCATGCAAGCG
CACATTACGCGTGCCCTGCATAACCCGGGTCACGTGATCCAGCCGAGCC
AAGCACTGGCAGCTGGCTTTCATCGCGGTAAACAGGAAGATGCTCACGA
ATTTCTGATGTTCACCGTCGACGCGATGAAAAAAGCCTGTCTGCCGGGC
CATAAACAGGTTGATCATCACTCTAAAGACACCACGCTGATTCACCAGA
TCTTTGGCGGTTATTGGCGTAGCCAAATTAAATGCCTGCATTGTCACGG
TATCTCTGATACCTTCGACCCGTACCTGGATATTGCGCTGGACATCCAG

185
GCGGCCCAAAGCGTGCAGCAAGCCCTGGAACAGCTGGTTAAACCGGAAG
AACTGAACGGCGAAAATGCGTATCATTGCGGTGTGTGTCTGCAGCGTGC
ACCGGCTAGCAAAACCCTGACGCTGCACACCTCTGCAAAAGTCCTGATT
CTGGTGCTGAAACGCTTCAGTGATGTTACGGGCAACAAAATCGCTAAAA
ATGTCCAGTATCCGGAATGCCTGGATATGCAGCCGTACATGTCCCAACC
GAACACCGGTCCGCTGGTGTATGTTCTGTACGCAGTCCTGGTGCATGCT
GGCTGGAGTTGTCATAATGGTCACTATTTTTCCTACGTGAAAGCACAGG
AAGGCCAATGGTACAAAATGGATGACGCAGAAGTTACCGCTAGTTCCAT
TACGAGTGTTCTGTCCCAGCAAGCCTATGTCCTGTTCTACATCCAGAAA
AGCGAATGGGAACGTCATTCCGAATCAGTGTCGCGTGGTCGTGAACCGC
GTGCACTGGGTGCTGAAGATACCGACCGTCGCGCGACGCAGGGTGAACT
GAAACGTGATCATCCGTGCCTGCAAGCGCCGGAACTGGACGAACACCTG
GTTGAACGCGCCACCCAGGAATCAACGCTGGATCATTGGAAATTTCTGC
AGGAACAAAACAAAACCAAACCGGAATTCAATGTGCGCAAAGTTGAAGG
CACGCTGCCGCCGGATGTTCTGGTCATCCATCAGTCGAAATACAAATGT
GGTATGAAAAACCATCACCCGGAACAGCAATCATCGCTGCTGAATCTGA
GCTCTAGTACCCCGACGCACCAGGAATCAATGAATACCGGCACGCTGGC
CTCGCTGCGTGGTCGCGCCCGTCGTAGTAAAGGTAAAAATAAACATTCT
AAACGCGCACTGCTGGTCTGTCAA

A.2
A.2.1

USP7 Nucleotide Sequences
USP7FL Sf9 Optimized Nucleotide Sequence (residues 1–1102)

AATCACCAACAGCAGCAGCAACAACAAAAAGCCGGAGAGCAACAGTT
GAGTGAACCTGAGGACATGGAGATGGAAGCAGGAGACACCGATGATCC
TCCGCGTATCACTCAAAATCCTGTGATAAACGGTAACGTCGCGCTTTCT
GATGGTCACAACACAGCGGAAGAAGACATGGAAGATGACACTTCCTGGA
GAAGCGAGGCCACCTTCCAGTTCACAGTTGAACGTTTCTCCCGCTTGAG
TGAATCCGTCCTTTCCCCTCCCTGCTTCGTGCGTAACTTGCCATGGAAA

186
ATCATGGTCATGCCCCGTTTCTACCCGGACAGGCCTCACCAAAAATCTG
TGGGATTCTTCCTTCAGTGCAATGCCGAGAGTGATAGCACATCTTGGTC
ATGTCACGCGCAGGCCGTGCTGAAAATTATCAACTACAGGGACGACGAG
AAGTCATTCTCCCGCCGCATCAGCCATCTTTTTTTTCATAAGGAAAACG
ATTGGGGCTTCTCAAACTTTATGGCCTGGTCCGAAGTAACCGATCCCGA
GAAAGGATTCATAGATGATGACAAAGTGACCTTCGAGGTCTTTGTTCAG
GCCGACGCTCCCCATGGCGTTGCATGGGACTCAAAGAAGCACACTGGTT
ATGTAGGCCTGAAGAACCAGGGCGCCACATGTTACATGAATAGTCTGCT
GCAGACTCTGTTCTTCACAAATCAACTGCGTAAAGCTGTTTACATGATG
CCCACTGAGGGAGATGATTCGTCGAAATCTGTTCCCCTCGCGCTTCAGC
GTGTGTTTTACGAGCTGCAGCACTCCGACAAGCCTGTGGGCACCAAGAA
ACTGACCAAGTCTTTTGGCTGGGAGACGCTTGATTCCTTCATGCAACAT
GACGTGCAAGAGCTGTGTAGGGTTCTCCTTGACAACGTCGAGAACAAGA
TGAAAGGTACCTGTGTGGAGGGCACAATCCCTAAGCTTTTTAGGGGCAA
GATGGTGTCTTATATCCAGTGCAAGGAAGTGGACTACCGTAGCGACAGG
AGGGAAGACTACTATGACATCCAGCTGTCCATCAAGGGAAAGAAGAATA
TCTTCGAATCGTTCGTAGATTATGTAGCTGTAGAACAGCTTGACGGTGA
CAACAAATACGACGCCGGTGAGCATGGACTGCAGGAAGCTGAGAAAGGT
GTGAAATTTTTGACTCTGCCGCCCGTGCTGCATTTGCAATTGATGCGCT
TCATGTACGACCCTCAAACGGATCAGAACATCAAGATCAATGACAGATT
TGAATTTCCCGAGCAGCTCCCATTGGATGAGTTCCTGCAAAAGACGGAC
CCGAAAGACCCAGCGAATTACATACTGCACGCTGTGCTGGTACACAGCG
GTGATAACCACGGTGGACACTACGTGGTATACCTCAACCCTAAAGGCGA
TGGCAAATGGTGTAAGTTCGACGATGATGTCGTTTCCCGCTGCACCAAG
GAGGAAGCGATTGAGCACAACTATGGCGGACATGACGACGACTTGTCAG
TACGCCACTGCACTAATGCGTATATGCTTGTCTATATCAGGGAAAGTAA
GTTGAGCGAGGTCCTGCAAGCTGTCACAGATCACGACATCCCGCAGCAA
TTGGTGGAGAGACTCCAAGAGGAAAAACGTATCGAGGCCCAGAAGCGTA
AGGAGAGGCAGGAAGCACATCTCTATATGCAAGTACAAATCGTTGCCGA

187
GGACCAGTTCTGCGGTCATCAAGGCAACGACATGTATGACGAAGAAAAG
GTTAAATACACCGTGTTTAAGGTGCTGAAGAATAGCTCCCTGGCGGAGT
TTGTACAGTCACTCAGTCAGACAATGGGTTTTCCCCAGGATCAGATCCG
CCTGTGGCCCATGCAGGCTAGATCAAATGGTACAAAACGCCCAGCTATG
CTCGATAATGAAGCCGACGGTAATAAGACCATGATCGAGTTGTCCGATA
ACGAAAATCCTTGGACAATCTTCTTGGAAACCGTGGACCCGGAGTTGGC
CGCTTCGGGCGCTACGCTGCCCAAATTCGATAAAGACCACGATGTCATG
CTGTTCCTCAAGATGTATGATCCCAAGACTAGGTCATTGAACTACTGTG
GTCATATTTACACTCCTATTAGCTGCAAGATTAGAGACTTGCTGCCTGT
TATGTGCGATCGCGCAGGCTTCATCCAGGATACCAGTCTGATCTTGTAC
GAAGAAGTGAAGCCGAACCTGACAGAACGTATCCAAGACTACGATGTGT
CACTGGACAAGGCTTTGGACGAACTCATGGATGGCGACATAATCGTCTT
CCAAAAGGACGATCCCGAAAACGACAATTCTGAGCTGCCCACTGCTAAG
GAATACTTCAGGGACTTGTACCACCGTGTCGACGTAATTTTCTGCGACA
AGACGATCCCTAACGATCCAGGTTTCGTGGTCACGCTGTCTAACAGAAT
GAACTATTTCCAAGTCGCTAAGACGGTTGCACAAAGACTGAACACTGAC
CCAATGCTCCTCCAGTTCTTCAAATCGCAAGGTTACCGCGATGGTCCAG
GAAACCCTCTCAGGCACAACTACGAGGGAACTCTGAGAGATCTCCTTCA
GTTTTTCAAGCCGAGGCAGCCCAAGAAGCTGTACTACCAACAATTGAAG
ATGAAGATTACCGACTTCGAAAACCGCAGGTCGTTTAAGTGTATCTGGT
TGAACTCTCAGTTTAGAGAAGAGGAGATCACCCTCTACCCAGACAAACA
TGGATGCGTTAGAGACCTGCTGGAAGAGTGCAAGAAGGCAGTTGAGTT
GGGAGAGAAGGCCTCCGGTAAGCTGCGCCTCCTGGAGATAGTCAGCTAC
AAGATAATTGGAGTACACCAAGAGGACGAGCTCCTCGAGTGCTTGAGCC
CAGCAACCTCACGCACCTTCAGGATTGAGGAAATCCCACTCGACCAGGT
CGATATTGATAAAGAAAATGAAATGCTCGTGACGGTTGCTCACTTCCAC
AAGGAGGTCTTCGGAACCTTCGGTATTCCTTTCCTCCTCCGTATCCATC
AGGGCGAACACTTCCGCGAGGTCATGAAACGTATTCAGAGTCTTCTCGA
CATTCAGGAGAAGGAGTTCGAGAAGTTCAAATTCGCTATCGTGATGATG

188
GGCAGACATCAATACATAAACGAGGACGAATACGAGGTCAACCTTAAGG
ACTTCGAGCCACAGCCAGGAAACATGTCTCACCCACGTCCATGGTTGGG
TCTTGACCACTTCAACAAGGCTCCTAAGCGCTCGCGTTACACTTATCTC
GAAAAGGCTATTAAGATTCACAACTAA

A.2.2

USP7CD Nucleotide Sequence (residues 208–560)

catcatcatcatcatcatgaaaacctgtattttcagggcAAAAAACATCTTCGAAAGCTTCG
TGGACTATGTGGCCGTGGAGCAGCTGGACGGCGACAACAAATACGACGC
GGGCGAACATGGTCTGCAAGAAGCCGAAAAAGGCGTTAAATTTCTGACG
CTGCCGCCGGTTCTGCACCTGCAGCTGATGCGCTTTATGTATGATCCGC
AGACCGATCAGAATATCAAAATTAACGACCGCTTTGAATTTCCGGAACA
GCTGCCGCTGGATGAATTTCTGCAAAAAACCGATCCGAAAGACCCGGCG
AACTACATTCTGCACGCGGTGCTGGTGCACAGCGGCGATAATCACGGTG
GCCACTATGTTGTTTACCTGAACCCGAAAGGCGATGGCAAATGGTGCAA
ATTTGACGATGACGTGGTTAGCCGTTGCACGAAAGAAGAAGCGATTGAA
CACAATTATGGCGGCCACGACGATGATCTGAGCGTTCGTCACTGCACCA
ATGCGTATATGCTGGTTTATATCCGCGAATCCAAACTGAGCGAAGTTCT
GCAGGCCGTTACCGACCACGATATTCCGCAGCAACTGGTTGAACGCCTG
CAGGAAGAAAAACGCATTGAAGCGCAGAAACGCAAAGAACGCCAGGAAG
CCCACCTGTATtaaggatcc

A.2.3

USP7CD –H4–5 Nucleotide Sequence (residues 209–1102 ∆567–879)

CATATGCACCATCATCATCATCACGAGAACCTGTACTTCCAGGGTAA
AAAGCACACCGGTTACGTCGGTCTGAAGAACCAAGGTGCAACGTGTTAC
ATGAACAGCCTGCTGCAAACTCTGTTCTTCACCAACCAGCTGCGTAAGG
CTGTTTACATGATGCCTACCGAAGGTGACGACTCTTCTAAGAGCGTCCC
TCTGGCTCTGCAACGTGTATTTTACGAACTGCAACATAGCGACAAACCT
GTCGGTACTAAGAAACTGACCAAAAGCTTCGGCTGGGAAACCCTGGACT

189
CTTTCATGCAGCATGACGTACAGGAACTGTGTCGTGTCCTGCTGGATAA
CGTAGAAAACAAGATGAAAGGTACCTGCGTGGAGGGTACTATCCCAAAA
CTGTTCCGTGGTAAAATGGTGTCCTACATCCAGTGCAAAGAGGTGGACT
ACCGTAGCGACCGTCGTGAAGACTACTACGACATCCAACTGTCTATCAA
GGGCAAGAAAAACATCTTCGAGTCCTTCGTCGATTACGTGGCGGTGGAG
CAGCTGGATGGCGATAACAAATACGACGCAGGTGAACATGGTCTGCAGG
AAGCAGAAAAAGGTGTGAAATTCCTGACCCTGCCACCAGTACTGCATCT
GCAACTGATGCGTTTCATGTACGACCCGCAGACTGATCAGAATATCAAG
ATCAACGACCGTTTCGAGTTCCCGGAACAGCTGCCGCTGGATGAATTCC
TGCAGAAAACTGATCCGAAAGACCCGGCTAATTATATCCTGCATGCTGT
GCTGGTACACTCTGGCGATAATCACGGTGGTCACTATGTAGTATACCTG
AACCCGAAAGGCGATGGCAAATGGTGCAAATTCGACGACGATGTGGTTT
CTCGTTGTACTAAAGAGGAGGCAATCGAGCACAACTACGGTGGTCACGA
TGACGATCTGTCTGTGCGTCACTGTACTAACGCATATATGCTGGTGTAC
ATCCGTGAAAGCAAACTGTCCGAGGTTCTGCAGGCTGTTACCGATCACG
ATATCCCGCAGCAGCTGGTAGAACGTCTGCAGGAGGAAAAACGTATTGA
AGCTCAGAAACGTAAAGAACGTCAGGAAGCCCACCTGCAGCTGAAAATG
AAAATCACGGACTTCGAAAACCGTCGTTCTTTCAAATGCATCTGGCTGA
ACTCCCAGTTCCGTGAGGAAGAGATCACGCTGTATCCGGATAAACACGG
TTGCGTTCGCGATCTGCTGGAAGAATGCAAGAAAGCCGTTGAACTGGGC
GAAAAAGCGTCTGGCAAACTGCGCCTGCTGGAAATTGTTTCTTACAAAA
TCATCGGCGTTCACCAGGAAGACGAACTGCTGGAATGCCTGAGCCCGGC
CACCTCCCGTACCTTTCGCATTGAAGAAATTCCGCTGGATCAGGTTGAT
ATTGATAAAGAAAACGAAATGCTGGTTACCGTTGCGCACTTCCACAAAG
AAGTTTTCGGCACCTTCGGCATTCCGTTTCTGCTGCGCATTCACCAGGG
CGAACACTTTCGCGAAGTTATGAAACGCATTCAGTCCCTGCTGGACATC
CAGGAAAAAGAATTTGAAAAATTCAAATTTGCGATCGTTATGATGGGCC
GCCACCAGTATATCAACGAGGACGAATATGAAGTTAACCTGAAAGACTT
TGAACCGCAGCCGGGCAACATGTCCCACCCGCGCCCGTGGCTGGGCCTG
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GACCACTTTAACAAAGCGCCGAAACGCTCCCGCTATACCTATCTGGAAA
AAGCGATTAAGATTCACAATTAAGGATCC

A.2.4

USP7CD –H1–5 Nucleotide Sequence (residues 208–1102

CATATGCATCACCACCATCATCACGAAAACCTGTACTTCCAAGGTAA
GAAGCACACGGGTTACGTAGGTCTGAAGAACCAGGGTGCTACTTGCTAC
ATGAACAGCCTGCTGCAAACGCTGTTCTTCACTAACCAGCTGCGTAAGG
CAGTTTACATGATGCCTACTGAAGGTGATGATAGCAGCAAGAGCGTACC
TCTGGCACTGCAACGTGTATTCTACGAGCTGCAACATTCTGATAAGCCT
GTCGGTACTAAGAAGCTGACGAAGTCCTTCGGTTGGGAAACTCTGGATT
CTTTCATGCAGCACGACGTACAGGAGCTGTGTCGTGTACTGCTGGATAA
CGTCGAAAACAAGATGAAGGGCACTTGCGTCGAGGGTACTATCCCTAAG
CTGTTCCGTGGTAAGATGGTCTCTTACATCCAATGCAAGGAGGTCGATT
ACCGTTCTGACCGTCGTGAAGATTACTACGACATCCAGCTGTCTATCAA
GGGCAAAAAAAACATCTTCGAGTCCTTCGTCGACTACGTGGCCGTCGAG
CAGCTGGATGGTGATAACAAATACGACGCGGGTGAGCATGGTCTGCAAG
AAGCTGAAAAAGGTGTGAAATTCCTGACGCTGCCTCCAGTGCTGCATCT
GCAACTGATGCGTTTCATGTACGATCCACAAACCGATCAGAACATCAAA
ATCAACGACCGCTTCGAGTTCCCGGAGCAACTGCCACTGGATGAATTCC
TGCAGAAAACCGATCCAAAAGACCCAGCTAACTACATCCTGCACGCAGT
GCTGGTTCACTCTGGTGATAACCACGGTGGTCATTACGTGGTTTACCTG
AACCCAAAAGGTGATGGTAAATGGTGCAAATTCGACGATGATGTGGTGT
CTCGTTGCACTAAAGAGGAGGCAATCGAGCACAACTACGGTGGTCACGA
TGACGACCTGTCTGTGCGTCACTGTACTAACGCATACATGCTGGTGTAC
ATCCGTGAGTCTAAACTGTCCGAGGTGCTGCAAGCAGTAACTGATCACG
ATATCCCGCAGCAGCTGGTTGAACGTCTGCAGGAAGAAAAACGTATCGA
GGCTCAGAAACGTAAAGAGCGTCAGGAAGCTCATCTGTACATGCAGGTG
CAGATCGTTGCAGAAGATCAGTTCTGCGGTCATCAGGGTAACGATATGT
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ACGACGAAGAAAAAGTGAAATACACCGTGTTCAAAGTGCTGAAAAACTC
CTCCCTGGCTGAATTCGTGCAGTCCCTGAGCCAGACGATGGGCTTCCCG
CAGGATCAGATCCGTCTGTGGCCGATGCAGGCTCGTTCTAATGGTACTA
AACGTCCGGCAATGCTGGATAATGAAGCTGATGGTAATAAAACCATGAT
CGAACTGAGCGACAACGAAAACCCGTGGACTATCTTCCTGGAAACCGTT
GACCCGGAACTGGCTGCCTCTGGTGCGACCCTGCCGAAATTTGATAAAG
ATCATGATGTAATGCTGTTCCTGAAAATGTACGACCCGAAAACGCGTTC
CCTGAACTACTGCGGCCATATCTACACCCCGATTAGCTGTAAAATCCGC
GACCTGCTGCCGGTTATGTGTGATCGTGCGGGCTTTATTCAGGATACCT
CTCTGATTCTGTACGAAGAAGTAAAACCGAACCTGACCGAACGTATCCA
GGATTATGACGTATCCCTGGACAAAGCGCTGGATGAACTGATGGACGGC
GACATCATCGTTTTCCAGAAAGACGACCCGGAAAACGACAACAGCGAAC
TGCCGACCGCCAAAGAATATTTCCGTGACCTGTATCACCGTGTTGACGT
TATCTTCTGCGACAAAACCATCCCGAACGACCCGGGCTTTGTTGTTACC
CTGTCTAATCGTATGAACTATTTCCAGGTTGCGAAAACCGTTGCGCAGC
GTCTGAACACCGACCCGATGCTGCTGCAGTTTTTTAAAAGCCAGGGCTA
TCGTGACGGCCCGGGCAATCCGCTGCGTCACAATTATGAAGGCACCCTG
CGTGACCTGCTGCAGTTCTTTAAACCGCGTCAGCCGAAAAAACTGTATT
ATCAGCAGCTGAAAATGAAAATTACCGACTTTGAAAACCGCCGCTCTTT
TAAATGCATTTGGCTGAACTCCCAGTTCCGCGAAGAGGAGATCACCCTG
TATCCGGACAAACACGGCTGTGTTCGCGATCTGCTGGAAGAATGTAAAA
AAGCGGTTGAACTGGGCGAAAAAGCCAGCGGCAAACTGCGCCTGCTGGA
AATTGTTTCTTATAAAATCATCGGCGTTCACCAGGAAGACGAACTGCTG
GAATGCCTGTCCCCGGCGACCTCCCGCACCTTTCGCATTGAAGAAATTC
CGCTGGACCAGGTTGACATTGACAAAGAAAATGAAATGCTGGTTACCGT
TGCGCACTTTCACAAAGAAGTATTCGGCACCTTCGGCATCCCGTTTCTG
CTGCGCATTCACCAGGGCGAACACTTTCGCGAAGTAATGAAACGCATTC
AGAGCCTGCTGGACATTCAGGAAAAAGAATTCGAAAAATTCAAATTCGC
CATCGTTATGATGGGCCGCCACCAGTATATCAACGAAGACGAATATGAA
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GTTAACCTGAAAGACTTCGAACCGCAGCCGGGCAACATGTCCCACCCGC
GCCCGTGGCTGGGCCTGGACCACTTTAACAAAGCGCCGAAACGCTCCCG
CTATACCTATCTGGAAAAAGCGATTAAAATTCACAACTAAGGATCC

A.2.5

TRAF–USP7CD Nucleotide Sequence (residues 1–560)

catatgCACCACCATCATCACCATGAGAACCTGTACTTCCAGGGTATGAA
CCACCAACAGCAGCAACAACAGCAAAAGGCAGGCGAGCAGCAGCTGTCT
GAACCTGAAGATATGGAAATGGAGGCTGGTGACACTGACGATCCTCCAC
GTATCACTCAGAACCCTGTTATCAACGGTAACGTGGCTCTGTCTGATGG
TCACAACACCGCAGAGGAAGACATGGAGGATGATACTAGCTGGCGCTCT
GAAGCAACTTTCCAGTTCACTGTCGAGCGTTTCTCTCGTCTGTCCGAAT
CTGTCCTGTCTCCACCATGTTTCGTACGTAACCTGCCATGGAAGATCAT
GGTCATGCCGCGTTTCTACCCGGATCGTCCGCATCAGAAATCTGTAGGT
TTCTTTCTGCAGTGTAACGCAGAATCCGATTCCACTTCCTGGTCTTGTC
ACGCACAGGCAGTACTGAAGATTATCAACTACCGTGACGACGAGAAGTC
CTTCTCCCGTCGTATCAGCCATCTGTTCTTCCACAAGGAGAACGACTGG
GGTTTCTCTAACTTCATGGCGTGGTCTGAGGTCACTGATCCGGAAAAGG
GTTTCATCGACGACGATAAGGTAACCTTCGAGGTCTTCGTTCAGGCTGA
CGCTCCGCACGGTGTAGCTTGGGATTCTAAGAAACATACCGGTTACGTT
GGTCTGAAAAACCAGGGTGCTACGTGTTACATGAACAGCCTGCTGCAGA
CCCTGTTTTTCACCAACCAGCTGCGTAAAGCGGTATACATGATGCCGAC
CGAAGGTGATGACTCTTCTAAAAGCGTTCCGCTGGCTCTGCAGCGTGTA
TTTTACGAACTGCAGCATTCCGATAAACCGGTGGGTACGAAAAAACTGA
CCAAATCCTTCGGCTGGGAAACCCTGGACTCTTTCATGCAGCACGACGT
TCAGGAACTGTGCCGTGTACTGCTGGATAACGTTGAAAACAAAATGAAA
GGCACCTGCGTGGAAGGCACCATCCCGAAACTGTTCCGTGGTAAAATGG
TGTCCTACATCCAGTGCAAAGAAGTGGACTACCGCTCCGACCGTCGTGA
AGACTACTACGACATCCAGCTGAGCATCAAAGGCAAAAAAAACATCTTC
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GAAAGCTTCGTGGACTATGTGGCCGTGGAGCAGCTGGACGGCGACAACA
AATACGACGCGGGCGAACATGGTCTGCAAGAAGCCGAAAAAGGCGTTAA
ATTTCTGACGCTGCCGCCGGTTCTGCACCTGCAGCTGATGCGCTTTATG
TATGATCCGCAGACCGATCAGAATATCAAAATTAACGACCGCTTTGAAT
TTCCGGAACAGCTGCCGCTGGATGAATTTCTGCAAAAAACCGATCCGAA
AGACCCGGCGAACTACATTCTGCACGCGGTGCTGGTGCACAGCGGCGAT
AATCACGGTGGCCACTATGTTGTTTACCTGAACCCGAAAGGCGATGGCA
AATGGTGCAAATTTGACGATGACGTGGTTAGCCGTTGCACGAAAGAAGA
AGCGATTGAACACAATTATGGCGGCCACGACGATGATCTGAGCGTTCGT
CACTGCACCAATGCGTATATGCTGGTTTATATCCGCGAATCCAAACTGA
GCGAAGTTCTGCAGGCCGTTACCGACCACGATATTCCGCAGCAACTGGT
TGAACGCCTGCAGGAAGAAAAACGCATTGAAGCGCAGAAACGCAAAGAA
CGCCAGGAAGCCCACCTGTATtaaggatcc

A.2.6

H1–5 Nucleotide Sequence (residues 560–1102)

CATATGCACCATCATCATCATCACGAAAACCTGTACTTCCAGGGTGA
AGCACATCTGTACATGCAGGTCCAGATCGTCGCAGAAGATCAGTTCTGT
GGTCATCAGGGTAACGATATGTACGACGAAGAAAAGGTCAAGTACACGG
TCTTCAAGGTGCTGAAGAACTCCAGCCTGGCAGAATTCGTGCAGTCTCT
GTCTCAGACTATGGGTTTCCCTCAGGATCAGATCCGTCTGTGGCCTATG
CAAGCACGTTCTAATGGTACTAAACGTCCAGCTATGCTGGATAACGAGG
CAGATGGTAACAAGACCATGATCGAGCTGTCTGACAACGAGAACCCATG
GACTATCTTCCTGGAGACTGTGGACCCAGAACTGGCTGCTTCTGGTGCT
ACTCTGCCAAAATTTGATAAAGACCACGACGTGATGCTGTTCCTGAAAA
TGTACGACCCGAAAACGCGTTCCCTGAACTACTGCGGTCATATCTACAC
CCCAATCTCTTGCAAAATCCGCGACCTGCTGCCGGTTATGTGTGATCGT
GCTGGTTTTATCCAGGATACTAGCCTGATCCTGTACGAAGAGGTGAAAC
CGAACCTGACTGAACGTATCCAGGATTACGACGTGTCTCTGGATAAAGC
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CCTGGATGAACTGATGGACGGTGACATCATCGTGTTCCAGAAAGACGAC
CCGGAAAACGATAACTCCGAACTGCCGACCGCTAAAGAATACTTCCGTG
ATCTGTACCACCGTGTAGATGTGATCTTCTGTGACAAAACCATCCCGAA
CGATCCGGGTTTCGTTGTTACCCTGTCTAACCGTATGAACTACTTCCAG
GTTGCGAAAACCGTTGCGCAGCGTCTGAACACCGATCCGATGCTGCTGC
AATTTTTCAAAAGCCAGGGTTACCGTGATGGTCCTGGCAATCCGCTGCG
TCACAATTATGAAGGCACCCTGCGTGATCTGCTGCAATTCTTTAAACCC
GCGTCAACCGAAAAAGCTGTATTATCAGCAGCTGAAAATGAAAATCACG
GACTTCGAGAACCGCCGCTCCTTCAAGTGCATCTGGCTGAACAGCCAGT
TCCGTGAAGAGGAGATCACGCTGTATCCGGACAAACACGGCTGTGTACG
CGATCTGCTGGAAGAATGCAAGAAAGCCGTTGAACTGGGCGAAAAAGCG
TCTGGCAAACTGCGTCTGCTGGAAATTGTTAGCTACAAAATCATCGGCG
TACACCAGGAAGACGAACTGCTGGAATGCCTGTCCCCGGCGACCTCCCG
TACCTTTCGTATTGAAGAAATTCCGCTGGACCAAGTTGACATTGACAAA
GAAAACGAAATGCTGGTTACCGTAGCGCACTTTCACAAAGAGGTTTTCG
GCACCTTCGGCATTCCGTTTCTGCTGCGTATTCACCAAGGCGAACACTT
TCGCGAAGTAATGAAACGCATCCAGTCCCTGCTGGACATTCAGGAAAAA
GAATTCGAGAAATTCAAATTCGCGATCGTTATGATGGGCCGCCACCAGT
ATATTAACGAGGACGAATATGAAGTAAACCTGAAAGACTTCGAACCGCA
GCCGGGCAACATGAGCCACCCGCGCCCGTGGCTGGGCCTGGACCACTTT
AACAAAGCGCCGAAACGCAGCCGCTATACCTATCTGGAAAAAGCCATTA
AGATTCACAATTAAGGATCC

A.2.7

H4–5 Nucleotide Sequence (residues 890–1102)

CATATGCACCATCATCATCATCACGAGAACCTGTACTTCCAGGGTAA
CCGTCGTTCTTTCAAATGCATCTGGCTGAACTCCCAGTTCCGTGAGGAA
GAGATCACGCTGTATCCGGATAAACACGGTTGCGTTCGCGATCTGCTGG
AAGAATGCAAGAAAGCCGTTGAACTGGGCGAAAAAGCGTCTGGCAAACT
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GCGCCTGCTGGAAATTGTTTCTTACAAAATCATCGGCGTTCACCAGGAA
GACGAACTGCTGGAATGCCTGAGCCCGGCCACCTCCCGTACCTTTCGCA
TTGAAGAAATTCCGCTGGATCAGGTTGATATTGATAAAGAAAACGAAAT
GCTGGTTACCGTTGCGCACTTCCACAAAGAAGTTTTCGGCACCTTCGGC
ATTCCGTTTCTGCTGCGCATTCACCAGGGCGAACACTTTCGCGAAGTTA
TGAAACGCATTCAGTCCCTGCTGGACATCCAGGAAAAAGAATTTGAAAA
ATTCAAATTTGCGATCGTTATGATGGGCCGCCACCAGTATATCAACGAG
GACGAATATGAAGTTAACCTGAAAGACTTTGAACCGCAGCCGGGCAACA
TGTCCCACCCGCGCCCGTGGCTGGGCCTGGACCACTTTAACAAAGCGCC
GAAACGCTCCCGCTATACCTATCTGGAAAAAGCGATTAAGATTCACAAT
TAAGGATCC

A.2.8

H1–2 Nucleotide Sequence (residues 560–775

GAAGCACATCTGTACATGCAGGTCCAGATCGTCGCAGAAGATCAGTT
CTGTGGTCATCAGGGTAACGATATGTACGACGAAGAAAAGGTCAAGTAC
ACGGTCTTCAAGGTGCTGAAGAACTCCAGCCTGGCAGAATTCGTGCAGT
CTCTGTCTCAGACTATGGGTTTCCCTCAGGATCAGATCCGTCTGTGGCC
TATGCAAGCACGTTCTAATGGTACTAAACGTCCAGCTATGCTGGATAAC
GAGGCAGATGGTAACAAGACCATGATCGAGCTGTCTGACAACGAGAACC
CATGGACTATCTTCCTGGAGACTGTGGACCCAGAACTGGCTGCTTCTGG
TGCTACTCTGCCAAAATTTGATAAAGACCACGGTGGACCCAGAACTGGC
TGCTTCTGGTGCTACTCTGCCAAAATTTGATAAAGACCACGACGTGATG
CTGTTCCTGAAAATGTACGACCCGAAAACGCGTTCCCTGAACTACTGCG
GTCATATCTACACCCCAATCTCTTGCAAAATCCGCGACCTGCTGCCGGT
TATGTGTGATCGTGCTGGTTTTATCCAGGATACTAGCCTGATCCTGTAC
GAAGAGGTGAAACCGAACCTGACTGAACGTATCCAGGATTACGACGTGT
CTCTGGATAAAGCCCTGGATGAACTGATGGACGGTGACATCATCGTGTT
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CCAGAAAGACGACCCGGAAAACGATAACTCCGAACTGCCGACCGCTAAA
GAATACTTCCGTGATCTGTACCACC

A.2.9

H1–3 Nucleotide Sequence (residues 560–888

GAAGCACATCTGTACATGCAGGTCCAGATCGTCGCAGAAGATCAGTT
CTGTGGTCATCAGGGTAACGATATGTACGACGAAGAAAAGGTCAAGTAC
ACGGTCTTCAAGGTGCTGAAGAACTCCAGCCTGGCAGAATTCGTGCAGT
CTCTGTCTCAGACTATGGGTTTCCCTCAGGATCAGATCCGTCTGTGGCC
TATGCAAGCACGTTCTAATGGTACTAAACGTCCAGCTATGCTGGATAAC
GAGGCAGATGGTAACAAGACCATGATCGAGCTGTCTGACAACGAGAACC
CATGGACTATCTTCCTGGAGACTGTGGACCCAGAACTGGCTGCTTCTGG
TGCTACTCTGCCAAAATTTGATAAAGACCACGGTGGACCCAGAACTGGC
TGCTTCTGGTGCTACTCTGCCAAAATTTGATAAAGACCACGACGTGATG
CTGTTCCTGAAAATGTACGACCCGAAAACGCGTTCCCTGAACTACTGCG
GTCATATCTACACCCCAATCTCTTGCAAAATCCGCGACCTGCTGCCGGT
TATGTGTGATCGTGCTGGTTTTATCCAGGATACTAGCCTGATCCTGTAC
GAAGAGGTGAAACCGAACCTGACTGAACGTATCCAGGATTACGACGTGT
CTCTGGATAAAGCCCTGGATGAACTGATGGACGGTGACATCATCGTGTT
CCAGAAAGACGACCCGGAAAACGATAACTCCGAACTGCCGACCGCTAAA
GAATACTTCCGTGATCTGTACCACCGACGACCCGGAAAACGATAACTCC
GAACTGCCGACCGCTAAAGAATACTTCCGTGATCTGTACCACCGTGTAG
ATGTGATCTTCTGTGACAAAACCATCCCGAACGATCCGGGTTTCGTTGT
TACCCTGTCTAACCGTATGAACTACTTCCAGGTTGCGAAAACCGTTGCG
CAGCGTCTGAACACCGATCCGATGCTGCTGCAATTTTTCAAAAGCCAGG
GTTACCGTGATGGTCCTGGCAATCCGCTGCGTCACAATTATGAAGGCAC
CCTGCGTGATCTGCTGCAATTCTTTAAACCCGCGTCAACCGAAAAAGCT
GTATTATCAGCAGCTGAAAATGAAAATCACGGACTTCGAGAACCGCCGC
TCC
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